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Abstract  
 
Inflammation is thought to be a pathological feature that drives the neuronal 
degeneration in Alzheimer (AD) and Parkinson’s diseases (PD). This is normally 
associated with classically activated microglia, which release pro-inflammatory 
cytokines. Recently, the heterogeneous nature of microglial activation states has been 
acknowledged and the focus has been shifting to the alternative activation state, an 
immunosuppressive state that promotes tissue maintenance and repair. This project 
examined microglia phenotypes in AD and PD, focusing on alternative activation and 
phagocytosis. Traumatic brain injury (TBI) cases were also studied to provide a 
comparison between an acute inflammatory reaction and chronic inflammation 
observed in AD and PD.  
  
An initial test using a battery of antibodies against microglia e.g. MHCII, Iba1, CD68, 
MRC1 was used to identify interesting targets for characterization in AD and PD. 
CD163 and CD14, both of which are thought to be exclusive to perivascular 
macrophages, were detected in parenchymal microglia in AD and PD, with a much 
more florid reaction observed in AD. Many of these microglia were associated with 
extracellular pathology i.e. A! plaques and extracellular Lewy Bodies. Experimental 
evidence from AD, PD and TBI cases suggest that these microglia were of local and 
systemic origin. A number of clinicopathological correlations were found in PD cases. 
Upregulation of CD14+ microglia in the substantia nigra was significantly correlated with 
absence of gait and balance problems as an onset symptom. Upregulation of CD163+ 
microglia in the cingulate cortex, entorhinal cortex, and locus coeruleus was 
significantly correlated with a lack of anxiety. In TBI cases, positive association was 
found between the upregulation of CD163+ microglia and survival time. My study 
demonstrates differential microglial activation in AD and PD, emphasizes the 
heterogeneity of microglia phenotype, and provides an insight into the influence of 
systemic inflammation on microglial activation. 
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Chapter 1: Introduction 
 
1.1 Inflammation and Microglia  
Inflammation is a defense mechanism that kicks in whenever a system is afflicted by 
mechanical injury, pathogenic infection, toxins, irradiation or autoimmunity. It can 
destroy affected cells and invading pathogens, remove cellular debris, or isolate, 
protect, and repair cells and/or the extracellular matrix (ECM)(Correale and Villa 2004). 
The chief mediators of neuroinflammation are microglia and astrocytes. Transient 
responses are required when the central nervous system (CNS) is compromised, but 
chronic inflammation as a result of a persistent aggravator e.g. in neurodegenerative 
diseases, can cause a self-sustaining cycle that can lead to neuronal death (Tansey 
and Goldberg 2010).  
 
1.1.1 Microglia and Macrophages  
Glia cells include microglia (Figure 1), oligodendrocytes, and astrocytes (Figure 3). In a 
mature human brain, 10-20% of the glial population are microglial cells (Kreutzberg 
1995, Borda et al. 2008, Ouchi et al. 2009). Microglia are derived from myeloid 
progenitor cells that infiltrate through the undifferentiated blood-brain barrier (BBB), and 
populate the CNS during embryogenesis (Ransohoff, Kivisakk and Kidd 2003). 
Differential expression of microglia’s immunoregulatory markers is found throughout 
various brain regions (de Haas, Boddeke and Biber 2008). Microglia have a very long 
lifespan and a slow turnover rate, both from local self-renewal or recruitment from the 
bone marrow (Ajami et al. 2007, Mildner et al. 2007).  
In a normal healthy condition, microglia are known to be in a resting state. Contrary to 
terminology, microglia are never “resting”. They are constantly surveying their 
environment for damaged neurons, debris, and infectious agents. Their default 
morphology is that of a ramified form, with highly motile ciliary processes to aid 
surveillance. It is hypothesized that these microglia are also giving continuous 
neurotrophic support. With age, microglia in the human brain were shown to become 
dystrophic e.g. fragmented cytoplasmic processes, and it has been theorized that 
neurodegeneration occurs as neurons lose their trophic support and protection from 
microglia (Streit et al. 2009). Upon activation, microglia secrete cytokines, chemokines, 
complement proteins, trophic factors, reactive oxygen species (ROS), nitric oxide (NO), 
and proteolytic enzymes, migrate to the affected area, and exhibit a capacity for 
localized phagocytosis. There is also de novo synthesis or upregulation of cell surface 
molecules (Lue, Walker and Rogers 2001, Perry, Nicoll and Holmes 2010).  
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In the CNS, the four main resident macrophages are microglia, meningeal, choroid 
plexus and perivascular macrophages (PVM). PVM (Figure 2) lie between the 
endothelial cells of cerebral blood vessels and glial basement membranes, also known 
as the Virchow-Robin space. By virtue of their location, PVM respond to inflammatory 
stimuli from both within the CNS and from the periphery (Galea et al. 2005). Unlike 
microglial cells, they are constantly replenished by peripheral/blood-derived 
monocytes, and also from proliferation of pre-existing PVM (Lassmann et al. 1993, 
Fabriek et al. 2005). The turnover rate of PVM is several months. PVM have many 
functions including phagocytosis, drainage of proteins from the brain (Carare et al. 
2008), antigen presentation, maintenance of the blood brain barrier (BBB) and the 
structural integrity of blood vessels, regulation of endothelial cell proliferation, etc. 
(Mendes-Jorge et al. 2009)  
Another type of brain-resident macrophage is the pericyte, which has an elongated and 
amoeboid morphology that follows the contours of the vascular element. The main 
difference between pericytes and PVM is their location- pericytes are found within the 
endothelial basal lamina. It is thought that pericytes are simply intermediates between 
peripheral monocytes and PVM (Thomas 1999, Vallieres and Sawchenko 2003). 
As of yet, there has been no single marker to distinguish between a macrophage and 
microglia. A combination of three immunological markers can help to distinguish 
between PVM and microglia. PVM are CD11b+CD14+ CD45+, while microglia are 
CD11b+ CD14"CD45" (Guillemin and Brew 2004). Some PVM are also not 
immunoreactive for Iba1, which is a reliable pan-microglia marker (Ito et al. 2001, 
Mendes-Jorge et al. 2009).  
 
1.1.2 Defining the phenotypes and roles of microglia and activation states 
The old school of thought looks at the activation of microglia along a linear scale, from a 
resting state, to a major transformation when triggered, including hypertrophy of the 
soma and shortening of the processes into an amoeboid form that is indistinguishable 
from typical peripheral macrophages. Microglia at their final stages of activation are 
thought to secrete pro-inflammatory cytokines, reactive oxygen species (ROS) etc., and 
are capable of phagocytosis. This interpretation of microglial activation is highly 
inaccurate, as their morphology is a poor indicator of their phenotype. Treatment with 
pro-inflammatory or anti-inflammatory cytokines results in mixed morphologies 
(Porcheray et al. 2005). Major histocompatibility complex (MHC)  
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Figure 1. Morphologies of microglia  
 
 
(A&B) Ramified microglia in a control case. Long, thin cell processes are seen extending from the cell 
body. (C&D) Bushy microglia in an Alzheimer case that has an elongated cell body and short, thickened 
cell processes (E&F) Amoeboid microglia in an Alzheimer’s case that has a large, round cell body and 
little to no cell processes. All images were captured at x40 magnification. Anti-Iba1 was used to stain for 
these microglial cells. Iba1 is a pan-microglial cell marker used to label both resting and activated 
microglia (Ito et al. 2001).   
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Figure 2. Perivascular macrophages 
 
 
 
 
 
(A) Meningeal macrophages in the temporal cortex of an AD case. Magnification x20. (B) A perivascular 
macrophage in the temporal cortex of an AD case. Magnification x40. Anti-MRC1 was used to stain both 
A & B. Anti-MRC1 is a specific marker for perivascular macrophages (Galea et al. 2005).    
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Figure 3. Astrocytes  
 
 
 
 
(A) Astrocytes in the pons of an AD case. Magnification x40. (B) Double staining of astrocytes and A! 
plaques in the pons of an AD case. Magnification x40. Anti-GFAP (glial fibrillary acidic protein) was used 
to stain for astrocytes in both A & B. Anti-GFAP is a marker for astrocytes (Jacque et al. 1978).    
!"
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class II molecules, which are required for antigen presentation, can be used to 
distinguish between activated and surveillance microglia (Graeber, Bise and Mehraein 
1994). It can be used to label both classical and alternative activation states (Colton 
and Wilcock 2010).  
In recent years, microglia have been found to be heterogeneous with respect to their 
activation states. A newer approach towards microglia’s activation separates them into 
three categories- classical activation associated with cytotoxicity and the release of pro-
inflammatory cytokines; alternative activation and acquired deactivation, both of which 
are associated with anti-inflammatory cytokines, immunosuppression and tissue repair 
(Colton 2009). However, it is most likely that their functions, inflammatory and cytokine 
profiles, and phenotypes overlap to a large extent. The phenotypes acquired by 
microglia are dependent on many factors, including age, stage of neurological disease, 
systemic inflammation, and location of misfolded protein – whether it’s internal or 
external to the cell (Perry et al. 2010). Thus, it becomes tricky to use surface antigens 
and/or morphology to classify/distinguish between different microglia phenotypes. 
Macrophages do not have a fixed phenotype and are able to adapt depending on the 
stimuli (Stout and Suttles 2004). Their functional plasticity disputes the theory that 
different populations of microglia/macrophages exist- variation in phenotypes might be 
attributed to preconditioning and their microenvironments. Approaches to studying their 
progressive phenotypes before and during a neurodegenerative disease becomes a 
problem when using post mortem brain specimens, which only reflect a static state 
during the terminal moments of a patient (McGeer and McGeer 2008).  
 
1.1.3 Pro-inflammatory function of microglia 
Microglia express several pattern recognition receptors including toll-like receptors, 
receptor for advanced glycation end products (RAGE) and scavenger receptors, 
nucleotide-binding oligomerization domain (NOD) proteins, and purinergic receptors 
(Sterka and Marriott 2006, Salminen et al. 2009). These receptors respond to the 
presence of damage-associated molecular pattern molecules (DAMPs) which are 
released from degenerating or injured cells, or pathogen-associated molecular patterns 
(PAMPs) (Bianchi 2007, Rubartelli and Lotze 2007). 
The resulting activation of microglia causes the production of pro-inflammatory 
cytokines including tumor necrosis factor " (TNF"), interleukin 1! (IL-1!), IL-6, IL-12, 
interferon # (IFN#) (Liu 2006, Colton 2009), reactive nitrogen species (RNS), and 
reactive oxygen species (ROS) including hydrogen peroxide (H2O2) and superoxide 
(Qian and Flood 2008). The non-specificity of these molecules poses a threat to the 
surroundings and may cause bystander injury. Upregulation of chemokines, 
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nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, cyclooxygenase-2 
(COX-2), secreted and cytosolic phospholipases A2, and other enzymes that generate 
prostaglandin, act to reinforce and intensify the inflammation reaction (Farooqui, 
Horrocks and Farooqui 2007).   
The chief mediators of cytotoxicity include TNF" (Floden, Li and Combs 2005, Taylor et 
al. 2005b) and IL-1! (Tikka and Koistinaho 2001), which are able to mediate neuronal 
apoptosis. These cytokines also act to reinforce the initial microglial response, resulting 
in an escalating inflammatory reaction (Colton 2009).  
Inducible nitric oxide synthase (iNOS) is also upregulated during a classical activation 
microglia response, generating free radical nitric oxide (NO). Upon reacting with 
superoxide, a much more lethal oxidant- peroxynitrate, is produced. Recent evidence 
suggests that peroxynitrate is the main culprit behind cytotoxicity, causing damage by 
oxidation and nitration of enzymes, lipids, and DNA (Pacher, Beckman and Liaudet 
2007).  
 
1.1.4 Anti-inflammatory function of microglia 
After an episode of classical activation, microglia/macrophages need to move away 
from a pro-inflammatory to an anti-inflammatory, reparative phenotype. Resolution of 
inflammation by reducing pro-inflammatory factors, restoration of tissue homeostasis by 
promoting repair and replacement of lost or damaged cells, as well as reparation of the 
extracellular matrix need to take place. This is especially important for the CNS, known 
to have limited neuroregenerative potential (Colton 2009).  
From the study of peripheral macrophages, 4 major anti-inflammatory cytokines have 
been discovered- IL-4, IL-13, IL-10 and transforming growth factor ! (TGF!) (Martinez, 
Helming and Gordon 2009). They can be produced by microglia, astrocytes, and/or 
neurons. IL-4 is produced by astrocytes (Brodie et al. 1998), IL-10 by glial cells 
(Ledeboer et al. 2000), IL-13 by microglia (Shin et al. 2004) and TGF! by all three 
(Finch et al. 1993). These four cytokines enable macrophages to switch from a pro-
inflammatory to an anti-inflammatory state by downregulating classical activation 
pathways and inducing genes and transcribing proteins associated with repair and 
resolution. This is known as the alternative activation state (Colton 2009).  
The classification of the repair/resolution behavior of microglia/macrophages into just 
one category under alternative activation has been viewed as inadequate. Instead, it 
has been proposed for the phenotype to be further split into two wide categories: 
alternative activation and acquired deactivation. In this classification system, alternative 
activation is microglia’s response to IL-4 and IL-13, while acquired deactivation is the 
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response to IL-10, TGF!, and/or exposure to apoptotic cells (Gordon 2003, Gordon and 
Taylor 2005). These two activation states demonstrate similar gene profiles, but can still 
be differentiated by their type of induction and functions (Colton 2009).  
 
1.1.4.1 Alternative activation of microglia 
Alternatively activated microglia has a lower tendency to produce pro-inflammatory 
cytokines. They are associated with tissue repair and humoral immunity (Gordon 2003).  
IL-4 and IL-13 share the IL-4 receptor " subchain, and although their signaling 
pathways diverge, both tend to lead to similar gene profiles (Colton 2009). Both IL-4 
and IL-13 suppress production of TNF", NOS2, COX-2, IL-1!, IL-6 and IL-12 caused by 
LPS stimulation of microglial/macrophage cell cultures (Ledeboer et al. 2000, Scotton et 
al. 2005, Colton et al. 2006). Instead, alternative activation state induces an increase in 
mRNA expression of cytokines and growth factors including IL-10, TGF!, insulin growth 
factor, nerve growth factor (NGF), peroxisome proliferation activation receptor # (PPAR-
#), arginase 1, mannose receptor, inflammatory zone 1 (FIZZ1) and chitinase 3-like 3 
(Ym1) (Brodie et al. 1998, Kitamura et al. 2000, Odegaard et al. 2007, Colton et al. 
2006, Colton 2009). In mouse microglia cultures, IL-4 opposed the action of IFN# by 
inhibiting IFN#’s induction of TNF" and iNOS (Colton et al. 2006).   
IL-4 and IL-13 regulate phagocytosis, albeit differently from IL-10 and TGF!. IL-4 
decreases expression levels of CD163 and Fc receptor I and II, while increasing 
expression of mannose receptor and dectin 1 (Schaer et al. 2002, Gordon 2003, 
Willment et al. 2003, Nimmerjahn and Ravetch 2006). IL-4 treatment restores 
phagocytic ability to fibrillar A! treated murine microglia even in the presence of LPS 
and pro-inflammatory cytokines IL-1! and IFN# (Koenigsknecht-Talboo and Landreth 
2005).  
 
1.1.4.2 Acquired deactivation of microglia 
Acquired deactivation involves immunosuppression and upregulation of scavenger 
receptors to enable phagocytosis of apoptotic cells.  Both TGF! and IL-10 induce this 
state in microglia, while phagocytosis of apoptotic cells stimulates production of IL-10 
and TGF! in a positive feedback manner (Gregory and Devitt 2004). IL-10 exerts its 
effects downstream via STAT3 (Mosser and Zhang 2008), while TGF!’s signaling is 
mediated by SMAD (Li et al. 2006). The effects of these two cytokines overlap. 
TGF! and IL-10 act in a positive feedback manner by autocrine and paracrine methods 
to further increase their production (Colton and Wilcock 2010). They negatively regulate 
the production of pro-inflammatory cytokines, chemokines, and suppress MHC II protein 
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expression (Lodge and Sriram 1996, Colton 2009). They also act as growth factors by 
activating B-cell lymphoma-2 (Bcl-2) and Bcl-XL (Weber-Nordt et al. 1996, Vivien and 
Ali 2006). Increased levels of TGF! and IL-10 are found at tight junctions of the blood-
brain barrier (BBB) (Wu et al. 2008).  
In LPS-induced rat mesencephelic neuron-glia culture, IL-10 significantly inhibits 
production of TNF", NO, IL-1!, IL-6, IL-12 and extracellular superoxide (Lodge and 
Sriram 1996, Ledeboer et al. 2000, Qian et al. 2006). IL-10 increases expression of IL-1 
receptor antagonist, which reduces inflammation by binding and inhibiting the actions of 
IL-1 (Williams et al. 2002), and CD163, a scavenger receptor most well known for 
clearing of haemoglobin-haptoglobin complexes (Pioli et al. 2004). IL-10 also 
upregulates IL-4R", a receptor for both IL-4 and IL-13, and IL-4 and IL-10 were found 
to act synergistically e.g. for the induction of arginase 1 (Biswas et al. 2011). One 
method by which IL-10 exerts its neuroprotective effect is by activating heme 
oxygenase 1, which has anti-inflammatory and anti-apoptotic effects (Lee and Chau 
2002, Weis et al. 2009).  
TGF! influences many cell functions including cell growth, differentiation, chemotaxis, 
apoptosis, and hematopoiesis (Qian and Flood 2008). In cell cultures, TGF! protects 6-
hydroxydopamine (6-OHDA) treated neurons (Polazzi et al. 2009, Ruocco et al. 1999). 
Its neuroprotective capability has also been shown in animal models of ischemia, 
excitotoxicity, facial nerve axotomy and oxidative stress (Ruocco et al. 1999, Henrich-
Noack, Prehn and Krieglstein 1996, Makwana et al. 2007). TGF! also regulates ROS 
production in microglia (Herrera-Molina and von Bernhardi 2005). TGF! is thought to 
exert neuroprotection directly on neurons, and indirectly via microglia and astrocytes 
(Qian and Flood 2008). TGF! negatively regulates pro-inflammatory cytokines TNF", 
NO, IL-12 (Lodge and Sriram 1996), and upregulates prostaglandin E2 (Levi, Minghetti 
and Aloisi 1998). However, TGF! is an important mediator of cell death in ontogenetic 
conditions. Ablation of TGF! in developing chick embryos reduced apoptosis and 
neuronal loss was significantly decreased (Krieglstein et al. 2000, Dunker, Schuster 
and Krieglstein 2001).  
The task of clearing apoptotic cells in the CNS falls mainly to microglia. There are many 
scavenger receptors on microglia that serve this purpose, e.g. phosphatidylserine (PS) 
receptors, CD36 and CD14. The apoptotic cells are recognized by PS on the cell 
surface. Minghetti et al. 2005 found that microglia co-cultured with apoptotic neurons 
actively suppressed synthesis of pro-inflammatory cytokines i.e. TNF" and NO, while 
increasing the release of TGF!, prostaglandin E2 and NGF (Minghetti et al. 2005).   
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1.1.5 Pro-inflammatory vs Anti-inflammatory functions of microglia 
While inflammation can act to destroy or protect, there is a misconception that 
destruction is associated with pro-inflammatory cytokines, while protection is associated 
with anti-inflammatory cytokines.  
The gradual degeneration of neurons often implicated in neurodegenerative diseases 
has been thought to trigger microglia activation. This can be either classical or 
alternative activation, or a mixture of both (Colton et al. 2006). Classical activation of 
microglia causes production and release of cytotoxic and pro-inflammatory cytokines, 
resulting in a positive feedback loop that give rise to further neuronal degeneration 
(Akiyama et al. 2000). Apoptosis of neurons in these diseases causes 
microglia/macrophages to switch to an acquired deactivation phenotype. In both AD 
patients and transgenic human amyloid precursor protein (hAPP) mice model, levels of 
pro-inflammatory cytokines are low, and plaques are not removed efficiently, providing 
evidence for an anti-inflammatory phenotype (Perry, Cunningham and Holmes 2007).   
This mixed microglia phenotype observed in neurodegenerative disease results from 
chronic inflammation where the stimulants for microglia activation are not removed 
effectively, causing their classical activation state to persist, while apoptosis of neurons 
fuels microglia to take on alternative activation/ acquired deactivation phenotypes.  The 
inefficient removal of plaques might be attributed to its incessant production and 
deposition in the ECM. Constant and repeated exposure to A! plaques can cause 
microglia to respond differently to this stimuli (Perry et al. 2007). This phenomenon was 
observed with repeated stimulation of microglia with LPS, causing a down-regulation of 
pro-inflammatory cytokines with subsequent stimulations (Ajmone-Cat, Nicolini and 
Minghetti 2003).  
 
1.1.6 Acute vs chronic inflammation 
Acute inflammation comes on rapidly, can be accompanied by pain, and has a 
spontaneous resolution (Serhan and Savill 2005). In contrast, chronic inflammation 
persists over the years and continues to exert damage to neurons through release of 
pro-inflammatory cytokines, chemokines and ROS (Farooqui and Farooqui 2011). 
Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) have been found to 
decrease the risk of developing AD and PD, further emphasizing the role of chronic 
inflammation in neurodegenerative diseases.  
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1.1.7 Systemic inflammation and its effects in the brain 
Systemic inflammation reaches the CNS via both neural and humoral pathways. There 
are three routes of communication between peripheral inflammation and the CNS. First, 
the vagal nerve sensory afferents signal from the thoracic abdominal cavity to the brain. 
Secondly, circumventricular organs, which lack a BBB, communicate through 
inflammatory mediators e.g. cytokines via the peripheral blood flow. Finally, these 
mediators can signal directly through the BBB to PVM by interacting with the 
endothelial cells (Perry et al. 2007). Microglia and macrophages in the brain react to 
these signals and in turn release their own inflammatory mediators. 
Microglia are long-lived and have an innate memory of challenges and assaults to the 
brain. Signaling reduction to microglia’s immunoreceptor tyrosine-based inhibition motif 
(ITIM) receptors due to neuronal loss with age or disease, in addition to the release of 
DAMPs, cause microglia to become ‘primed’- they demonstrate an amplified response 
to systemic inflammation (Perry et al. 2010).  
Microglia priming occurs with age, but this simply means a higher probability of having 
been exposed to pesticides or head trauma, systemic diseases, repeated infection of 
the brain, or cellular dysfunction and abnormal deposition of protein in the extracellular 
matrix (Tansey and Goldberg 2010). This may cause a decreased production of 
neuroprotective molecules and hence a reduction of trophic support for neurons, and 
amplification of pro-inflammatory reaction to further stimuli. The resulting toxic 
environment might contribute to the development of brain diseases (Dilger and Johnson 
2008, Streit et al. 2009). One study using a triple transgenic mice model of AD found 
that repeated administration of LPS promoted neurofibrillary tangle formation (Kitazawa 
et al. 2005).  
Microglia from a diseased brain are more sensitive towards systemic challenges 
compared to a healthy control brain. Systemic inflammation that occurs in a setting of a 
brain disease has been found to exacerbate disease progression (Perry et al. 2010). 
This has been proven in both humans and animal models. An intracerebral challenge 
with LPS in a mouse model of prion disease resulted in a severe pro-inflammatory 
response, which brought on an exaggerated sickness behaviour and increased 
neuronal apoptosis (Cunningham et al. 2005). Similar results were observed in a mice 
model of PD (Pott Godoy et al. 2008).  
Delirium is a medical term used to describe an acute, fluctuating syndrome that is 
transient and reversible. Clinical features are divided into hypoactive- with lethargy, 
sedation and slow response time; and hyperactive -with agitation, restlessness, 
hallucinations and delusions; or mixed delirium, where patients exhibit both types of 
symptoms. It occurs at a higher rate, and accelerates cognitive decline in patients with 
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dementia. It can be caused by illness and infection, drug complication or surgery. We 
now know that in certain situations, delirium is not reversible, and can result in 
functional decline and permanent damage to the brain (Fong, Tulebaev and Inouye 
2009). Episodes of infection that do not result in delirium are also associated with an 
increased risk of developing dementia (Dunn et al. 2005).  
 
1.1.8 Differentiating between peripheral and parenchymal macrophages 
Resident microglia migrate into the CNS during embryogenesis and are long lived. 
Peripheral-derived macrophages, also known as blood-borned macrophages, are 
recently recruited from the blood, and exert very different functions compared to 
resident microglia (Simard and Rivest 2004). It is most crucial to be able to differentiate 
between them and their roles in both healthy and diseased brains.     
Resident and peripheral microglia/macrophages exhibit a variety of phenotypes. They 
can be distinguished by expression of markers, morphology, and function. While one 
can differentiate a quiescent ramified microglia easily from a rounded macrophage 
(Figure 1), it becomes virtually impossible to use morphology as a distinguishing factor 
between a macrophage, and an activated microglia assuming an amoeboid shape with 
shortened processes and a swelled soma.  
Microglia and peripheral macrophages also share many antigens, differing only in their 
levels of expression. No single marker is capable of distinguishing between the two; 
instead a combination of three to four of the following markers- CD68, CD45, CD11b, 
MHCII and CD14, can be utilized using flow cytometry to reliably separate the two 
populations (Guillemin and Brew 2004).   
Macrophages seem more adapt at phagocytosis compared to microglia. An example 
that demonstrates human macrophages’ capability for phagocytosis is during 
comorbidity of AD with stroke, where ! amyloid fibrils were found in the lysosomes of 
peripheral-derived macrophages. Microglia did not contain any A! (Wisniewski, 
Barcikowska and Kida 1991). Simard et al. 2006 also revealed that blood-derived 
microglia had the ability to phagocytose A! plaques efficiently and restrict their 
deposition in the ECM. This can be attributed to their phenotype flexibility by virtue of 
being located in the periphery and having a dynamic life cycle, while brain-resident 
microglia have a limited range of responses to preserve the fragile and vulnerable 
environment of the CNS (Gate et al. 2010). Despite their effectiveness at phagocytosis, 
blood-derived macrophages’ entry into the brain is probably restricted, with or without 
compromise of the BBB (Wenkel, Streilein and Young 2000, Soulet and Rivest 2008). 
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1.2 Alzheimer’s Disease 
 
1.2.1 Epidemiology of AD 
Alzheimer’s Disease (AD) is the leadng cause of dementia in a population with a rapidly 
increasing proportion of elderly, and the leading age-related neurodegenerative 
disorder.  
AD is a progressive disease that accelerates neuronal demise, leading to memory loss 
and decline of other cognitive domains. It first manifests by affecting episodic memory, 
eventually affecting other cognitive functions e.g. executive function, language, praxis, 
complex visual processing (Dubois et al. 2007). It is distinguished neuropathologically 
by extracellular aggregates of ! amyloid protein (A! plaques), along with intracellular 
inclusions of hyperphosphorylated tau e.g. neurofibillary tangles (NFT) or neuropil 
threads (NT), and marked gliosis.   
Incidence of AD increases exponentially with age, and reaches a peak around ages 70-
90. As of 2012, there are approximately 36 million people with dementia in the world, 
with 800 000 sufferers in the UK alone. North America and Western Europe take the 
lead in number of patients afflicted with dementia, followed by Latin America and China 
(Reitz, Brayne and Mayeux 2011). This figure was projected to reach 115 million 
worldwide by 2050. With such prevalence and no way for treatment, AD places an 
enormous strain on the public health system, making it imperative to find a cure, or a 
method to delay and prevent this devastating disease.  
Several factors are known to cause an increased propensity for AD, including 
cerebrovascular disease (Pendlebury and Rothwell 2009), blood pressure (Kivipelto et 
al. 2001a, Kivipelto et al. 2001b, Whitmer et al. 2005, Kalaria 2010, Deane, Wu and 
Zlokovic 2004), type 2 diabetes (Luchsinger et al. 2001, Ott et al. 1999), body weight 
(Whitmer et al. 2008, Gustafson et al. 2003), smoking (Cataldo and Glantz 2010), 
depression (Barnes et al. 2006), and traumatic brain injury (TBI) (Guo et al. 2000, 
Johnson, Stewart and Smith 2010, Plassman et al. 2000). Despite identifying these 
risks, the molecular mechanisms that underlie the etiology of AD remain vague. 
 
1.2.2 History of AD 
AD was first brought to attention when Alois Alzheimer, a German psychiatrist and 
neuropathologist received a 51-year-old patient exhibiting strange behaviour, including 
paranoia, aggression, progressive sleep and memory disturbance, and confusion. In 
1907, he brought forth his histological findings to the 37th meeting of South-West 
German Psychiatrists in Tubingen, describing an extracellular ‘peculiar material’ deposit 
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on the cortex and fibrils of ‘characteristic thickness and peculiar impregnability’ within 
cells (LaFerla, Green and Oddo 2007, Hippius and Neundorfer 2003).  
However, this discovery was not received well by the general and scientific community 
for the next five decades. The National Institute on Aging was established in 1974, but 
its research on AD did not generate enough scientific interest and consequently, 
funding. Only in the 1980s did the severity and scope of the disease gained recognition, 
and research networks and clinical trials were established in response. The histological 
data from Alois Alzheimer were also revealed to be what we now know are amyloid 
plaques and NFT respectively. 
 
1.2.3 Neuropathology of AD 
There are several gross changes that can be seen in a brain afflicted with AD, without 
looking under the microscope. These include atrophy of the hippocampus and the 
cerebral cortex, including the fronto-temporal association cortex, and a symmetrical 
dilation of the lateral ventricles (Perl 2010).  
While these visible changes might give an indication to the presence of AD, a definitive 
diagnosis can only be made when presence of neuritic A! plaques and NFT distributed 
in specific brain regions is observed. Other pathological changes also abound, including 
inflammation, oxidative stress and mitochondrial dysfunction (de la Monte and Wands 
2006, Gotz et al. 2008, Ferreiro et al. 2012). These changes begin early in life (10 to 20 
years before clinical symptoms), and are pervasive even in mildly demented individuals 
(Perrin, Fagan and Holtzman 2009, Jack et al. 2010).  
Though the correlation between moderate/severe AD neuropathology (plaques and 
tangles) and the occurrence of dementia is robust in patients below the age of 80, this 
association is attenuated when dealing with the oldest old (older than 95 years), with 
extensive overlap in the amount of neuropathological changes between those with and 
without dementia.  However, atrophy in the neocortex remains just as robust for 
differentiating between dementia and non-dementia sufferers throughout the ages 
(Knopman et al. 2003, Kril 2009).  
AD pathology, which includes toxic abnormal protein aggregates and inflammation, 
eventually culminates as neuronal and synaptic loss (Caselli et al. 2006). Not 
surprisingly, there is extensive synaptic loss in brains afflicted with AD, as observed by 
several groups using electron microscopy, stereological techniques, 
immunohistochemistry e.g. staining for synapsin 1, synaptopodin and synaptophysin, 
and MRI. The damage is more apparent in certain brain areas like the neocortex and 
the hippocampus, including frontal cortex (Reddy et al. 2005), temporal cortex (Scheff 
and Price 1993), molecular and granular layer of the hippocampal dentate gyrus 
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(Hamos, DeGennaro and Drachman 1989, Scheff, Sparks and Price 1996, Scheff and 
Price 1998), and the entorhinal cortex, CA1 and CA2, and subiculum (Rossler et al. 
2002, Mueller et al. 2010). Synaptic loss is highly associated, and may well be the best 
correlate with the severity of dementia (Clare et al. 2010). Neuronal loss in CA1 and the 
subiculum positively correlates with the formation of NFT and ghost tangles (Rossler et 
al. 2002).  
Certain neurons are more vulnerable to degeneration and death, including 
glutaminergic e.g. in the hippocampus, cholinergic e.g. in the basal forebrain, 
noradrenagic e.g. in the locus coerelus, dopaminergic e.g. in the striatum and 
serotonergic e.g. dorsal raphe nucleus (Mann, Yates and Hawkes 1982, Ouchi et al. 
2009, Chen et al. 2011, Holtzman, Morris and Goate 2011). Therapy directed at 
modification of these neurotransmitter systems may offer symptomatic relief.  
 
1.2.4 A!  plaques and APP 
1.2.4.1 Structure and properties of APP  
Amyloid precursor protein (APP) is highly expressed in the brain, especially by neurons 
(Holtzman et al. 2011). It is made up of a large extracellular region and a small 
cytoplasmic tail, with a transmembrane portion in between (Gralle and Ferreira 2007).   
APP is proposed to have a role in cell adhesion and migration due to its localisation to 
the plasma membrane (Sabo et al. 2001, Soba et al. 2005). Higher concentrations of 
APP are found in regions with more intensive synaptic modifications (Loffler and Huber 
1992), also influences synaptic formation and transmission, as observed in cultured 
mice neurons lacking APP (Priller et al. 2006). APP knockout mice exhibit behavioral 
deficits and decrease in spatial learning abilities (Ring et al. 2007).   
APP is naturally cleared from the brain either by proteolytic degradation, or via efflux 
into the periphery. This occurs by protein mediation e.g. low-density lipoprotein 
receptor-related protein-1 (Sagare et al. 2007) across the BBB, and also by drainage 
into the interstitial fluid (Lee and Landreth 2010).   
 
1.2.4.2 APP processing and formation of A! 
A! is mostly produced in the secretory pathway and at the plasma membrane, but also 
in the endoplasmic reticulum, Golgi bodies, and endosomal-lysosomal system (Gouras, 
Almeida and Takahashi 2005, LaFerla et al. 2007). Their physiological role is still under 
investigation, but it is most likely that they influence synaptic formation and function by 
depression of excitatory synaptic currents (Priller et al. 2006). A! is naturally cleared 
from the brain. This occurs via several pathways- namely receptor mediated clearance 
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and proteolytic degradation, as well as elimination into the periphery via active transport 
through the BBB, and drainage via interstitial fluid (Charidimou, Gang and Werring 
2012). 
There are three groups of enzymes involved in the processing of APP, namely "-, !-, 
and #-secretases. "-secretase activity has been narrowed down to three enzymes from 
the  ADAM (A disintegrin and metalloproteinase) family (Allinson et al. 2003). BACE (!-
site APP-cleaving enzyme 1) has been revealed as the sole contributor to the activity of 
!-secretase (Vassar et al. 1999). On the other hand, activity of #-Secretase relies on 4 
separate components, presenilin, nicastrin, anterior pharynx-defective 1 and presenilin 
enhancer 2 (Edbauer et al. 2003).  
The non-amyloidogenic pathway for APP processing involves "-Secretase, which 
activity serves to cleave APP within the A! domain, 83 amino acids from the carboxyl-
terminus (C-terminus). This produces a secreted form of amino-terminal (sAPP"), while 
precluding formation of A!. sAPP" has a neuroprotective function and is found to 
stimulate proliferation and increase neurite outgrowth (Milward et al. 1992, Mattson et 
al. 1993, Caille et al. 2004). The C-terminal is retained in the membrane before being 
cleaved by #-secretase to generate p3 (Haass et al. 1993, LaFerla et al. 2007).  
The amyloidogenic pathway involves !- and # -secretases. Cleavage from !-secretase 
(99 amino acids from the C-term of APP) produces sAPP! from the N-terminal, and a 
C-terminal (C99). C99 contains the A! sequence, with its N-terminal corresponding to 
the first amino acid of A!. The first 28 amino acids of A! come from the extracellular 
portion of APP, while amino acids 29-43 are acquired from within the membrane region. 
#-secretase then proceeds to cleave C99 to determine the length of A!, leaving behind 
A! intracellular cytoplasmic domain (Gotz and Ittner 2008). #-secretase can cleave at 
various sites of APP within the membrane region, with A!40 being the most common 
and A!42 (~10%) being the most fibrillogenic species due to two additional C-terminal 
hydrophobic amino acids (Yan et al. 2003, LaFerla et al. 2007). While A!42 are 
predisposed to form plaques, A!40 are more likely to be seen deposited in 
leptomeningeal and grey matter cortical blood vessels (Perl 2010). A!40 has been 
showed to be able to prevent aggregation of A!42 (Yan and Wang 2007).  
 
1.2.4.3 Structure and formation of A! plaques 
A!42 accumulates intraneuronally with increasing age. When observed with immuno-
gold electron microscopy in mice, the accumulation occurs within multivesicular bodies 
especially in synaptic compartments and distal processes (Gouras et al. 2005). 
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Monomeric A! has a tendency to aggregate into multimeric complexes- from low-weight 
oligomers to protofibrils and fibrils. While monomers are not known to be toxic and (both 
A!40 and A!42) actually exhibit neurotrophic effects at low nanomolar concentrations, 
oligomers have been proven to be most pathological of the A! species, compromising 
neuronal viability more than 10x that of fibrils and ~40x that of monomers (Dahlgren et 
al. 2002). Ranging from dimers to 24mers, oligomers disrupt long-term potentiation and 
synaptic function in rodent models, even before the development of plaques and NFT 
(Walsh et al. 2002, Oddo et al. 2003b, Cleary et al. 2005). They were also found to 
inhibit proteasome function, causing accumulation of A! and tau in transgenic mice 
(Tseng et al. 2008).  
There are several theories involving the formation of !-sheet conformations of A! from 
monomers. This is known to take place intracellularly, as verified by studies in 
transgenic mouse models (Oddo et al. 2006) and using human neuronal cells (Walsh et 
al. 2000). Though its formation process is still controversial, one hypothesis involves a 
straightforward nucleation process starting from monomers, that coalesce to form 
paranuclei, and then large oligomers followed by protofibrils, before the final fibril 
product. This is formed either by association of protofibrils, or by annealing of 
monomers and dimers to protofibril ends, thought to be an irreversible procedure 
(Walsh et al. 1997, Lomakin et al. 1997, Bitan et al. 2003). One concern about this 
theory is that the state of oligomers are might be stable enough to prevent spontaneous 
fibrillogenesis (Arimon et al. 2005).  
Diffuse plaques (Figure 4b) are amorphous aggregates of nonfibrillar A! peptides that 
do not contain dystrophic neurites. They do not stain for Congo red, faintly with 
thioflavin-S or thioflavin–T, but intensely with silver dyes (Patton et al. 2006). These 
plaques occur quite frequently in the elderly, and do not associate with cognitive 
impairment (Morris et al. 1996). Diffuse plaques are thought to evolve into neuritic 
plaques, which then become cored plaques (Sheng, Mrak and Griffin 1997b), though 
others believe they develop independently of each other.  
Neuritic plaques (Figure 4a) are characterized by a central core of !-pleated sheets 
arranged in radial spikes, and surrounded by a corona of astrocytic processes, and 
swollen and dystrophic neurites which are often axonal instead of dendritic. These 
neurites contain dense bodies and clusters of paired helical filaments (PHF). The beta-
pleated sheet that makes up these plaques confer its ability to bind to Congo red. 
Dense-cored plaques, also known as burnt out or end-stage plaques, consist of only a 
persistent condensed core of A!, and do not contain any neuritic or cellular components 
(Sheng et al. 1997b).  
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The fibrillar form of A! has notoriously been known for their pathological presence in 
AD (Walsh et al. 1999); another school of thought suggests that they are formed as a 
defense mechanism to collect soluble toxic A! into inert pools (Haass and Selkoe 
2007). A! plaques evoke microglia activation and production of IL-1! over time, causing 
chronic inflammation (White et al. 2005). However their presence are not known to 
correlate with dementia severity (Cortes-Canteli and Strickland 2009). A clinical trial 
involving immunization with A!42 was conducted by Elan Pharmaceuticals, 
demonstrating that although A! plaques might be cleared successfully, progression of 
neurodegeneration was neither halted nor delayed, even in patients with close to 
complete plaque removal. No improvement was observed in the rate of cognitive 
decline and survival times of patients (Holmes et al. 2008).  
       
1.2.4.4 Correlation to clinical symptoms 
PET imaging for [11C]PiB (Pittsburgh Compound B), cerebrospinal fluid (CSF) A!42 and 
autopsy studies all revealed extensive and widespread amounts of A! plaques in up to 
20-40% elderly who are cognitively intact. It is posit that this is an indication of MCI, and 
AD pathology starts one to two decades before the onset of clinical symptoms (Price 
and Morris 1999, Knopman et al. 2003, Mintun et al. 2006, Aizenstein et al. 2008). 
While A! plaque pathology does not seem to significantly impair cognitive function, CSF 
biomarkers might be a good indication for preclinical AD; there is a reduction of 
baseline CSF A!42 levels in patients with MCI who go on to develop AD 1-10 years later 
(Fagan et al. 2007, Buchhave et al. 2012).  
 
1.2.5 Cerebral amyloid angiopathy 
Cerebral amyloid angiopathy (CAA) is a common vessel disorder, affecting more than 
half of dementia sufferers, and over 90% of AD patients (Jellinger 2002). CAA was 
found to correlate significantly with the incidence of dementia, and has a compounding 
effect (together with other AD pathology) on cognitive function (Pfeifer et al. 2002). It is 
characterized by progressive A! deposition in blood vessels, mostly of A!40, and 
occurs more often in arterioles than capillaries, rarely affecting veins. It initially 
accumulates around the smooth muscle cells of the tunica media and tunica externa, 
but proceeds to completely enclose the vessel, along with loss of smooth muscle cells. 
Finally, dissociation of the vessel walls may occur, along with dyshoric changes, e.g. 
deposition of A! in the intermediate parenchyma (Attems et al. 2011). The most 
frequent and severe CAA is observed in the occipital lobe (Figure 4c & d), followed by 
the rest of the neocortical regions and the allocortex. The most advanced stages of 
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CAA would see the basal ganglia, thalamus and cerebellum being affected (Attems et 
al. 2007, Attems et al. 2011). Blood vessels in the white matter are usually spared. 
A! deposition in vessels is most probably caused by impairment in clearance of A! 
from the CNS via perivascular drainage. A! is released into the interstitial fluid, which 
drains out through the basement membranes of the capillaries and between smooth 
muscle cells of arteries. The drainage is aided by pulsations of the vessels, which 
causes A! to be trapped and deposited along the vessel walls when hindered, resulting 
in CAA (Preston et al. 2003, Weller et al. 2009). Increase risk of CAA can result from a 
higher ratio of A!40 to A!42, and the presence of ApoE alleles !2 and !4 (McGowan et 
al. 2005, Revesz et al. 2003).  
CAA has extremely adverse effects on the vasculature of the brain, including occlusion 
of lumen, atrophy of smooth muscle and endothelial cells, causing vessels to become 
weak and vulnerable to rupture and leakage (Charidimou et al. 2012). It is also known 
to be a risk factor for ischemic infarctions (Cadavid et al. 2000). CAA varies between 
cases, some with CAA only in leptomeningeal and cortical vessels, while others with 
CAA in capillaries as well (Thal et al. 2002). Only capillary CAA correlates with 
dementia and high Braak stages (Attems and Jellinger 2004). This might be due to the 
effects of capillary blockage, which is capable of impeding cerebral blood flow, as 
demonstrated in mice models (Thal et al. 2009).  
 
1.2.6 Tau pathology 
Another pathological hallmark of AD are neurofibrillary lesions, which consist mostly of 
aggregates of hyperphosphorylated tau (HP-tau). These aggregates usually take on the 
shape of the neurons they inhabit. They can be found as flame-shaped neurofibrillary 
tangles (NFT)- thick, parallel fibrils, surrounding the nucleus in the soma and extending 
into the apical dendrite in pyramidal neurons of the ammon’s horn of the hippocampus 
(Figure 5a); or globoid NFT made up of interweaving fibers in rounder neurons like 
those in the locus coerulus (LC) or nucleus basalis of Meynert (NBM). They also appear 
as neuropil threads in distal dendrites (Figure 5b), and as abnormal neurites in neuritic 
plaques. These fibrils are made up of paired helical filaments, each filament measuring 
10nm in diameter, with a periodicity of 80nm (Gotz et al. 2008, Perl 2010).  
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Figure 4. Abeta accumulation in AD 
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(A & B) A! plaques in the occipital cortex of AD cases. A neuritic plaque with a halo of dystrophic 
neurites around a central core, and a diffuse plaque with an amorphous form and absence of dystrophic 
neurites, are seen in the centre of images A and B respectively. (C) CAA in a meningeal vessel in the 
occipital lobe of an AD case. (D) CAA in a cortical vessel with dyshoric changes in the occipital lobe of 
an AD case. All images were taken at magnification x20. 
!
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Figure 5. Tau pathology in AD   
 
 
 
 
 
 
 
 
 
Neurofibrillary tangles (A) and neuropil threads (B) in the hippocampus of an AD case. Magnification 
x40. 
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Like A! plaques, thioflavin S, or silver dyes can be used to visualize NFT, which are 
mainly composed of !-pleated sheets. 
Tau is a 50-70 kDa protein that belongs to the microtubule (MT) associated protein 
(MAP) family. It is mainly localized to the axons under physiological conditions.  6 
isoforms of tau exist, differing by the number of inserts in the N-terminal region, and 
number of MT-binding repeat motifs in the C-terminal region (Lei et al. 2010). It has a 
role of stabilizing microtubules by binding to tubulin, and also contributes significantly to 
the regulation of axonal transport via interaction with motor proteins dynein and kinesin 
(Dixit et al. 2008). It has over 80 sites for phosphorylation, although the role of each 
distinct site remains to be solved (Hanger, Anderton and Noble 2009). An increase in 
phosphorylation reduces its affinity to bind to MT. HP-tau in AD is found to be 
phosphorylated to a greater extent, and at additional sites compared to tau in controls 
(Pritchard et al. 2011). HP-tau dissociates from MT and amasses in the somatodendritc 
compartment. They then undergo further phosphorylation, which predispose them to 
aggregation (Stoothoff and Johnson 2005, Spires-Jones et al. 2011).  
Similar to the new theories regarding toxicity of A!, soluble tau oligomers, instead of 
fibrils, are suspected to be responsible for causing neuronal dysfunction. HP-tau is 
hypothesized to destabilize the integrity of cytoskeletal network and hinder axonal 
transportation. HP-tau oligomers are seen in the prefrontal cortex of Braak stage 1 
patients before the onset of clinical symptoms, and may precede the formation of NFT 
(Maeda et al. 2007). As seen in mice bearing the non-mutant human tau gene, dying 
neurons did not contain NFT, while those bearing NFT maintained robust nuclear 
morphology (Andorfer et al. 2005). HP-tau is found to sequester normal tau, MAP1 and 
MAP2; polymerization into PHF is actually protective and minimizes its toxicity (Alonso 
2006). However, the area occupied by NFT would probably reach a saturation point, 
after which normal neuronal function would be affected, inevitably causing neuronal 
death (Spires-Jones et al. 2011, Alonso 2006). NFT, unlike neuritic A! plaques, are 
found to associate strongly with disease duration of AD and dementia severity 
(Arriagada et al. 1992, Bierer et al. 1995). Measurement of total and phosphorylated tau 
levels in the CSF give indication 3-4 years before the onset of MCI (Fagan et al. 2007).  
 
1.2.6.1 Staging of neurofibrillary pathology  
NFT are distributed in the brain of AD patients in a stereotypical pattern, with regions 
like CA1 of the hippocampus, layer II of the entorhinal cortex, and the neocortex 
developing severe tangle pathology (Perl 2010). Staging systems including the 
Consortium to Establish a Registry for AD (CERAD) strategy, Braak staging in 1991, 
! %"!
and the National Institutes of Health- Reagan (NIH-Reagan) criteria for 
neuropathological diagnosis of AD which combined both CERAD and Braak systems, 
had experimental setups based on thick sections, thioflavin S preparation or silver 
staining, and were not specific nor easily replicable (Alafuzoff et al. 2008a).   
A staging system has been developed by Braak and colleagues based on the temporal-
spatial distribution of hyperphosphorylated tau protein using an immunostain against 
AT8, and can be performed on paraffin-embedded sections of 5-15 µm, making it a very 
useful system that is easy to replicate.  
Braak’s staging system comprises of six stages. AT8-immunoreactivity is initially 
detected in the transentorhinal and entorhinal regions in stages 1 and 2, while stage 3 
sees the pathology spreading to the allocortex and fusifom and lingual gyri. It then 
extends into the middle temporal gyrus at stage 4. Finally, the pathology reaches the 
higher order association areas of the frontal, parietal, and occipital neocortex in stages 
5 and 6. The two final stages are differentiated by the expanding of pathology from the 
peristriate and parastriate areas into the striate area of the occipital cortex (Braak et al. 
2006).  
 
1.2.6.2 Relationship between A! and Tau pathology  
One theory suggests that tangles are formed as a reaction to the presence of plaques, 
resulting in synaptic and neuronal loss, and ultimately leading to dementia (Hardy and 
Selkoe 2002, Sommer 2002, Caselli et al. 2006). This is in agreement with the amyloid 
hypothesis, including A! pathology being an event upstream of tau pathology.  It has 
been shown in vivo using transgenic mice models that tau and A! seemed to be 
depend on each other to exert their neurotoxicity. In mice models expressing human 
APP, reduction of endogenous tau ameliorates A! induced behavioral deficits, while A! 
levels remain unchanged (Roberson et al. 2007). Tau pathology was worsened when 
coupled with the predilection for A! plaque formation (Gotz et al. 2008). One hypothesis 
on how this might occur is demonstrated using SH-SY5Y neuroblastoma cell system- 
tau and A! independently affect mitotic changes on a genetic level, resulting in aberrant 
cell cycle re-entry and apoptosis (Hoerndli et al. 2007). Another theory is that A! and 
tau have high binding affinity both in solution and in vivo using extracts of AD and 
control brains. They have been shown to aggregate intracellularly in the same neurons 
(Guo et al. 2006).  
Yet, neurodegeneration processes that cause A! plaques and NFT might not be directly 
related, as most A! plaques are observed in the temporal cortex, in comparison with 
NFT which occurs in the hippocampus (Valente et al. 2010). Tau pathology first starts in 
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the hippocampus and spreads to the cortical regions, while the opposition occurs for A! 
plaque deposition (Oddo et al. 2003a).   
Furthermore, mutations in the tau gene that result in autosomal dominant 
frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) show 
that A! plaque formation does not necessarily accompany NFT to cause neurological 
impairment (Hutton 2000). Other observations further disprove the amyloid hypothesis. 
For one, the presence of A! plaques is common to both AD and non-demented elderly, 
and the failure of A!42 immunization trials to allay disease progression (Holmes et al. 
2008) indicate that A! plaques might not be directly involved in the pathogenesis of AD 
(Maccioni et al. 2010).  
 
1.2.7 Causes of AD – Sporadic and Genetic 
The majority of AD cases is sporadic and has a late onset, i.e. before the age of 65. 
Approximately 5% of AD patients suffer from an earlier onset, i.e. around the third to 
fifth decades of their lives. It is essential to note that out of these early onset cases, 
only 20% (~1% of total AD population) have a familial disorder (Joshi et al. 2012). 
Though genetic defects probably contribute to cases with late onset, not many have 
been uncovered (Lambert and Amouyel 2007). More recently, APP and presenilin 
(PSEN) 1 mutations have also been found in late onset cases (Kauwe et al. 2007, 
Cruchaga et al. 2012).  
Familial AD is passed down via autosomal dominant transmission that involves 
mutation in one of these three genes: amyloid precursor protein (APP) (Goate et al. 
1991), PSEN 1 (Sherrington et al. 1995) and 2 (Levy-Lahad et al. 1995, Cruts et al. 
1998), located on chromosomes 21, 14 and 1 respectively.  
Attention was first drawn to APP mutations when Down syndrome individuals who are 
susceptible to early-onset AD had an extra copy of this gene in chromosome 21 
(Rocchi et al. 2003). APP mutations cause aberrant APP processing and early A! 
deposition (Miyoshi 2009), e.g. Swedish mutation at APP 670/671, in proximity to the !-
secretase cleavage site, causes elevated levels of soluble A! peptide (Johnston et al. 
1994); Flemish mutation at APP 692 increases the ratio of A!42 to the less fibrillogenic 
A!40, resulting in both presenile dementia and cerebral haemorrhage due to CAA 
(Haass et al. 1994), London mutation at APP 717 causes increased production of A!42 
by more than two folds (Suzuki et al. 1994).  
PSEN mutations cause an increase in the ratio of A!42 to A!40. PSEN1 is known to act 
as a co-factor for #-secretase (Edbauer et al. 2003, Takasugi et al. 2003). #-secretase 
is involved in the cleavage of APP to form A! of varying lengths, and mutations 
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increase A!42 production, leading to increased propensity for aggregation and plaque 
formation (McGowan et al. 2005, Holtzman et al. 2011). It is difficult to target #-
secretase specifically using drugs, as it also cleaves other substrates e.g. Notch, which 
is involved in cell proliferation (Liu et al. 2011b); cognitive decline was worse in patients 
treated with an inhibitor Semagacestat compared to placebos in a clinical trial by Eli Lily 
and Elan (Schor 2011). In the past two years, a solution seemed to have arisen via the 
form of #-secretase modulators, that while optimizing the production of A! forms, does 
not affect cleavage with other usual substrates (Kounnas et al. 2010).  
An unusual type of plaque, also known as cotton wool plaques, is observed with several 
PSEN1 mutations. It differs from the usual plaques by being eosinophilic and unreactive 
to thioflavin S. It is formed from A!42, degenerated synapses, neuropils, but little or no 
amyloid fibrils (Houlden et al. 2000). This might indicate that pathogenesis of AD is 
mediated by A! in forms other than its fibril form, e.g. molecular or oligomeric form; in 
agreement with the absence of correlation between the amount of amyloid plaques and 
clinical symptoms or neuronal loss.  
Within the sporadic late-onset cases, dozens of polymorphisms have been found, but 
only apolipoprotein E (ApoE) variations pose as a substantial risk for developing AD, 
depending on the allele carried (Rocchi et al. 2003, Chen et al. 2012). ApoE has three 
major isoforms, !2, !3, and !4. While !2 allele is associated with the lowest risk of 
developing late onset AD, !4 carriers have the highest risk (~3x for heterozygotes, ~12x 
for homozygotes) and a younger onset age (~5 years per !4 allele), effecting in a dose-
dependant manner (Corder et al. 1994, Holtzman et al. 2011); !3 being the most 
frequent and considered neutral (Corbo and Scacchi 1999). !4 homozygotes suffering 
from AD also have the fastest rate of cognitive decline when compared with all other 
allele groups (!3/4, !3/3, !2/3) (Craft et al. 1998). However, only 20% of sporadic AD 
cases actually carry the ApoE $4 allele, and individuals positive for $4 might not go on 
to develop AD (Williamson, Goldman and Marder 2009).   
APOE is a plasma glycoprotein containing 299 amino acids, and is synthesized by 
neurons, glia cells, macrophages and monocytes (Siest et al. 1995). It has many 
functions including transportation of cholesterol during neuronal growth and 
regeneration after injury (Mahley 1988). APOE receptors belong to a low-density 
lipoprotein receptor family, and have a direct influence on the production and cellular 
uptake of A! (Bu, Cam and Zerbinatti 2006). Individuals with !4 alleles were found to 
have more neuritic plaques and higher frequency of CAA (Olichney et al. 1996, Morris 
et al. 2010). Effect of !4 on quantity of amyloid deposition was further confirmed to 
exceed that of !3 via transgenic mice models that were humanized for pathogenic APP 
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and APOE !3 or !4 genes (Holtzman et al. 2000). Unlike !3, !4 does not bind to tau in 
vitro, and accumulation of phosphorylated tau was a great deal more abundant in mice 
with !4 genes than !3 genes, raising the possibility that !4 might be less neurotrophic 
and does not confer as much protection against phosphorylation of tau and formation of 
NFT (Brecht et al. 2004, Strittmatter et al. 1994).   
 
1.2.8 Clinical criteria and ratings for AD and dementia  
Current criteria for diagnosis of AD was established in 1984 by the National Institute of 
Neurological Communicative Disorders and Stroke/Alzheimer’s Disease and AD 
requires dementia with deficits in at least 2 cognitive domains, insidious progression, 
onset ages between 40-90, and absence of other brain or systemic diseases that might 
explain the symptoms. A definite diagnosis of AD is only made upon histological 
confirmation (McKhann et al. 1984). Another set of criteria is based on the Diagnostic 
and Statistical Manual of Mental Disorders, fourth edition (DSM-IV-TR). It involves the 
presence of a memory disorder and cognitive impairment that interferes with social 
functioning and activities of daily living (ADL), and disturbance in at least one additional 
cognitive domain, excluding causes by any other neurologic, psychiatric, substance-
induced or systemic diseases (Laboratories).  
At around the same time, CERAD also developed a battery of assessments for the 
diagnosis of AD, with the aim to provide a standard and reliable method that will 
facilitate comparison.  This included protocols for clinical profile, neuropsychology, 
neuropathology, family history assessment, and a behaviour rating scale for dementia 
(Fillenbaum et al. 2008).  
Alzheimer’s Association and National Institute on Aging recently proposed changes to 
the guidelines based on the advancement in technology and the capability to identify 
and differentiate AD from other diseases early on in the disease course. These 
technologies include functional neuroimaging techniques like PET (positron emission 
tomography) imaging, SPECT (single-photon emission computed tomography), and 
MRI (magnetic resonance imaging).  
A few staging systems are available for rating dementia severity from normal aging 
through to dementia. They include mini-mental state examination (MMSE), clinical 
dementia rating (CDR), and global deterioration scale (GDS). Correlations between 
CDR and GDS, with MMSE were high, but there was slight discrepancy especially in 
the early stages involving mild cognitive impairment (Choi et al. 2003, Perneczky et al. 
2006).  
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1.3 Neuroinflammation in Alzheimer’s Disease 
Inflammation is a prominent feature of AD, with the association of activated microglia 
with A! plaques providing strong evidence. Inflammation in AD is chronic- it starts even 
before the onset of AD symptoms, and is thought to be a driving force in acceleration of 
neuronal demise (Walker et al. 2006). Levels of inflammation correlate with synaptic 
loss and presence of NFT and A! plaques (Lue et al. 1996).  
The classic view of inflammation in AD is that of a self-perpetuating cycle- microglia can 
become activated by triggers including toxic aggregates of protein, neuronal death, 
oxidative stress, head trauma, systemic infections and damage signals etc, resulting in 
an overproduction of pro-inflammatory and neurotoxic factors, leading to neuronal 
dysfunction and death (Fernandez et al. 2008, Maccioni et al. 2010).  
Treatment with NSAIDs has also been shown to reduce/delay the development of AD, 
which further supports the theory that inflammation plays an important role in the 
pathogenesis of the disease (Etminan 2003).   
 
1.3.1 Relationship between microglia and A!   
Microglia are associated very closely with extracellular A! plaques, both neuritic and 
diffuse (Sheng et al. 1997b). A! plaques attract microglia, which can be seen from their 
graded concentration with respect to their proximity from the plaques. In response to A! 
plaques, both post mortem samples and experimental murine microglia have been 
shown to increase expression of pro-inflammatory cytokines e.g.  
surrounding neurons (Akiyama et al. 2000, Lue et al. 2001, Yan et al. 2003, Colton et 
al. 2006).   
In vitro studies using both human and rodent microglia show activation by fibrillar and 
oligomeric A! to release pro-inflammatory cytokines, chemokines, matrix 
metalloproteinases (MMP) and ROS (Maezawa et al. 2011, Li et al. 2013). This was not 
accompanied by an increase in phagocytic markers (Walker et al. 2006). In fact, 
evidence points to the suppression of phagocytic capabilities of microglia with 
increasing pro-inflammatory stimulation (Koenigsknecht-Talboo and Landreth 2005). 
Conversely, it was found that overexpression of IL-6, a pro-inflammatory cytokine found 
in enhanced levels in AD patients, increased microglia’s uptake of A! in vitro, and 
attenuated A! deposition in AD mice models (Chakrabarty et al. 2010).  
Microglia can interact with A! plaques through many receptors including CD14, toll-like 
receptors (TLR)- TLR2, TLR4, and TLR6 (Reed-Geaghan et al. 2009), pattern 
recognition receptors (Salminen et al. 2009), and a multi-component receptor complex 
made up of CD36, scavenger receptor A, CD47 and "6!1 intergrin (Bamberger et al. 
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2003). Binding of fibrillar A! to CD36 have been shown to induce a classical activation 
state, releasing cytokines, chemokines, ROS, and stimulating cell migration (El Khoury 
et al. 2003).  
Although microglia express receptors for A!, microglia still cannot clear A! plaques 
efficiently (Koenigsknecht and Landreth 2004). No immunoreactive A! has been 
detected within microglia in vivo, which might be due to immediate processing and 
degradation, or their inability at phagocytosing these A! plaques (Malm et al. 2008). 
The immune system in AD patients has been found to be defective in the clearance of 
A! plaques compared to controls. Monocytes from controls were able to phagocytose 
plaques from AD patients, while those from AD clearly demonstrated defective 
clearance ability, including downregulated TLR expression (Fiala et al. 2007). 
Macrophages from AD patients were also more susceptible to apoptosis upon exposure 
to soluble, protofibrillar, and fibrillar A! (Zaghi et al. 2009). One culprit that might 
prevent macrophages from recognizing A! plaques, as well as NFT, is serum amyloid 
P, which also prevents efficient proteolysis (Tennent, Lovat and Pepys 1995). The 
insoluble nature and persistence of these plaques are thought to cause an ongoing 
chronic inflammation in AD. 
Naturally occurring anti-A! antibodies also exist in the blood and CSF of both AD and 
controls. They are found to be neuroprotective (Britschgi et al. 2009, Deleidi and 
Maetzler 2012). The levels of these antibodies are reduced in the sera of AD patients 
compared to healthy individuals (Weksler et al. 2002).  
In a study with hAPP transgenic mice, ganciclovir application caused nearly complete 
microglia ablation, but this did not affect plaque formation and maintenance, nor plaque 
associated neural dystrophy (Weksler et al. 2002). This provides further evidence for 
microglia being inept at fibrillar A! clearance; and despite their association with a pro-
inflammatory and neurotoxic reaction, microglia might not be involved in A!-driven 
neurotoxicity.  
 
1.3.2 Relationship between microglia and neurofibrillary pathology 
Using Ricinus communis agglutinin-1 to label microglia, Sheffield et al. found a 
correlation between the density of microglia with the frequency and distribution of NFT 
(Sheffield, Marquis and Berman 2000). Tangle maturation stages from granular 
perikaryal tau reactivity to neuronal inclusions and finally ghost tangles, also show 
positive association with the frequency of IL-1" positive microglia (Sheng, Mrak and 
Griffin 1997a).  The idea that microglia are driving or sustaining NFT formation has 
been proposed (Mrak 2012).  
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In line with the tau hypothesis of AD, it has been postulated that pro-inflammatory 
cytokines released by microglia cause signaling cascades in neurons- both TNF" and 
IL-6 act to induce cell cycle entry without proliferation. This causes dysfunction of the 
enzymes involved in tau phosphorylations, e.g. kinases and phosphates, leading to 
hyperphosphorylation and aggregation of tau into toxic oligomers and fibrillar tangles 
(Morales, Farias and Maccioni 2010). The toxicity brought about by pathological tau 
aggregates brings about additional neuronal degeneration and death that further 
activates microglia, resulting in a feedback loop (Maccioni et al. 2010).  
 
1.3.3 Alternative activation in AD 
Although A! is known to elicit a pro-inflammatory reaction from classically activated 
microglia, its binding to A! receptors on microglia can also induce an alternative 
activation state, resulting in a heterogenous mix of pro and anti-inflammatory behavior 
(Colton 2009). Colton et al. found higher expression levels of alternative activation 
genes e.g. arginase 1 and chitinase 3-like 1, higher levels of TNF", but similar levels of 
NOS2 and IL-1! in AD compared to age-matched controls (Colton et al. 2006). In a 
mouse model of AD, microglia around A! plaques expressed high levels of Ym-1, the 
mouse homolog for chitinase 3-like 1 in humans that serves as an alternative activation 
marker (Jimenez et al., 2008).  
The reasoning behind co-existence of microglia’s multiple activation states can be 
attributed to chronic inflammation in AD. Classical activation of microglia serves to 
remove and limit the amount of A! plaques. As mentioned in the earlier section, this is 
not done efficiently, and A!’s persistence in the extracellular environment would 
probably result in an excessive pro-inflammatory reaction. In order to prevent too much 
damage done to the surrounding neurons, microglia also need to assume a partial 
immunosuppressive and reparative phenotype (Colton 2009).  
It has been shown that the four major cytokines associated with alternative activation of 
microglia- IL-4, IL-10, IL-13, and TGF! enhanced microglial uptake of fibrillar A!. While 
pro-inflammatory factors like TNF", IL-1!, CD40L and IFN# suppress its phagocytosis, 
this can be restored by anti-inflammatory cytokines (Koenigsknecht-Talboo and 
Landreth 2005). TGF! and IL-10 have been found at high levels in AD patients 
compared with controls (Parachikova et al. 2007). However, the presence of TGF! 
might not be beneficial in AD patients. It was found that genetic blockade of TGF! 
drastically reduced the amount of A! plaques and helped improve behavioral and 
spatial working memory in mice models of AD (Town et al. 2008).  
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1.3.4 Treatment – Immunization in AD 
Immunization in both humans and mice models of AD have shown successful removal 
of A! plaques, but with rather different outcomes. Immunization, both passive and 
active, significantly reduces the amount of plaques and has been found to increase 
cognitive performance in mice (Schenk, Hagen and Seubert 2004).   
Clinical trials were carried out using AN-1792 + QS-21- A!1-42 and saponin adjuvant 
respectively. While phase 1 trials were tolerated well by patients, a larger-scaled phase 
II clinical trial with 300 treated individuals and 72 on placebo had to be halted due to 
development of aseptic meningoencephalitis in 18 vaccinated subjects (Patton et al. 
2006). While no significant improvement in cognitive function was found using 
psychometric tests, their z-score composite across the neuropsychological test battery 
favored antibody-responsive patients. In some of these antibody responders, the level 
of tau in the CSF was found to be significantly lower (Gilman et al. 2005).  
Immunization with AN-1792 enabled clearance of neuritic plaques, especially in parts of 
the neocortex, while remaining plaques were associated with microglia (Nicoll et al. 
2003). However, the amount of diffuse plaques and vascular amyloid deposits remain 
unchanged. Soluble levels of A! were also increased in both grey and white matter 
(Patton et al. 2006). This poses a risk as soluble amyloid are thought to be toxic, and 
for this reason were aggregated into inert fibrils in the first place (Lee et al. 2004). 
Soluble A! peptides can cause vasoconstriction, impair cerebral blood flow and inhibit 
angiogenesis (Iadecola 2003, Paris et al. 2004).   
ELISA techniques revealed no reduction in total A! levels in the brain, an indication that 
the rate of soluble A! removal from the brain is slow and ineffective. An increase in 
vascular amyloid deposition correlates with a decrease in the amount of neuritic plaque, 
and also causes further compromise of the BBB and impairing brain perfusion. The 
severity of CAA in vaccinated patients raises the possibility that A! was retained in the 
vasculature during egress from the brain, which might be caused by pre-existing 
obstruction of interstitial fluid drainage (Patton et al. 2006).  
 
1.3.5 Effect of NSAIDs on AD 
NSAIDs are used to provide analgesic and antipyretic effects. They act to inhibit COX2, 
and activate the PPAR-# pathway, which has an anti-inflammatory effect (Hirsch and 
Hunot 2009). Some NSAIDs also directly scavenge NO radicals from neurons, thus 
exerting a neuroprotective effect (Asanuma et al. 2001). A study by Koenigsknecht-
Talboo et al. 2005 used cell cultures to demonstrate that NSAIDs relieve the 
suppression of phagocytosis of fibrillar A! caused by pro-inflammatory cytokines. There 
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is conflicting evidence about their ability to reduce the risk of developing AD, or halt its 
progression. NSAIDs have been shown to decrease the risk of developing AD (Etminan 
2003, Vlad et al. 2008).  
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1.4 Parkinson Disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disease after 
AD, and the most common progressive neurodegenerative disease in the category of 
motor function disorders, with an onset around 65 years of age. Approximately 1% of 
the population above the age of 60 is afflicted by PD (Abou-Sleiman, Muqit and Wood 
2006, Probst, Bloch and Tolnay 2008), and there are around six million sufferers of PD 
worldwide (Litteljohn et al. 2010). While final stages of this multicentric disease often 
involve cognitive impairment, early and mid stages of PD are plagued by debilitating 
motor symptoms.  
Patients suffering from PD exhibit four cardinal symptoms known as TRAP- tremor, 
rigidity, akinesia and postural instability. Other motor symptoms include bradykinesia, 
freezing, and flexed posture (Jankovic 2008). They are not spared from non-motor 
dysfunctions, with the disease also affecting autonomic and cognitive functions 
(Langston 2006), many of which are observed even before the decline of motor 
functions e.g. hyposmia and other olfactory disturbances, sleep disorders, hypotension 
and psychological disturbances like anxiety and depression (Litteljohn et al. 2010).  
PD is diagnosed clinically by an asymmetrical onset of bradykinesia, rigidity, with 
resting tremor, and a sufficiently good response to dopaminergic (DA) treatments e.g. 
with levodopa (L-dopa), a DA precursor or DA agonists.  
 
1.4.1 Epidemiological aspects of PD 
PD affects ~0.3% of the world’s population. The number of PD patients is expected to 
double by 2050 (Schapira 2009). The incidence and prevalence of PD drastically 
increases with age after 60 years (Van Den Eeden et al. 2003), affecting up to 4% of 
those above 80 years of age (de Lau and Breteler 2006), but seem to declines in the 
oldest old group (90 years of age) (Driver et al. 2009). Approximately 5-10% of PD 
patients are young onset i.e. they become symptomatic before 40 years old (Vanitallie 
2008). The life expectancy and anticipated age at death for PD patients are lower 
compared to the general population, but the effect is even greater for patients with PD 
onset before 40 years of age (Ishihara et al. 2007). Both incidence and prevalence are 
higher in men than women (Van Den Eeden et al. 2003).  
Premorbid depression is observed more frequently in patients with PD than controls 
(Ishihara and Brayne 2006). Obesity (Hu et al. 2006), higher cholesterol levels (de Lau 
and Breteler 2006), and type 2 diabetes mellitus are risk factors for PD. Patients with 
diabetes are 1.85 times more likely to develop PD (Hu et al. 2007b). One hypothesis for 
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the increased risk of PD might be attributed to chronic metabolic stress (Vanitallie 
2008).   
Dietary and lifestyle also present as risk factors to the development of PD. Smoking has 
an inverse association with PD. A study by Thacker et al. 2007 found that smoking 
could decrease risk of PD by up to 60%, depending on the intensity and duration of 
smoking, and number of years before onset of PD. Cigarettes contain nicotine, which 
protects against nigrostriatal damage (Quik, Perez and Bordia 2012). Nicotine is 
capable of inhibiting "-syn fibril formation and stabilizes soluble oligomeric forms 
(Hong, Fink and Uversky 2009).  
Intake of coffee and tea is also associated with a decreased risk of PD (Hu et al. 
2007a). On the other hand, intake of dairy milk increases the risk of PD (Chen et al. 
2007). Milk’s effect on lowering uric acid levels might be one of the reasons for this 
observation, as uric acid is an neuroprotective antioxidant that has been found to lower 
the risk of developing PD (De Vera et al. 2008).  
 
1.4.2 History of PD 
James Parkinson first gave a clinically based description of this disease in 1817, in “An 
essay on the shaking palsy”. He goes on to define “shaking palsy” separately from 
“paralysis agitans”. Shaking palsy is a combination of resting tremor, lessened muscular 
power, abnormal truncal posture, and festinent, propulsive gait. He also illustrated six 
case reports. Charcot subsequently named the disease after him in the 19th century 
(Kempster, Hurwitz and Lees 2007).  
The cause of motor symptoms observed in PD was discovered in 1919 when it was 
found that patients suffered from cell loss in the substantia nigra. In 1957, the function 
of dopamine as a neurotransmitter was unveiled. Discovery of the severe loss of 
dopamine in the striatum of PD patients by Ehringer and Hornykiewicz in 1960 led to a 
treatment for the symptoms of PD. Trials administering L-dopa via intravenous therapy 
and oral intake were carried out simultaneously by Birkmayer and Barbeau respectively 
(Hornykiewicz 2006).  
 
1.4.3 Neurotransmitter Deficits in PD 
Extrapyrimidal deficits are evident in PD. These manifest when there is a loss of DA 
neurons in the SN pars compacta (SNpc) that project into the striatum, causing 
denervation via a loss of DA terminals, particularly in the dorsal and caudal putamen, 
leading to a depletion of dopamine (Lotharius and Brundin 2002). It is thought that 
dopamine depletion is responsible for the TRAP syndrome observed in PD patients 
(Farooqui and Farooqui 2011). There is a presymptomatic phase of about 6 years 
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between the start of DA neuron loss and the onset of visible motor symptoms, by which 
time there is a loss of ~50% of DA neurons in the SNpc, and ~70% reduction in 
dopamine levels in the basal ganglia (Schapira and Obeso 2006).  
To date, the most effective symptomatic treatment for PD is L-dopa, as its application 
allows almost completely alleviation of motor dysfunction. Unfortunately, chronic use 
can cause severe motor and psychiatric side effects, such as dyskinesia, dopamine 
dysregulation syndrome, and hallucinations (Teismann and Schulz 2004). Clinicians 
tend to use this drug only as a last resort.  
Many other regions of the brain are also affected, for instance the prefrontal cortex, LC, 
hippocampus, and striatum, causing a system-wide multi-neurotransmitter dysfunction 
that also affects autonomic, cognitive and psychological functions (Wolters and Braak 
2006, Kostic et al. 2010, Litteljohn et al. 2010). These neurotransmitter systems include 
mesocortical dopaminergic (ventral tegmental area), noradrenergic (LC), serotoninergic 
(dorsal raphe nuclei), cholinergic (NBM), and histaminergic (Probst et al. 2008, 
Schapira 2009). Regions outside the brain e.g. the olfactory bulb and mesenteric 
system, are also affected in PD (Hirsch 2009).  
 
1.4.4 Clinical aspects of PD  
There are a number of diagnostic tests for PD, although none of them are definitive. 
The only confirmation lies in an autopsy evaluation of the presence of Lewy Body 
pathology. UK Parkinson’s Disease Society Brain Bank and the National Institute of 
Neurological Disorders and Stroke have both developed diagnostic criteria for PD 
(Jankovic 2008).  
There are also a number of rating scales for measurement of impairment and disability. 
The Hoehn Yahr scale is a 5-point system that assesses disease progression, severity 
and disability, ranging from stage 0 (no symptoms) to stage 5 (severe disability). The 
Unified Parkinson’s Disease rating scale (UPDRS) is a 4 part multimodal system for 
assessing impairment and disability, and is most well established. It includes evaluation 
of motor examination, complications from therapy, activities of daily living, mentation, 
behaviour and mood (Ramaker et al. 2002).   
 
1.4.4.1 Motor deficits  
As mentioned in previously, clinical features of tremor, rigidity, akinesia and postural 
instability are characteristic of PD. In this section, they will be elaborated in greater 
detail.  
Bradykinesia is an easily recognizable trait that is most characteristic of PD. It affects 
movement planning, initiation and execution, and manifests as slowness in movement 
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and reaction time, and performing repetitive sequential and simultaneous movements 
(Berardelli et al. 2001). Bradykinesia is associated with DA deficiency in areas including 
the striatum, specifically the putamen, globus pallidus and accumbens-caudate 
complex (Lozza, Marie and Baron 2002), and the motor cortex (Turner et al. 2003, 
Jankovic 2008).  
Rest tremor is the most common feature of PD, affecting ~70% of PD patients at 
disease onset, and can be mistaken for essential tremor. It has a frequency of 4-6 Hz, 
starts off unilateral, rarely involves the lower limbs, and is characteristically displayed by 
a supination-pronation, or “pill-rolling” tremor involving the thumb and forefinger. Tremor 
can be confined to one limb or one side for many years, before progressing to the 
proximal joints of the same limb, and involving the other upper limb or ipsilateral lower 
limb (Factor 2002). It was found that PD patients without tremor had a sparing of the A8 
neurons in the midbrain (Jankovic 2008). Tremor dominant PD has the slowest rate of 
neurodegenerative decline (Schapira 2008). Within SNpc, the ventrolateral part is 
severely affected in akinetic-rigid dominant PD, but is less affected in tremor dominant 
form. This is reversed for the medial part of SNpc (Probst et al. 2008).  
Rigidity is caused by increased muscle tone, resulting in resistance to passive 
movement, and can be sustained or intermittent and ratchetty, especially when coupled 
with tremor. Rigidity is usually asymmetrical during initial stages of PD, but progresses 
to affect the whole body to cause a “flexed posture” (Factor 2002). While disruption in 
the activity of the motor cortex and basal ganglia is thought to cause bradykinesia, the 
basis for rigidity and tremor is linked to DA cell loss in the nigrostriatal system (Jankovic 
2008, Schulz-Schaeffer 2010).  
Postural instability and gait disturbances (PIGD), caused by a loss of postural reflexes, 
sets in during the later stages of PD, usually 9 years after its onset. This latency period 
distinguishes PD from other parkinsonism disorders, e.g. ~1 year for progressive 
supranuclear palsy and ~3 years for multiple system atrophy (Wenning et al. 1999). 
Impairment of postural reflexes is a major cause of frequent falls and bone fractures 
(Williams, Watt and Lees 2006).  
 
1.4.4.2 Non-motor Symptoms  
Non-motor symptoms (NMS) are prevalent, yet underrecognized among sufferers of 
PD.  Efforts have been made to increase understanding in this field, including a 
systemic review by Chaudhuri et al. in 2006. The prevalence of NMS increases from 
21% at the initial diagnosis, to 88% after 7 years of follow up (Bonnet et al. 2012). While 
NMS can precede the onset of motor symptoms, they coexist with, and even surpass 
the disabling features of motor dysfunction during late stages of the disease. The cause 
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of NMS is not just isolated to depletion of dopamine, but involves a network of 
malfunctioning neurotransmitter systems. These symptoms include sleep disorders, 
sensory, autonomic and gastrointestinal symptoms, and neuropsychiatric dysfunction, 
which will be covered in the following chapters (Chaudhuri et al. 2006).  
 
1.4.4.3 Dementia  
A study by the Sydney Multicentre study of PD found that approximately 80% of PD 
patients exhibited cognitive decline, with half of them meeting the criteria for dementia 
after 15 years (Hely et al. 2005). Dementia is able to predict mortality risk in PD 
patients. The mortality risk for PD with dementia (PDD) cases is almost double that of 
non-demented PD cases (Louis et al. 1997, Levy et al. 2002).  
Several risk factors in PD have been found to cause a predilection for dementia. These 
include older age at disease onset and a longer duration of the disease (Bonnet et al. 
2012). Patients with symptoms of rigidity and PIGD usually suffer from a rapid cognitive 
decline. PIGD-dominant subtype, but not tremor-dominant subtype, is found to have a 
much higher risk of developing dementia (Alves et al. 2006). Other cognitive symptoms 
like posterior cortically based deficits (Williams-Gray et al. 2007),visual hallucinations 
(Aarsland et al. 2003), and apathy (Pedersen et al. 2009) were also found to associate 
with an increased risk of dementia.  
Dementia in PD differs from AD in several aspects. Attention deficit, executive 
dysfunction, visuo-perceptual and visuo-spatial processing is more pronounced in PDD 
than AD patients, while language functions, visual recognition and verbal memory are 
impaired to a lesser extent than AD. These differences are most prominent during the 
early and mid stages of dementia, while there is a large overlap of impairment across 
the cognitive domains in late stages (Emre et al. 2007).  
The pathophysiology of dementia in PD can be partly attributed to monoaminergic and 
cholinergic deficit, causing a “subcortical dementia” that differs from the dementia of 
AD. The demise of neurons in the basal forebrain causes a loss of cholinergic input into 
the cortex (Whitehouse et al. 1983). Lewy Bodies (LB) were found to be extensive in 
the cortex of PDD patients as opposed to non-demented PD patients (Hurtig et al. 
2000), and density of LB and Lewy neurites (LN) in the limbic regions-including CA2-3 
of the hippocampus, the transentorhinal cortex and amygdala were statistically higher in 
PDD than PD patients (Churchyard and Lees 1997).  
 
1.4.4.4 Anxiety and Depression 
Anxiety and depression are common non-motor symptoms in PD. Both disorders 
indicate an increased risk of developing PD, and are thought to be an early 
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manifestation of the disease (Bonnet et al. 2012). This corresponds with the Braak 
staging system for PD, which specifies the degradation of neurons in the dorsal raphe 
nuclei (DRN) and dorsal motor vagus nerve (DMV) before that of DA neurons in the SN. 
Anxiety and depression do not correlate with cognitive decline or severity of motor 
dysfunction (Eskow Jaunarajs et al. 2011).  
Anxiety is found in ~20% of PD patients (Nuti et al. 2004). PD patients are twice as 
susceptible to anxiety compared to the rest of the population. Anxiety can further 
aggravate motor and cognitive dysfunction already present in PD. Subtypes include 
generalized anxiety, panic disorder, social and other phobias (Bonnet et al. 2012).  
Depression is most impactful on patients’ quality of life (Schrag 2006), and can affect 
up to 45% of PD patients (Lemke 2008). Depression can precede motor symptoms, but 
can occur any time during the disease course. It consists of major and minor depressive 
disorder and dysthymia. Diagnosing depression comes as a challenge as its symptoms 
might be a psychological consequence of PD. However, PD patients with depression do 
not usually exhibit guilt, feelings of failure, nor suicidal tendencies (Costa et al. 2012).   
The neurotransmitter systems thought to be involved in depression and anxiety include 
noradrenaline in the LC, dopamine in mesocortical and mesolimbic pathways, and 
serotonin in the DRN. PET imaging shows diminished noradrenergic activity in the LC 
and thalamus of both depressed and/or anxious patients (Remy et al. 2005). Neuronal 
loss and gliosis in the LC was 7 times greater in PD with depression than those without 
depression (Frisina, Haroutunian and Libow 2009). PET imaging also demonstrated 
dopamine deficiency in the putamen of depressed PD patients (Remy et al. 2005). PET 
studies on serotonergic function by assessing availability of serotonin transporter 5-HTT 
found higher 5-HTT binding in the amygdala, hypothalamus, caudal raphe nuclei, and 
posterior cingulate cortex, indicating lower serotonin levels (Politis et al. 2010).  
 
1.4.4.5 Psychosis 
Definition of psychosis includes hallucinations and/or delusions in patients with a clear 
sensorium. It can only be assessed by questioning the patient. Late onset PD, DA 
therapies, older age, REM sleep disorders and cognitive impairment are some 
examples that can cause an increased risk of psychosis. Incidence and prevalence of 
hallucinations are eight out of a hundred, and 46% respectively (Fenelon et al. 2000, 
Forsaa et al. 2010). Psychosis usually occurs in PD patients due to PD medications, 
and this factor can be used to differentiate between PD and dementia with lewy bodies 
(DLB) during diagnosis, as visual hallucinations are a core feature of DLB, regardless of 
treatment (McKeith et al. 2005).  
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Hallucinations can be differentiated into two types. Benign hallucinations are mostly 
well tolerated and typically do not require treatment. Most hallucinations are visual, 
while auditory, tactile or olfactory ones are less common. The other group exhibits 
complex psychotic symptoms that involve elaborated hallucinations and persecutory 
delusions that are usually disabling (Marsh et al. 2004, Fenelon and Alves 2010).  
Most hallucinations are induced by PD drugs, and improvement can be seen with 
reduction of drug intake. These drugs include L-dopa, dopamine agonists, monoamine 
oxidase inhibitors, and anticholinergics. The DA medications might act to overstimulate 
dopamine receptors in the frontal and limbic regions, interfere with GABAergic neurons 
and upset the balance of dopamine and serotonin levels (Wolters 1999, Wolters 2001).   
 
1.4.5 Neuropathology of PD 
The histopathological hallmark of PD are alpha-synuclein (!-syn) inclusions throughout 
the central and peripheral nervous system, and are found in the cell bodies and axons 
of neurons as LB and LN respectively.  
Many aberrant neurochemical pathways have been implicated in PD, e.g. inflammation, 
dysfunction of mitochondria, oxidative stress and increased production of ROS and NO, 
excitotoxicity, protein modification e.g. phosphorylation, and degradation e.g. ubiquitin-
proteosome system, and toxicity of misfolded protein aggregates (Riederer et al. 2008, 
Hirsch and Hunot 2009, Farooqui and Farooqui 2011).  
 
1.4.6 Neuronal loss in PD 
Neuronal loss is prominent in the SN, and the loss of pigmented DA neurons is obvious 
even to the naked eye. However loss of neurons in other areas of the brain is found to 
be variable (Halliday et al. 2011). Neuronal loss is associated with selective brain 
regions where LB and LN are present, e.g. the SN, LC, DRN, NBM and DMV (Dickson 
et al. 2009).  
 
1.4.7 Lewy inclusions and "-synuclein  
LB are round eosinophilic inclusions (Figure 6) found in the soma of neurons of PD 
patients, and are required for definitive diagnosis of PD. Similar inclusions can also be 
found in neurites, and are called LN. LB are also found in the brains of non-PD, non-
demented elderly (Parkkinen et al. 2001, Parkkinen et al. 2005). There are two types of 
LB, classical LB displaying a dense hyaline core and a pale periphery under light 
microscope, and cortical LB that are less well defined, lacking a distinct core and halo, 
and are less dense (Spillantini 1999). Pale bodies often accompany LB within the same 
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neuron, raising the possibility that they might be precursors to LB (Dale et al. 1992). 
The main component of LB is !-syn filaments measuring 200-600nm in length and 5-
10nm in diameter with a !-sheet structure. Mutations and multiplications of the !-syn 
gene (SNCA) that cause autosomal dominant PD lead to discovery of its abnormal 
deposition in sporadic PD (Polymeropoulos et al. 1997). Other constituents of LB 
include ubiquitin (Kuzuhara et al. 1988), heat-shock proteins (Auluck et al. 2002), 
synphilin-1 (Eyal et al. 2006) and tyrosine hydroxylase (Riederer et al. 2008). 
!-syn is transcribed from the SNCA gene found on chromosome 4q21, which consists 
of six exons, five of which are transcribed. There are three isoforms of !-syn, with the 
most focus placed on the longest (140 a.a.), most common isoform in the human brain 
(Xia et al. 2001). This particular isoform consists of three regions- an N-terminus with 
lipid binding properties, a hydrophobic non-amyloid component region in the center that 
is prone to aggregation, and an unfolded C-terminus that interacts with other proteins 
and has a chaperone function (Halliday and McCann 2008). The N terminal and central 
region have 5-7 repeats of the consensus sequence KTKEGV separated by repeats of 
5-8 amino acids, and resemble apolipoprotein-like-A2 helix. The N terminal is 
susceptible to genetic mutations (Spillantini and Goedert 2000, Halliday and McCann 
2008).   
In normal physiological conditions, !-syn is found in neuronal presynaptic terminals in 
close proximity to synaptic vesicles, half of which are associated with synaptic 
membranes, and the other half found in the cytosol. In the cytosol, !-syn maintains a 
soluble random coil formation, but changes its secondary structure to 83% "-helix upon 
binding to phospholipids. This binding domain is found in its amino-terminal (Davidson 
et al. 1998). !-syn is probably involved in the cycling of synaptic vesicle between the 
reserve pool via interaction with synapsin 1. When !-syn was depleted by antisense 
oligonucleotides in cultured neurons, reduction of synaptic vesicles in the distal reserve 
pool was observed (Murphy et al. 2000). !-syn is also found in non-neuronal cells like 
astrocytes and oligodendrocytes (Mori et al. 2002) and vascular endothelial and smooth 
muscle cells (Tamo et al. 2002).  
Oligomers of !-syn can aggregate to form !-pleated sheets called protofibrils, which 
then further aggregate into fibrils. A30P mutation retards the formation of fibrils from 
protofibrils, which first drew focus to the toxicity of protofibrils (Conway et al. 2000). 
Protofibrils were also observed in the brains of familial PD with SNCA triplication (Miller 
et al. 2004). These protofibrils are capable of forming pores and permeabilizing 
vesicles. While formation of protofibrils are further enhanced by A30P and A53T 
mutations, only A53T promotes fibril formation (Volles and Lansbury 2002). Ala30Pro 
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mutation eliminates monomeric !-syn ability to bind vesicles through creation of a 
structural kink, while Ala53Thr reduces its ability to interact with planar lipid membranes 
(Lotharius and Brundin 2002).  
LB are thought to be neuroprotective, while the !-syn protofibrils are cytotoxic. Hence, 
the process of aggregating protofibrils into inert fibrils, and finally sequestering them 
into LB, would aid the cell in limiting damage from toxicity (Tompkins and Hill 1997). 
However, it is only a matter of time that LB will hinder cellular functioning with the 
increasing amount of space it takes up within the cell (Lotharius and Brundin 2002). !-
syn found in LB is post-translationally modified, e.g. phosphorylation (Ser 87 and 129), 
nitration, truncation of carboxy terminal and ubiquitination. These modifications are 
thought to increase !-syn toxicity and susceptibility to aggregation (Tofaris and 
Spillantini 2005, Beyer and Ariza 2013).  
Vulnerability of SN DA neurons has been attributed to oxidative stress, increased iron 
levels (Hirsch 2009), dopamine metabolism and H2O2 production. Auto-oxidation of 
dopamine produces dopamine-quinone molecules, which increase the toxicity of 
protofibrils by inhibiting the formation of fibrils through the formation of covalent  
adducts with !-syn protofibrils (Conway et al. 2000). However, these vulnerabilities 
cannot explain the degeneration of non-DA neurons e.g. serotoninergic, 
catacholinergic, which are also prominent in PD. 
One hypothesis for the transmission of !-syn pathology is via a trans-synaptic spread. 
Patients who received foetal mesencephalic neurons as striatal transplant developed 
LB-like inclusion 11-13 years later in the grafted neurons (Kordower et al. 2008). This 
phenomenon was also observed in an !-syn transgenic mice model (Desplats et al. 
2009). Extracellular !-syn is taken up by neurons via endocytosis, which then seeds 
aggregates by recruiting endogenous !-syn (Hansen et al. 2011, Volpicelli-Daley et al. 
2011).  
No correlation was found between LB and clinical disease symptoms or cell loss, 
suggesting that PD spreads in a format not indicated by the presence of LB (Schulz-
Schaeffer 2010).  
 
 
 
 
 
 
 
 
! &*!
Figure 6. Lewy pathology in PD 
 
 
 
 
 
 
 
 
 
(A & B) Lewy bodies (arrows) and Lewy neurites (arrowheads) in the nucleus basalis of 
Meynert of a PD case. Magnification x40 
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1.4.8 Ubiquitin-proteosome system 
The ubiquitin-proteosome system (UPS) is essential for clearance of unwanted or 
damaged proteins; as such its dysfunction in PD has several consequences. The 
impaired degradation of proteins results in disruption of cellular processes that depend 
on the proper functioning of UPS, including the accumulation of !-syn (Lotharius and 
Brundin 2002). Defects in the 26/20S proteosome have been found in the SN of 
sporadic PD patients, which might cause protein accumulation, formation of LB and 
subsequent DA neuron cell death (McNaught and Jenner 2001). Binding of !-syn 
oligomers and filaments to this proteosome markedly inhibited its activity (Lindersson et 
al. 2004).   
Mutations in genes PARK2 and PARK5 are implicated in the ubiquitin-processing 
pathway. PARK2 encodes for parkin, a component of the E3 ubiquitin-ligating enzyme 
(Zhang et al. 2000), while PARK5 encodes for ubiquitin carboxy-terminal hydrolase L1, 
a deubiquitinating enzyme that recycles ubiquitin (Lotharius and Brundin 2002). 
Patients who are autosomal recessive for parkin mutation have an early onset and do 
not develop LB.  
 
1.4.9 Staging of Lewy related "-synuclein pathology 
Lewy pathology spread in a predictable topographical pattern in most cases, from the 
brainstem to limbic structures, and finally affecting the cerebral cortices. Lewy 
pathology first appears in the olfactory and medullary regions, and also in peripheral 
autonomic nervous system, including the gastrointestinal tract and enteric plexus, and 
autonomic nuclei in the spinal cord (Probst et al. 2008). Widespread cortical LB are 
found in end-stage PD, and these patients are afflicted with cognitive impairments 
(Tsuboi, Uchikado and Dickson 2007). Two most commonly utilized staging systems 
are the Braak’s staging and DLB consortium of LB pathology (Braak et al. 2003, 
McKeith et al. 2005).   
In 2003, Braak and colleagues developed a staging system using !-syn as a marker. 
Braak stages start from the DMV and olfactory bulb during stage 1, and moves up into 
the lower raphe nuclei, magnocellular reticular formation, and the LC in stage 2. Both 
these stages are asymptomatic in terms of motor dysfunction, but exhibit autonomic 
dysfunction. Stage 3 sees the infamous SN being affected, together with the onset of 
motor symptoms. The basal forebrain and amygdala also develop Lewy pathology. The 
pathology extends to the cortex in stage 4, affecting the temporal mesocortex and CA2 
of the hippocampus. By stage 5, Lewy inclusions are observed in the cingulate gyrus, 
insular cortex, and the temporal neocortex. The final stage of PD comes with Lewy 
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inclusions in the secondary and even primary fields of the neocortex (Braak et al. 
2006).   
An oversight of these two systems is the failure to include a subset of PD cases that 
have !-syn pathology that initially bypasses the brainstem and begins in the limbic 
system, specifically the amygdala. Hence, Leverenze et al has sought to resolve this 
problem by adding an amydala-predominant category (Leverenz et al. 2008). In 2009, 
BrainNet Europe (BNE) published a new staging system that combines both Braak and 
McKeith staging systems and incorporates the amygdala-predominant stage, in addition 
to brainstem, limbic, and neocortical-predominant types (Alafuzoff et al. 2009).   
While these staging systems suggest a stepwise progression of !-syn pathology in PD, 
incidental Lewy body disease tells a different story. Both central and peripheral nervous 
systems are concurrently affected by Lewy pathology even when there are no 
symptoms for PD, indicating the possibility that a multicentric spread of !-syn pathology 
might also be taking place (Dickson et al. 2008). Some cases of PD were also observed 
to have Lewy pathology in the neocortex before the brainstem and limbic system were 
involved (Beach et al. 2009).   
 
1.4.10 Causes of PD 
1.4.10.1 Genetic causes of PD 
Approximately 5-10% of PD cases are due to genetically inherited mutations, while the 
rest are idiopathic (Farooqui and Farooqui 2011). Genetic mutations give insight to 
aberrant proteins and pathways underlying the pathology of PD, and can be helpful in 
further defining the cause of PD. The PD-related genes are named PARK1-16, of which 
some of the better-known ones will be elaborated.  
Genes that cause autosomal dominant PD include PARK1/SNCA on chromosome 4q21 
that codes for !-syn, PARK3 on chromosome 2p13 of which gene product is still 
unknown, PARK5 found on chromosome 4q21 that codes for ubiquitin-C terminal 
hydrolase-L1 (UCH-L1), and PARK8 on chromosome 12 that codes for leucine-rich 
repeat kinase. Genes related to autosomal recessive PD include PARK2 on 
chromosome 6q25 coding for Parkin, PARK6 on 1p35-36 coding for PTEN-induced 
putative kinase 1 (PINK1), PARK7 and PARK9 on 1p36 that codes for DJ-1 and 
ATP13A2 protein respectively (Klein and Westenberger 2012).  
Mutations in Parkin, an E3 ubiquitin ligase, UCH-L1, and ATP13A2- a lysosomal 
ATPase, all indicate a faulty protein degradation pathway (Ramirez et al. 2006, 
Wirdefeldt et al. 2011). Mutations in PINK1, a mitochondrial kinase, and DJ-1 have 
been associated with mitochondrial dysfunction, and protecting against oxidative stress 
(Mitsumoto and Nakagawa 2001, Valente et al. 2004).   
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1.4.10.2 Toxins 
Both pesticides and metals have been linked to a higher risk of parkinsonism. However, 
it has been deemed by several groups that there is insufficient evidence to link 
pesticides exposure to PD (Li et al. 2005, Brown et al. 2006, Dick 2006). No association 
was found between metals and PD as well (Firestone et al. 2010, Wirdefeldt et al. 
2011).  
The most studied toxin models that result in parkinsonism include 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA). MPTP causes 
severe akinetic rigid syndrome when accidentally administered by a group of drug 
addicts, consistent with end-stage PD in a matter of days (Langston et al. 1983). It 
affects DA neurons of SNpc, but unlike in PD, those in the LC are spared (Forno et al. 
1986). No LB-like inclusions have been observed in human or animal models either 
(Teismann et al. 2003). Administration of 6-OHDA causes extensive depletions of 
dopamine and noradrenaline. Application of 6-OHDA to the SN immediately obliterates 
the DA neurons in the region, while application to the striatum results in a slower 
progressive degeneration in the SNpc (Teismann and Schulz 2004).  
Pesticides like paraquat and rotenone are chemically similar to MPTP (Litteljohn et al. 
2010) and can also cause parkinsonism. These pesticides produce a neuropathological 
profile that resembles idiopathic PD more than MPTP i.e. they cause LB-like neuronal 
inclusions of !-syn (Manning-Bog et al. 2002, Cannon et al. 2009). They also exert 
toxicity through microglia, by triggering the release of pro-inflammatory cytokines and 
causing oxidative damage through the activation of NADPH oxidase (Gao et al. 2003, 
Wu et al. 2005).  
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1.5 Neuroinflammation in Parkinson’s Disease 
Inflammation is thought to contribute significantly to the pathogenesis of PD. This is 
most evident in the SN of PD patients, where there is pronounced microglia activation, 
coupled with massive DA neuronal cell loss (Hirsch et al. 2003, Croisier et al. 2005). 
The midbrain of the rat contains 4.5 times more microglia compared to other brain 
regions (Kim et al. 2000). SNpc is predisposed to neurodegeneration in PD. This might 
be due to having a high density of microglia, as well as DA neurons’ susceptibility to 
oxidative stress (Qian and Flood 2008). Using PET scanning for activated microglia with 
marker [11C](R)-PK11195, Ouchi et al. found that microglial activation positively 
associates with DA terminal loss in the midbrain (Ouchi et al. 2005).   
An increase in oxidative stress mediators like COX-2 and iNOS, cytokines e.g. TNF", 
IL-1!, IL-2, IL-4, IL-6, TGF! and IFN#, and a decrease in neurotrophic factors like brain 
derived neurotrophic factor (BDNF) and NGF are observed in the nigrostriatal regions 
and in the cerebrospinal fluid of PD patients (Hunot et al. 1996, Mogi et al. 1996, Knott, 
Stern and Wilkin 2000, Nagatsu et al. 2000, Liu 2006). COX-2 increases production of 
dopamine-quinone, an oxidative product that is harmful to mitochondria (Teismann et 
al. 2003). The release of MMP-3 by apoptotic neurons further induces microglia to 
release TNF", IL-6 and IL-1! that activates the NF-kB pathway and exacerbate 
neuronal death (Kim et al. 2005). Increased expression of TNF-R1, B-cell lymphoma 2 
(bcl-2), and caspases 1 and 3 were also seen in the neurons of nigrostriatal regions 
(Mogi et al. 2000, Nagatsu et al. 2000).  
It is crucial to know that microglia activation is not restricted to the SN and striatum, but 
is widespread throughout the brain in PD. Activated microglia are also found in 
subcortical regions including the hippocampus, pons, striatum, pallidum and thalamus; 
as well as cortical regions including cingulate and precentral gyri, and frontal and 
temporal lobes. As revealed by PET imaging, microglia are activated even during early 
stages of PD, but do not correlate with disease progression and severity. Hence, the 
demise of DA neurons in the SN and striatum cannot be attributed to inflammation 
alone (Imamura et al. 2003, Gerhard et al. 2006).  
Along the lines of inflammation, NSAIDs are thought to exert a protective effect against 
PD based on their anti-inflammatory actions. Their effects have been largely debated. A 
meta-analysis showed that NSAIDS did not offer any neuroprotection, although 
ibuprofen had a slight effect of lowering the risk of PD (Samii et al. 2009).  
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1.5.1 Inflammation caused by "-synuclein 
!-syn is known to cause florid neuroinflammatory responses that trigger neuronal death 
(Tansey and Goldberg 2010). In a mouse model of PD, overexpression of human !-syn 
alone, without significant neurodegeneration, was sufficient to activate microglia, 
triggering a pro-inflammatory reaction and the gradual demise of DA neurons in the SN 
(Theodore et al. 2008). Inflammation in mice models engineered to express human or 
mutant !-syn resulted in aggregation of !-syn and neuronal death (Gao et al. 2008).  
There has been no evidence of intracellular aggregates of !-syn attracting nor 
triggering microglia activation (Rozemuller et al. 2000). Microglial activation defined by 
the expression of MHCII in the SN correlates positively with the amount of intracellular 
and extracellular !-syn deposits, but do not show any association with clinical severity 
or disease progression (Croisier et al. 2005).  
On the other hand, extracellular aggregates of !-syn are able to activate microglia. This 
happens when damaged DA neurons release !-syn into the extracellular environment. 
As demonstrated using murine cell cultures, neurotoxicity of !-syn is mediated by its 
phagocytosis and subsequent activation of microglia, leading to an increase in 
expression of NAPDH oxidase and production of superoxide and ROS (Zhang et al. 
2005).   
It has been suggested that microglia might be dysfunctional in PD, affecting their 
capacity for phagocytosis, which causes a buildup of excess of synuclein (Halliday and 
Stevens 2011). For example, activation of microglia with LPS in cell cultures slows the 
degradation of phagocytosed !-syn, resulting in accumulation of !-syn in cytoplasm of 
microglia (Lee et al. 2008).   
 
1.5.2 Inflammation caused by neuromelanin 
Extraneuronal neuromelanin (NM) deposits increase with pathological stages of PD, 
together with a gradual loss of melanized neurons (Braak et al. 2003). Phagocytes from 
the SN are also observed with NM. These NM pigments are derived from degenerated 
DA neurons. As one of the main functions of microglia is debris clearance, this freely 
accessible NM is most likely to attract and activate microglia (Croisier et al. 2005).   
NM is a pigment that exerts its neuroprotective role by chelating iron, and can be found 
in the DA neurons of the SN and LC (Sulzer et al. 2000, Farooqui and Farooqui 2011). 
The higher levels of iron in PD might saturate the iron-binding sites of NM, 
overwhelming its protective capacity. The interaction between hydrogen peroxide 
(H2O2) and ferrous iron can generate hydroxyl radicals via the Fenton reaction. Iron can 
also disrupt the ubiquitine-proteosome system in mitochondria, leading to a failure to 
eliminate and regulate the levels of !-syn (Gerlach, Riederer and Double 2008).  
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Injection of human NM into rat SN caused a strong, pervasive microglia reaction 
together with a significant loss of DA neurons (Zecca et al. 2008). NM is able to induce 
chemotaxis and production of TNF", IL-6, hydrogen peroxide, superoxide, and NO in 
murine microglia cultures via activation of NF-kB (Wilms et al. 2003, Zhang et al. 2011). 
An excess of NM in the extracellular matrix might ultimately lead to chronic 
inflammation (Ouchi et al. 2009). 
 
1.5.3 Oxidative Stress 
ROS is produced naturally as a by-product of metabolism. Oxidative stress occurs 
when there is insufficient scavenging of ROS and it overwhelms the antioxidant system, 
causing oxidative damage to proteins, lipids, and DNA. Microglia are able to detect and 
respond to neurodegeneration caused by oxidative stress, adopting a pro-inflammatory 
profile and releasing even more ROS, RNS and pro-inflammatory cytokines (Valko, 
Morris and Cronin 2005, Farooqui and Farooqui 2011).  
ROS are produced upon the breakdown of dopamine. This can happen spontaneously 
in the presence of iron, resulting in the production of toxic dopamine-quinone, 
superoxide anions, and H2O2. Dopamine can be broken down via catalysis by 
monoamine oxidase, which also generates H2O2. While H2O2 is not harmful by itself, it 
can be catalysed by iron into cytotoxic hydroxyl radicals via the Fenton reaction 
(Lotharius and Brundin 2002). Another enzyme that produces ROS is COX-2, which is 
increased in DA neurons of the SN of PD patients and in mice models of MPTP 
(Teismann et al. 2003). It is obvious that several factors predispose DA neurons to 
oxidative stress- elevation of iron due to its affinity with NM (Sofic et al. 1991), reduced 
levels of antioxidants e.g. peroxidase and glutathione due to a sustained oxidative 
stress burden (Sian et al. 1994), and oxidation of mitochondrial complex 1 that 
increases the risk of neuronal apoptosis (Perier et al. 2005, Keeney et al. 2006). 
Indeed, a higher frequency of lipid, protein, and DNA oxidation were observed in the SN 
of PD patients.  
Aside from DA neurons, other monoaminergic neurons that are affected in PD, e.g. 
noradrenaline and serotonin, are also prone to damage due to a high oxidative potential 
(Lotharius and Brundin 2002).  
 
1.5.4 Trophic support in PD 
Trophic factors have been considered a possible avenue for the protection of 
degenerating neurons, and a way to attenuate progression of PD. Some of them are 
produced by microglia, such as BDNF and glial-derived neurotrophic factor (GDNF). 
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BDNF are expressed at lower levels in the nigral melanised neurons of PD compared to 
control cases (Parain et al. 1999), and higher levels in the microglia surrounding 
fragmented nigral neurons (Knott et al. 2002). The lower number of BDNF-positive 
melanised neurons in PD might indicate that BDNF does not aid in neuronal survival, or 
that the lack of BDNF in nigral neurons results in a higher rate of cell death. 
Upregulation of BDNF in glia cells might be an attempt at providing neurotrophic 
support to the dying neurons (Knott et al. 2002). The latter is most likely the case as 
BDNF has been shown to increase survival rates of both mice and human fetal AD 
neurons using in vitro cell cultures (Zhou, Bradford and Stern 1994).  
GDNF also exerts neurotrophic effects. Similar to BDNF, it has been shown to support 
the survival of postnatal nigral DA neurons in cell cultures (Burke, Antonelli and Sulzer 
1998). Both BDNF and GDNF are able to induce DA fiber sprouting in a mice model of 
striatal injury (Batchelor et al. 1999). Intracerebroventricular injections of GDNF given to 
a 65-year-old PD patient had no effect on disease progression, nor was a reduction in 
loss of nigrostriatal neurons observed (Kordower et al. 1999). However, a later trial on 
five patients where GDNF was administered by continuous intraparenchymal infusion 
into the posterior putamen over 2 years resulted in an improvement in UPDRS scaling 
of the motor and activities of daily living, and health-related quality of life measure 
(Patel et al. 2005).  
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1.6 Traumatic brain injury 
Traumatic brain injury (TBI) is an alteration of brain function or pathology brought about 
by an external force (Menon et al. 2010). Causes of TBI include falls, motor vehicle 
accidents, assaults, sports-related events, and blast injury (Nolan 2005, Ling et al. 
2009, Mangat 2012). TBI is a major global health issue, with more than 10 million 
people affected every year (Hyder et al. 2007). This is especially relevant to the ageing 
population who are prone to falls and have the highest mortality rate linked to TBI 
(Rosenfeld et al. 2012).  
TBI can range from mild to severe, and this can be measured using the Glasgow Coma 
Scale, a neurological scale developed by Teasdale and Jennett from the University of 
Glasgow in 1974, and which is the most commonly used scale today. It is able to 
provide a reliable assessment of the conscious state of a patient between 3-8 for 
severe TBI, 9-12 for moderate TBI, and 13-15 for mild TBI (Smith, Meaney and Shull 
2003). While severe TBI usually results in death, survivors of TBI can go on to develop 
motor, cognitive and social disabilities (Moretti et al. 2012).  
 
1.6.1 Pathophysiology of TBI 
TBI refers to the original insult, but also evolves with time to cause further tissue 
damage. Injury can be classified as primary and secondary. The initial assault, also 
known as primary injury, directly damages the neuronal tissue and glial cells. Primary 
injuries can be further divided into focal and diffuse lesions based on pathology. 
Secondary injury arises as a normal physiological response to primary injury.  
The type of impact determines the mechanism of primary injuries. Mechanistic 
classification includes inertial loading injuries, impact, penetrating or blast injuries 
(Smith 2013). Acceleration-deceleration/ inertial injuries comprise of two types- linear 
acceleration, which is relatively well-tolerated, and rotational acceleration which is 
particularly damaging to the human brain (Cantu 1996). Impact injuries can be a result 
of motor vehicle crashes, falls, and assaults, and are the most common form of TBI. 
Penetrating injuries, including bullet wounds, are caused by a breach of the skull and 
entry into the brain with a sharp or blunt object. Blast injuries are a combination of both 
blunt and penetrating forces (Nolan 2005).  
Secondary injuries cause patients’ conditions to deteriorate even further. They should 
be anticipated and prevented by caregivers. These injuries can be caused by 
dysregulation of CSF resulting in increased intracranial pressure (ICP) (Hiler et al. 
2006), spreading depolarizations that result in a worse clinical outcome (Hartings et al. 
2011), ischaemia, hypoxia, haemorrhage, cerebral oedema, and systemic changes in 
haemodynamics and temperature (Nolan 2005).   
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Molecular processes can also contribute to secondary damage e.g. mitochondrial injury 
resulting in metabolic impairment (Coles et al. 2004), uncontrolled inflammation and 
oxidative stress (Deng-Bryant et al. 2008), ionic imbalance and excitotoxicity caused by 
excessive glutamate (Rosenfeld et al. 2012). The neuronal membrane defects triggered 
by primary injuries cause mechanical damage to voltage sensitive sodium channels, 
increasing the amount of sodium in the neuron. Through the reversal of the sodium-
calcium exchanger, and depolarization of voltage gated calcium channels, calcium level 
in the cell is increased (Smith, Hicks and Povlishock 2013). Calpain, a calcium activated 
protease, degrades the inactivation gate of sodium channels, causing a feed-forward 
process of increasing sodium influx, leading to a further rise in neuronal calcium levels 
(von Reyn et al. 2009). This in turn intensifies the release of glutamate, which binds to 
N-methyl-D-aspartate receptors to cause further depolarization and calcium influx 
(Barkhoudarian, Hovda and Giza 2011). Deregulation of calcium also causes 
microtubule disassembly and mitochondrial damage (Smith et al. 2013).  
 
1.6.2 Focal brain injury 
Focal brain injuries are localized and arise from impact forces. They include subdural 
and extradural haematomas (SDH and EDH), cerebral contusions with intracerebral 
haemorrhages (ICH) and traumatic subarachnoid haemorrhages (SAH) (Mangat 2012). 
As focal injuries arise from severe direct impacts, they are usually found in cases of 
severe TBI (Blennow, Hardy and Zetterberg 2012).  
EDH are located outside the dura mater and are caused by an arterial tear. SDH 
develop below the dura mater and are venous in nature. A contusion is a bruise to the 
brain tissue with multiple microhaemorrhages, caused by compression of the brain 
against the skull at the point of impact, and 180o from the point of impact. The frontal 
and temporal lobes are especially susceptible to contusions. Brain compression causes 
cerebral oedema, which may increase ICP, leading to secondary injury. ICH results 
from hypertension or gunshot wounds, and SAH from head injury or aneurysmal rupture 
(Nolan 2005).  
 
1.6.3 Diffuse brain injury 
Diffuse lesions differ from focal injuries in that they arise from inertial forces- shaking, 
shearing, in the absence of impact forces. Hence, it can occur in cases of mild TBI. 
Diffuse brain injuries can also result in secondary injury similar to that seen with focal 
injuries. Cerebral concussion and diffuse axonal injury (DAI) are the two main forms of 
diffuse brain injury (Nolan 2005). Long-term effects of diffuse brain injury can result in 
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prolonged microglia activation and increased susceptibility to AD. This will be covered 
in the following sections.  
Cerebral concussion is a temporary neurological dysfunction caused by a force to the 
brain that can be transmitted directly or indirectly from other parts of the body. It causes 
functional disturbance in the absence of a structural injury, and can range from mild to 
moderate. Mild concussions may cause dizziness, nausea, headaches, and attention, 
concentration and memory problems. Moderate concussions can involve loss of 
consciousness (McCrory et al. 2009). Patients are susceptible to transient symptoms 
after the trauma; this is referred to as post-concussion syndrome (Hall and Chapman 
2005).  
 
1.6.3.1 Diffuse Axonal Injury 
Rapid rotational motions distort the white matter and cause shearing of axons, resulting 
in DAI. DAI occurs in vulnerable regions in the brain- in deep and subcortical white 
matter especially in parasagittal white matter like the brainstem, corpus callosum, and 
internal capsule and thalamus (Smith et al. 2003, Smith et al. 2013). It disrupts cortical-
subcortical pathways and causes extensive neurological dysfunction (Moretti et al. 
2012). Mild TBI patients usually exhibit concentration and memory deficits, which might 
be a sign of DAI (Smith et al. 2003). Recently, a technique known as diffusion tensor 
imaging has been found to be effective in identifying DAI pathology (Mayer et al. 2010).  
After shearing of axons, axonal transport becomes disrupted and axonal bulb and/ or 
varicosities are observed. Axonal varicosities occur when transport is still intact, and 
slight disruption occurs at multiple sites along the axon. As for axonal bulb, the distal 
segment of the axon is disconnected from the soma via Wallerian degeneration due to 
a complete interruption of axonal transport, while the proximal segment may die due to 
lack of connection from other neurons (Tang-Schomer et al. 2012, Smith et al. 2013). 
These pathology can be observed even years after the initial TBI incident- an indication 
that degeneration of axons is progressive (Chen et al. 2009). Due to a loss of 
connections, neuronal loss distal from the injury site might occur (Neumann 2003). It is 
thought that axonal pathology most likely contributes to the development of AD in TBI 
patients (Johnson, Stewart and Smith 2012).  
APP is the benchmark for detection of DAI in standard neuropathological procedures. 
Normal levels of APP are not detected by immunohistochemistry. However after 
rupturing of axonal membranes, APP accumulates via anterograde axonal transport in 
damaged regions and becomes detectable (Gentleman et al. 1993).  
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1.6.4 Chronic Traumatic Encephalopathy 
Chronic traumatic encephalopathy (CTE) is observed in boxers and can be associated 
with other types of contact sports e.g. wrestling, hockey, rugby, etc. as well as military 
personnel prone to blast injuries. The effects range from a decline in attention, memory 
and concentration, disorientation, dizziness and headaches, to deafness, dementia, 
Parkinsonism, and behavioral changes (McKee et al. 2009). Pathological 
characteristics of CTE include cerebellar, hippocampal, and cortical atrophy, 
degradation of SN, cavum septum pellucidum, DAI, gliosis, and deposits of A!, NFT, 
and Tar DNA-binding protein-43 (Corsellis, Bruton and Freeman-Browne 1973, Orrison 
et al. 2009, Levin and Smith 2013).  
CTE is thought be a result of repeated mild TBI to the head. The initial concussion 
disturbs the cerebral physiology, and increases the susceptibility of the brain to further 
injury. Metabolic dysfunction and sodium channelopathy can both contribute to the 
increased vulnerability as well (Vagnozzi et al. 2008).  
 
1.6.5 Long-term effects of TBI 
The progressive nature of TBI, especially DAI, is thought to cause a predilection to the 
development of neurodegenerative diseases. Long-term structural deficits include white 
matter loss, size reduction of the frontal and temporal cortices, corpus callosum and 
hippocampal volume (Tasker et al. 2005, Wilde et al. 2005). Other pathological 
changes are also observed e.g. inflammation, wallerian degeneration, dendritic 
alterations, neurotransmitter imbalances, and impairment of metabolism (Johnson et al. 
2012, Moretti et al. 2012).  
TBI is one of the strongest risk factors for the development of AD (Mortimer et al. 1985, 
Fleminger et al. 2003). TBI could induce neuroplasticity for damage repair, while 
simultaneously draining the resources for neuroplasticity required later in life to 
counteract aging (Moretti et al. 2012). A! plaques and NFT are found in survivors of TBI 
of more than a year (Johnson et al. 2012). Even without the development of AD, 
concussions have resulted in a compromise of episodic memory and frontal lobe 
function (Moretti et al. 2012).   
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1.7 Neuropathology of TBI 
 
1.7.1 A!  
Extensive A! plaques can be found in victims of acute TBI and CTE. They are formed 
within hours of the injury and are found even in young individuals. Diffuse A! plaques 
are found in 30% of TBI patients, and are similar to those found in AD and Down’s 
syndrome patients (Roberts et al. 1994, Gentleman et al. 1997). However, neuritic 
plaques were absent in cases of CTE (Smith 2013).  
APP is upregulated in response to TBI and neuronal damage due to its neurotrophic 
functions, including synaptogenesis and a role in axonal sprouting (Blennow et al. 
2012). Administration of soluble APP in a rat model of TBI reduced neuronal and axonal 
injury, apoptosis, and improved functional outcome (Thornton et al. 2006). In DAI, the 
accumulation of APP in damaged axons can serve as a source for A! plaque formation. 
APP, caspases, presenilin-1 and !-site APP cleaving (BACE) enzymes are all brought 
to close proximity in the axonal bulb (Chen et al. 2004, Chen et al. 2009). Whether the 
accumulation of A! and plaque formation leads to AD has been contested, as Chen et 
al. 2009 found virtually no plaques in long-term survivors (Tran et al. 2011).  
 
1.7.2 Tau 
NFT, NT, and glial tangles are found in survivors of moderate to severe TBI and CTE. 
The tau in these deposits is phosphorylated and ubiquitinated at the same amino acids 
as those found in AD. This raises the possibility that the same pathological pathways 
are affected in both AD and TBI, thus predisposing TBI patients to develop AD (Schmidt 
et al. 2001, Smith 2013). However, tau pathology in TBI is found in different locations 
from that in AD- tau pathology is found in both deep and superficial layers of the cortex 
in AD. In TBI cases, it is found in the superficial cortical layers of the frontal and 
temporal cortices, and with an apparent perivascular distribution. They also existed in 
irregular patches, and were most concentrated in sulci depths. The irregularity of their 
deposition can be attributed to the random direction of shearing forces that occur during 
TBI (McKee et al. 2009).  
When #-secretase inhibitors were used to treat cortical impact traumatic axonal injury 
(TAI) in mice models of AD, A! accumulation was attenuated, but tau pathology was 
not. This suggests that NFT formation is independent, and not downstream of A! 
plaque formation (Tran et al. 2011). Tau phosphorylation and accumulation in TBI can 
be explained by the activation of c-Jun N-terminal kinase (JNK), which is deregulated in 
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TBI. Inhibition of JNK reduced the accumulation of total tau and phosphorylated tau in 
injured axons of a mice model of TAI (Tran, Sanchez and Brody 2012).  
 
1.7.3 Inflammation 
During the acute phase of TBI, compromise of the BBB would allow leukocytes, T cells, 
natural killer cells, and macrophages to infiltrate the brain from the periphery. These 
cells release free radicals, complements, chemokines and pro-inflammatory cytokines 
with a goal of limiting tissue damage and initiate repair (Ziebell and Morganti-Kossmann 
2010).  
Microglia are the key mediators of the inflammatory response to TBI. They migrate 
towards lesions, and utilize their ramifications to form a protective barrier between the 
injured and healthy tissue. This is mediated by the release of ATP from damaged 
tissue, which activates microglia and induces chemotaxis (Davalos et al. 2005). 
Microglia also release a plethora of pro-inflammatory cytokines and neurotoxic 
substances like ROS and RNS (Ziebell and Morganti-Kossmann 2010). While the 
number of peripheral lymphocytes in the brain decreases rapidly, microglia and 
macrophages remain activated, even at areas remote from the lesion, for up to 18 
years post-injury. PET imaging of activated microglia using the PK ligand also showed 
chronic inflammation up to 17 years after TBI, and florid activation were observed in 
brain regions remote from focal lesions, especially in subcortical structures like the 
thalamus and putamen (Ramlackhansingh et al. 2011). Hence, persistent 
neuroinflammation is thought to contribute to the long-term effects of TBI (Gentleman et 
al. 2004, Johnson et al. 2013).  
Long-term survivors of TBI were observed to have amoeboid microglia that were 
immunoreactive for CR3/43 and CD68 throughout various regions of the brain, 
especially in the corpus callosum. These microglia were not associated with lesions and 
are linked to DAI. In these areas with dense microglia activation, luxol fast blue staining 
revealed a reduction in myelin density and disruption of white matter, demonstrating a 
progressive degeneration of the white matter. As seen with the long-term effects of TBI, 
inflammation might contribute substantially to the development of AD (Johnson et al. 
2013, Smith 2013).   
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Hypothesis 
Microglia phenotype, an indication of classical and alternative activation states, differs 
in AD, PD and TBI. 
 
Aims 
Inflammation is a common denominator in many neurodegenerative diseases. Microglia 
in AD and PD are associated with classical activation and pro-inflammatory factors. 
This led to the proposition that microglia are driving the pathogenesis of these 
diseases, ultimately causing synaptic and neuronal loss. The current perception of the 
role of microglia in neurodegenerative diseases is an injurious one. However, recent 
evidence revealed an increase in the mRNA of alternative activation markers in AD.  
This study is based on the theory that microglia exist in a heterogeneous state in 
chronic neurodegenerative diseases. The purpose of this study is to explore the 
phenotypic profile of microglia and find evidence of alternatively activated microglia in 
AD and PD in order to disprove the notion that the sole outcome of microglial activation 
is the destruction of neurons.  
Pathological similarities exist between AD, PD, DLB and TBI- evidence of !-syn has 
been found in AD, especially in the amygdala, while AD pathology also exist in PD and 
DLB cases. In fact, distinguishing between the contributions of !-syn, tau and A! 
pathology towards the clinical symptoms of DLB remains an issue. A theory that AD, 
PD, and DLB exist as part of a continuum has been proposed. These pathologies might 
instigate divergent microglial behaviour, resulting in a range of diseases with different 
progression and symptomatology. Investigation into microglia’s association with 
different pathological hallmarks will be carried out.  
Chronic inflammation after TBI is thought to predispose patients to an increased risk of 
AD later in life. Studying microglia in TBI cases may provide an insight into the 
contribution of inflammation towards the development of cognitive impairment. 
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Aims of the thesis:  
 
1. Characterize the phenotype of microglia in AD using markers of classical and 
alternative activation. 
 
2. Evaluate the consistency and reliability of microglial quantification methods 
 
3. Investigate the spatial and temporal distribution of alternatively activated 
microglia, and their associations with other pathologies and clinical symptoms in 
AD and PD.   
 
4. Compare microglial phenotype in TBI (acute) with AD and PD (chronic) 
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Chapter 2: Materials and Methods 
 
2.1 Tissue specimens 
Post-mortem brain specimens were obtained from the Corsellis archival collection (AD 
and control samples) and the Parkinson’s UK Tissue Bank (UKPDSTB) at Imperial 
College London (PD, DLB and control samples).  
31 AD cases of Braak stages 5 and 6 obtained from the Corsellis Archival Collection 
were used in this study. The patient cohort comprised of 21 females and 10 males, age 
range 65-88, mean age at death 76. The information on age at death, gender, and 
cause of death are listed in Table 2. Formalin-fixed, paraffin embedded samples from 
frontal cortex, hippocampus, and occipital cortex were obtained from all AD cases. 
27 cases of LBD were obtained from the UKPDSTB- 10 cases from Braak stage 6, and 
6 cases each from stages 4 and 5, and 5 cases from stage 3 were obtained from the 
UKPDSTB. This was made up of PD and DLB cases. The patient cohort comprised of 9 
females and 18 males, age range 57-96, mean age of death 74. The age at death, 
gender, and cause of death for these cases are listed in Table 5. Formalin-fixed, 
paraffin-embedded samples from the frontal cortex, cingulate cortex, striatum, basal 
forebrain, hippocampus, midbrain, pons, and medulla were obtained from all LBD 
cases. Frozen sections from the frontal and cingulate cortices were obtained from 10 
cases of LBD.  
16 cases with no neurological or systemic disease were also selected as controls. 
These were classified as NPD (no psychiatric disease), and were obtained from both 
the Corsellis collection and the UKPDSTB. The patient cohort comprised of 8 females 
and 8 males, age range 59-81, mean age at death 70. Information on these cases is 
listed in Table 6. There were no significant differences in age at death between the AD, 
LBD and control group. 
 
2.1.1 Clinical assessments of cases 
Cases diagnosed with senile dementia by their respective physicians were obtained 
from the Corsellis archival collection. They were then neuropathologically assessed for 
both tau and A! pathology to ascertain that they were afflicted with AD.   
Clinical records from the UKPDSTB were compiled retrospectively by Dr Ronald K.B. 
Pearce. Information on the gender, age of onset, age at death, and duration of disease; 
mode of motor onset i.e. tremor, akinetic-rigid syndrome, gait and balance impairment; 
as well as the presence of neuropsychiatric complications including dementia, anxiety, 
depression, visual hallucinations, and psychosis were also noted under the guidance of 
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Dr Pearce.  Two or more of the cardinal signs- rigidity, bradykinesia, resting tremor and 
postural instability, and a good response to levodopa determined presence of PD. 
Development of dementia one year after onset of motor signs were classified as PDD, 
while DLB cases developed cognitive impairment within one year of, or preceding motor 
signs.  
 
2.1.2 Neuropathological assessment of cases 
Confirmation of patients’ AD status was determined by assessing AT8 
immunohistochemical (IHC) staining based on the staging protocol from BNE (Alafuzoff 
et al. 2008a), and the presence of A! plaques using 4G8 antibody. Those with Braak 
stages 5/6 were chosen for this study.  
Neuropathological diagnosis of PD and screening for confounding pathology were 
based on haematoxylin and eosin staining, as well as IHC staining for A!, tau, and !-
syn on 13 diagnostic blocks. Neuropathological assessment was carried out by four 
neuropathologists- Professor Steve M. Gentleman, Dr Federico Roncaroli, Dr Illaria 
Bravi and Professor Manuel B. Graeber. Using BNE’s staging protocol for !-synuclein 
pathology (Alafuzoff et al. 2009), 10 cases from Braak stage 6, and 6 cases each from 
stages 4 and 5, and 5 cases from stage 3 were selected for this study. There were no 
significant differences in age at death between the AD, PD and control group (p=0.001). 
 
2.1.3 Sectioning and processing of formalin-fixed, paraffin-embedded tissue 
Formalin-fixed, paraffin-embedded blocks were refrigerated prior to sectioning for an 
easier cut. The blocks were mounted on the microtome and sectioned at 7 µm. The 
sections were then transferred to a 40OC water bath and floated out for ~2 minutes or 
until smooth, before mounting onto Superfrosted slides. The slides were placed in an 
37oC oven overnight for drying and stored at room temperature before use. 
Before the staining process, paraffin was removed from the slides via two xylene 
washes. They were then rehydrated by soaking in 4 industrial methylated spirits (IMS) 
washes of different concentrations, in the order – 100%, 100%, 90% and 70% for 5 
minutes each. Sections were blocked for endogenous peroxidase activity by incubating 
in 1% hydrogen peroxide for 30 minutes, followed by rinsing in phosphate-buffered 
saline (PBS). If required, antigen unmasking is carried out at this point.  
Formaldehyde fixation creates hydroxylmethyl groups that cross-links with adjacent 
proteins via the formation of methylene bridges, hence masking antigens from detection 
by steric interference. Antigen retrieval destroys the cross-links and re-exposes the 
antigen/epitope for antibody recognition and binding (Bogen, Vani and Sompuram 
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2009). Power Block reagent (BioGenex, UK) was used before application of the primary 
antibody to reduce non-specific binding and background staining.  
 
2.2 Antibodies 
Monoclonal antibodies are generated by a single B-cell clone and hence recognize the 
same epitope on the antigen. After immunization against the antigen, B-lymphocytes 
from the animals e.g. mouse, rabbit, or rat, are retrieved from the spleen and fused with 
an immortalized myeloma cell line, also called a hybridoma. A stable clone with a high 
antibody production capacity is picked and isolated from the hybridoma cell line. Large 
amounts of antibody can be generated from the hybridoma cell cultures using 
bioreactors.  
While monoclonal antibodies are more consistent and less likely to cross-react than 
polyclonal ones, the multi-clonality of polyclonal antibodies makes them less vulnerable 
to destruction of epitopes during tissue processing. Polyclonal antibodies are generated 
from different B-cell clones of an animal, and thus comprise of a heterogeneous 
concoction of antibodies with different specificities recognizing a range of epitopes from 
the same antigen. They can be produced in different animals, the most common being 
rabbits due to a lower frequency of human antibodies against rabbit proteins and easier 
maintenance.  
All primary antibodies employed in IHC, double immunofluorescence (DIF), Western 
blotting (WB) are shown their respective results chapters. Both monoclonal and 
polyclonal antibodies labeling the same antigens were utilized for the purpose of DIF. 
Secondary antibodies used in DIF and WB are listed in table 1.  
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Table 1: List of secondary antibodies used in the study 
Alexa Fluor 488 Alexa Fluor 568 
Donkey anti-goat IgG Donkey anti-goat IgG 
- Donkey anti-rabbit IgG 
Donkey anti-mouse IgG - 
Goat anti-rabbit IgG Goat anti-rabbit IgG 
Goat anti-mouse IgG Goat anti-mouse IgG 
Goat anti-mouse IgG1, IgM Goat anti-mouse IgG1 
Goat anti-mouse IgG3 - 
- Goat anti-mouse IgG2a 
 
Non-Alexa Fluor conjugated antibodies Conjugation 
Goat anti-Chicken IgY Northern lights 493 
Rabbit anti-Goat IgG Biotinylated 
 
2.3 Methodology of immunohistochemistry   
The Super Sensitive Polymer-HRP (horse-radish peroxidase) Detection system 
(BioGenex, UK) was used in most IHC experiments in this study. The detection system 
is suitable for both rabbit and mouse antibodies. For goat-derived antibodies, 
Vectastain Elite ABC detection system (Vector labs, UK) was used instead. For all 
solutions mentioned in this chapter, please refer to the appendix for their ingredients. 
The primary antibody was diluted in PBS to its appropriate concentration, applied to the 
tissue and left overnight at 4OC in a moist incubation chamber.  After rinsing any 
unbound primary antibody (all rinses were done with 3 x PBS for 5 minutes each), the 
Super Enhancer was added for 20 minutes before rinsing again. Application of the Poly-
HRP reagent followed and was left on for 30 minutes. A final rinse was done before 
staining was carried out using a solution of chromogen 3,3’-diaminobenzidine (DAB). 
Sections were incubated for 3 minutes and rinsed in distilled water. This was followed 
by counter-staining with haematoxylin for 10 seconds before transferring to running tap 
water.  
Steps for using Vectastain Elite ABC kit are similar to that of the Super Sensitive 
Polymer-HRP system. The primary antibody was diluted to its appropriate concentration 
in PBS and the animal serum corresponding to the host species of the secondary 
antibody. The addition of the serum serves to prevent non-specific binding from the 
secondary antibody. The secondary antibody was used in place of the Super Enhancer 
and left on for an hour before rinsing. Vectastain ABC kit was used in place of Poly-
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HRP reagent, and applied for another hour before rinsing. DAB and counterstaining 
steps remain the same.  
The sections were dehydrated by soaking in 3 IMS washes of different concentrations, 
in the order of 70%, 90% and 100%, for 5 minutes each, before transferring to xylene. 
Cover slips were adhered to tissue sections with the help of DPX, a xylene-based 
mountant, and dried in the fume hood overnight. All slides were examined with an 
Olympus Vanox AHBT3 light microscope, pictures were captured with an attached 
Qimaging micropublisher 3.3 RTV camera and analysed using Image Pro Plus 7.0.  
Control slides were included in each run of IHC procedure where possible. Negative 
control slides were processed the exact same way as test slides with omission of 
primary antibody; they should remain unstained in the absence of non-specific binding. 
Positive control slides were performed using known positive tissues; if no 
immunoreactivity was observed, the results from the same run were rendered invalid.  
 
2.4 Methodology of double immunofluorescence  
Two primary antibodies were selected based on their animal source and 
immunogloubulin type or subtype. Both primary antibodies to be analysed were 
prepared by diluting an appropriate amount of antibody with a diluent containing PBS 
and the animal serums corresponding to the host species in which the secondary 
antibodies was generated from. The appropriately diluted antibodies were then applied 
simultaneously to the tissue and left overnight at 4OC in moist incubation chambers, 
before rinsing in 3 x PBS.  
Secondary antibodies conjugated to fluorophores of different emission spectra were 
diluted to their respective concentrations in PBS and added to the sections for an hour 
before rinsing in 3 x PBS. During this time, all sections were kept in the dark to prevent 
photobleaching. 0.3% Sudan Black was applied for 10 minutes and rinsed under 
running water for 5 minutes. This was done to eliminate autofluorescence. Finally, 
sections were mounted with ProLong Gold Anti-fade reagent with DAPI (Invitrogen, UK) 
and cover-slipped. 4’,-6-diamidino-2-phenylindole, also known as DAPI, is used as a 
counterstain and forms a complex with double-stranded DNA, especially at A-T 
clusters, to produce a fluorescence signal. All fluorescent slides were examined with 
Nikon Eclipse 50i microscope, images were captured with an attached Nikon DS-2MBW 
camera and analysed using NIS-Elements F 3.0.  
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2.5 Analysis of immunohistochemical staining 
Sensitive, reliable, and easily replicable methods are required for quantification of 
microglia. While flow cytometry and western blotting can reliably separate and quantify 
microglial cells, they would require unfixed, frozen tissue sections. They would also be 
unable explore the associations of immunoreactive microglia with other components in 
the tissue. Immunohistochemically stained sections are commonly used for this 
purpose, and a variety of markers can be used to label and distinguish microglia 
heterogeneity. Methods for assessing IHC microglia staining include observer based 
subjective estimations, semi-quantitative assessment based on gray scale intensity, 
percentage area measurements, manual counting, and stereology (Reinacher et al. 
1999, Blackbeard et al. 2007).   
Although some papers have compared and verified these methods, they can still be 
hard to replicate due to several factors. With regards to stereology, the assumption that 
systemic randomized sampling will give a proper representation of an evenly distributed 
stain cannot be applied in a situation where the distribution of staining is 
inhomogeneous, as this can result in systemic errors. Other sources of systemic error 
include uneven compression of tissue along the z-axis, especially with use of paraffin 
as an embedding material. One also needs to have access to the entire brain region, 
which is usually not possible when an invaluable source is utilized i.e. human tissue 
(Schmitz and Hof 2005).  
There are several considerations with regards to assessing microglia quantity and 
activation using IHC stained sections. Most studies have performed microglia 
quantification in rodent tissue. The size difference between rodent and human tissue 
sections makes it hard to properly assess immunoreactivity across a large area of 
interest. Distribution of microglia with the use of different markers can range from an 
even distribution to a patchy one. While evenly distributed microglia cells are relatively 
easy to quantify, as a small area would serve as a good representative for the entire 
section, quantifying an erratic microglia distribution over a large area would prove a lot 
more problematic. The following chapters will attempt to address this issue. Finally, the 
shape of microglial cells can also cause difficulties with pixel measurements. The 
ramifications of a microglial cell can occasionally be too fine to be picked up imaging 
programs. An amoeboid microglia cell would not present with the same problems as the 
fine processes of a resting or semi-activated microglial cell. It is essential to train an 
observer for consistency in determining the cut-off point between the staining of 
microglial processes and background.  
Semi-quantitative methods can be performed rapidly in large-scale studies, but 
judgmental errors can arise while distinguishing between classes of abundance, 
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especially when dealing with a new scale. Training for intra-rater and inter-rater 
consistency can minimize these errors (Armstrong 2003).  
In this thesis, two semi-quantitative methods and Western blotting were used to assess 
the upregulation of microglial markers. Semi-quantitative methods were done blinded to 
case numbers. Microglial cells were rated by percentage area (%area) of detected cells 
based on the region with the highest density of microglial cells (subjectively assessed), 
and subjective assessment of microglial abundance based on scores 0-3, representing 
absent, mild, moderate and severe respectively (referred to as microglia load). More 
details on how they were assessed will be covered in chapters 4 and 5. Before ratings 
were performed on all cases, 20 of them were picked and rated four times or more in a 
span of 3 months, each time in a randomized order. The measurements were 
performed blinded to previous values. This served as training to reduce intra-rater 
variability. Cronbach’s alpha was used to assess the internal consistency- only after its 
value exceeded 0.95 was the training considered sufficient. 
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2.6 Protein extraction and quantification 
 
2.6.1 Protein extraction  
Grey matter from the frontal and cingulate cortices was extracted from frozen tissues 
where possible. The tissues were weighed and added to volume of PBS 8 times the 
mass of the tissue (with Roche complete protease inhibitor cocktail). They were then 
homogenized with Peqlab minilys homogenizer at 3000 rpm for 1 minute.  The 
supernatant (containing the water-soluble proteins of the interstitial fluid and cytoplasm) 
was removed and stored at -80OC for use in enzyme-linked immunosorbant assays 
(ELISAs).  
Lysis buffer (4 times the volume of tissue) was then added to the pellet, mixed, and left 
on ice for 20 minutes before centrifugation at 9000 rpm for 10 minutes. The supernatant 
derived from this procedure contained membrane-associated proteins for use in gel 
electrophoresis, and was stored at -80OC.  
 
2.6.2 Protein quantification  
Quick Start Bradford Protein Assay (Bio-Rad, UK) was added to 5 µl of supernatant 
from the protein extraction step and 20ul of bovine serum albumin (Sigma, UK) protein 
standards (0.2 mg/ml, 0.4 mg/ml, 0.6 mg/ml, 0.8 mg/ml and 1mg/ml) to make up a total 
of 1ml per sample. These were added in triplicates to a 96-well plate, and read using a 
spectrophotometer (Molecular Devices VersaMax ELISA Microplate Reader) using 
SoftMax Pro software.  
A protein standard curve was derived from the average of the bovine serum albumin 
(BSA) readings. The concentrations of protein in the samples were derived from the 
curve and multiplied by 4. 
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2.7 Western Blotting 
 
2.7.1 Gel preparation 
For running a protein of size 130kDa, 8% running gel of 0.75mm thickness was used. 
Running gel mixture was added to the glass mould up to the indicator, leaving space for 
the stacking gel. Isopropanol was added to get rid of air bubbles. After letting the gel 
polymerize for an hour, the isopropanol was removed and the stacking gel was poured 
on top of the running gel. A comb was placed to create wells, before allowing the gel to 
polymerize for another 20 minutes.  
 
2.7.2 SDS-PAGE gel electrophoresis 
10 µl of sample buffer was added to the samples (volumes containing 50 µg of protein), 
and boiled for 10 minutes. In the meantime Mini-PROTEAN Tetra 4-gel vertical 
electrophoresis system (Bio-Rad, UK) was set up, gels were fitted into the cell, and 1 
litre of running buffer was added to the cell. After boiling, the samples were allowed to 
cool before being loaded into the gel. 5 µl of molecular weight marker (SeeBlue Pre-
stained standard from Invitrogen) was also added to the first lane of each gel.  
The gels were ran at 120mV for 1 hour 30 minutes, or till the samples have reached the 
end of the gel.  
 
2.7.3 Transfer and Detection 
The Mini Trans-Blot cell (Bio-Rad, UK) was used for western blotting. PDVF 
membranes (Millipore, UK) were wetted with methanol. The gel was removed from the 
electrophoresis cell. The PDVF membrane and gel were then sandwiched in filter 
papers and foam pads that were pre-soaked in transfer buffer, and held together by a 
cartridge. (Figure 7) Care was taken to eliminate any air bubbles.  
These were placed into the tank together with an ice block and 1 litre of transfer buffer, 
and ran at 400mA constant amp for an hour. The blot was then removed and blocked in 
5% nonfat milk in Tris-Buffered Saline with Tween 20 (TBST) for another hour. A wash 
step was next, involving 3 x TBST washes for 10 minutes each. The primary antibody 
was diluted to its appropriate concentration in TBST with 5% nonfat milk and added to 
the blot for an overnight incubation at 4OC on a shaker. Another wash step was done, 
before incubation with HRP-conjugated secondary antibody diluted in TBST with 5% 
nonfat milk for an hour on the shaker, and a final wash step.    
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The membranes were developed using electrochemiluminescence (ECL) reagents and 
Hyperfilm ECL autoradiography film in an automated developer from Konica (SRX 
101A).  
 
Figure 7: Blot transfer arrangement 
 
  
 
2.7.4 !-actin normalization 
The membranes were incubated in stripping solution (Reblot Plus Strong Antibody 
Stripping Solution 10x from Millipore, UK) for 20 minutes at room temperature, before 
washing once with TBST. Blocking was done with 5% nonfat milk in TBST for an hour, 
before washing in 3 x TBST for 10 minutes each. Steps for probing with antibodies and 
membrane development were repeated, this time replacing the primary antibody with !-
actin antibody (mouse monoclonal, Abcam, UK), and its secondary antibody HRP-
conjugated goat anti-mouse IgG (Sigma, UK).  
The films were scanned, band intensities were analysed with ImageJ (NIH) and 
normalized to the bands of !-actin.  
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2.8 Enzyme-linked immunosorbant assay  
50µl of coating antibody was added to each well of a 96-well plate and left overnight. 
After emptying the plate and doing three washes with their respective wash buffers, the 
block buffer was added and left on for 1 hour. This was followed by another three 
washes.  
Two-fold serial dilutions of protein standards were performed seven times and added in 
triplicates to the wells. In the last row, only diluent was added to serve as a blank. 
Equalized samples were also added in triplicates to the plate. The amount of samples 
and standards added to each well varied with the antibody kits used. The plates were 
incubated for 2 hours at room temperature on a shaker, and washed five times. The 
detection antibody was added next and incubated for another 2 hours before five 
washes.  
Two color development systems were used for detection- HRP/TMB and HRP/ABTS. 
1N hydrochloric acid and 1% SDS were used as stop solutions respectively. 3,3',5,5'-
tetramethylbenzidine, also known as TMB, yields a blue color upon reaction with HRP. 
It oxidizes at a faster rate and results in a quicker color development. 2,2'-Azinobis [3-
ethylbenzothiazoline-6-sulfonic acid]-diammonium salt, or ABTS, yields a green color 
instead, and takes more time to develop compared to TMB substrate. !
After applying the stop solutions, plates were read with a spectrophotometer (Molecular 
Devices VersaMax ELISA Microplate Reader) using SoftMax Pro software. The antigen 
concentration in the samples were derived from the protein standard curve, and 
correlated back to the dilution factor used during protein equalization to give the original 
antigen concentrations.  
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Chapter 3: Evaluating microglia phenotypes in AD 
 
3.1 Introduction 
The heterogeneity of microglia activation has been demonstrated in AD patients and 
animal models of AD. Both classical and alternative activation markers are expressed 
by microglia in AD (Colton et al. 2006). However, there is relatively little evidence of 
alternative activation in PD. Additionally, most of these markers have only been 
characterized in peripheral macrophages. Studying these markers in microglia is 
essential for identifying their functions and detecting their response to pathology. Co-
localization of these markers may prove useful in defining the phenotypic subtypes of 
microglia. 
A summary of the functions and activation states conferred by specific microglia 
markers used in this chapter will be covered based on current literature. They are major 
histocompatibility class II antigen (MHCII), CD68, ionized calcium binding adaptor 
molecule 1 (Iba1), mannose receptor, C type 1 (MRC1), IL-1", Arg1, Arg2, CD163, 
CD14 and CD36.  
 
3.1.1 Non-specific markers 
 
3.1.1.1 MHCII 
The functions of MHCII include antigen presentation and activation of CD4 T helper 
cells. MHCII are expressed on the surface of lymphocytes and other antigen presenting 
cells. It is upregulated by the actions of IFN#, IL-4 and IL-13, but drastically 
downregulated by IL-10, hence low expression is observed in acquired deactivation 
state. In cell cultures, human adult microglia have a high baseline of MHCII expression. 
However it is downregulated when exposed to granulocyte macrophage colony-
stimulating factor (GM-CSF) and IL-4. This downregulation is accompanied by an 
increase in production of IL-10. This is in stark contrast to blood monocytes, which took 
on a pro-inflammatory profile, and strongly increased MHCII expression (Gordon 2003).  
MHCII was once thought to indicate a pro-inflammatory state, but is now known to be 
expressed by both classically and alternatively activated macrophages (Colton 2009). 
When double stained with Iba1, MHCII labeled a smaller group of microglia, suggesting 
that it is more discerning for activated microglia than Iba1. MHCII immunoreactive 
microglia are associated with amyloid and NFT pathology in AD. Their immunoreactivity 
increases along with microglial morphological changes indicating activation (Lue et al. 
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2001). MHCII expression in primates also increases along with age (Sheffield and 
Berman 1998).  
 
3.1.1.2 CD68 
CD68 is an 110kDa intracellular late endosomal glycoprotein that can be found in the 
cells of mononuclear phagocyte lineage (Rabinowitz and Gordon 1991). It labels 
microglial lysosomes associated with phagocytosis, hence is often used to depict 
evidence of phagocytic activity (da Silva and Gordon 1999). Minocycline, a tetracycline 
derivative antibiotic that is known to downregulate inflammation, does not affect 
lipopolysaccharide (LPS)-induced CD68 immunoreactivity (Malm et al. 2008).  
Macrosialin, the murine counterpart of CD68, is heavily glycosylated. This confers 
several advantages, including resistance to proteolysis especially in a lysosomal 
environment, and a higher affinity of the terminal sialic acid residues for pathogens 
including viruses, bacteria and tumor cells (Rabinowitz and Gordon 1991).  
 
3.1.1.3 Iba1 
Iba1 is a 17kDa protein that performs as a marker highly specific for 
microglia/macrophages (Imai et al. 1996). It also stains other cells belonging to the 
monocytic lineage (Ito et al. 1998). It contains two EF hand motifs that bind to calcium, 
and is involved in membrane ruffling and phagocytosis through the actions of actin –
bundling and reorganization. Iba1 expression is upregulated in activated microglia 
(Ohsawa et al. 2004).  
 
3.1.1.4 MRC1 
MRC1 is a type 1 transmembrane C-type lectin that recognizes branched mannose-
containing carbohydrate structures and thus acts as a pattern recognition receptor for 
pathogens including bacteria and viruses (Allavena et al. 2004). Its expression is also 
linked to MHCII through the increase of antigen internalization, thus facilitating antigen 
presentation (Taylor, Gordon and Martinez-Pomares 2005a).  
MRC1 also recognizes endogenous ligands and participates in the clearance of self-
antigens (McGreal, Miller and Gordon 2005), induces secretion of cytokines and 
facilitates endocytosis and phagocytosis. This is initiated by binding of MRC1 to its 
ligand, causing cross-linking of the receptors and subsequent phagocytosis of the 
ligand (Galea et al. 2005). This in turn stimulates an anti-inflammatory phenotype 
(Chieppa et al. 2003). Endocytosis through MRC1 by primary human macrophages is 
enhanced by IL-4 and IL-13 but downregulated by IL-10 and IFN# (Montaner et al. 
1999).  
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3.1.2 Classical activation markers  
 
3.1.2.1 IL-1" 
IL-1" is a 17kDa pro-inflammatory cytokine with a diverse range of functions, e.g. 
induction and amplification of the inflammatory response, activation of T cells, fibrosis 
and angiogenesis (Mrak and Griffin 2001). It is constitutively expressed at a low level in 
a healthy adult brain, but highly expressed by microglia in AD, Down syndrome 
patients, head injury, multiple sclerosis (MS), and HIV (Griffin and Mrak 2002). IL-1 
immunoreactive microglia are found in close proximity to A! plaques in AD patients, but 
not in controls, suggesting that IL-1 might be a contributing factor to the pathogenic 
nature of plaques in AD. As IL-1 promotes neuronal synthesis and !APP processing, 
overexpression of IL-1 causes neuronal dysfunction, excessive growth of dystrophic 
neurites, and increased deposition of A! plaques (Griffin et al. 1998).  
    
3.1.2.2 TNF" 
TNF" is a pro-inflammatory cytokine that orchestrates a self-propelling inflammatory 
reaction by inducing microglial activation and further production of pro-inflammatory 
cytokines (Qin et al. 2007). It is involved in the acute-phase reaction, stimulates 
chemoattraction of inflammatory cells, and mediates systemic reactions e.g. lowered 
blood pressure and septic shock. The effects of TNF" can be conflicting- on one hand, 
high levels of TNF" have been found to cause cytotoxic effects in demyelinating CNS 
diseases, on the other hand presence of TNF" in animal models of ischemia and 
excitotoxicity has a protective effect on neuronal survival (Gosselin and Rivest 2007).   
TNF" production is suppressed by IL-4 and IL-13. Treatment of cultured murine 
microglia with IL-4 or IL-13 drastically reduces TNF" mRNA expression (Colton et al. 
2006). Exposure to apoptotic cells, IL-10, or TGF! also decreases the levels of TNF" 
(Lodge and Sriram 1996, Minghetti et al. 2005). TNF" is also able to suppress cell 
proliferation, as seen in TNF" receptor 1-KO mice- increased neuroblast production in 
the subventricular zone (SVZ) was observed after a stroke (Iosif et al. 2008). However, 
administering TNF" antibody decreased survival rates of the newly formed neurons in 
the SVZ, suggesting a role for TNF" receptor 2 in neuroprotection (Ekdahl, Kokaia and 
Lindvall 2009).  
Age is also a contributing factor to an increased microglial pro-inflammatory cytokine 
profile. This is shown in microglia of older transgenic AD mice, which had an increased 
TNF" expression, when compared to young mice (Jimenez et al. 2008). Neurotoxicity 
towards DA neurons caused by administering MPTP in TNF receptor KO mice was 
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attenuated (O'Callaghan, Sriram and Miller 2008). Higher levels of TNF" have also 
been detected in the CSF and brain parenchyma of PD patients (Reale et al. 2009).  
 
3.1.3 Alternative activation markers  
 
3.1.3.1 Arginase 1 and 2 
There are two isoforms of arginase. Arginase 1 (Arg1) is the cytosolic form mostly found 
in the liver, while arginase 2 (Arg2) is the mitochondrial form that is also found in many 
other cell types include macrophages (Witte and Barbul 2003). Arg1 is inducible and 
expressed by both neurons and microglia, while Arg2 is constitutively expressed 
throughout the brain at low levels and does not participate in the innate immune 
response. These findings are obtained from murine models, and may be different in the 
case of humans (Xia et al. 2001, Colton and Wilcock 2010). Arg1 is thought to be 
expressed by alternatively activated macrophages. Treatment with IL-4 and IL-13 
increases expression of Arg1. The addition of A! further increases expression of Arg1, 
an indication that A! may act to promote the alternative activation state of microglia 
(Colton et al. 2006).  
Arginase competes with NO synthase for arginine, limiting the production of NO. 
Arginase also promotes polyamine synthesis and cell proliferation. TGF! stimulates 
arginase while inhibiting the actions of iNOS, coordinating the actions of both enzymes 
to ensure effective wound healing. Ornithine, a precursor for the synthesis of proline, is 
also produced by arginase. Hence, arginase has been touted to play a role in wound 
healing and tissue reparation by indirectly affecting production of proline-rich proteins 
like collagen (Morris 2007). However, chronically high levels of TGF! can go on to 
cause excessive matrix production, increased collagen levels in the vasculature and 
thickening of the blood vessel walls. This situation is observed in both mouse models of 
AD and in AD patients (Colton and Wilcock 2010).  
 
3.1.3.2 CD36 
CD36 is a class B scavenger receptor that is localized on the plasma membrane. It 
plays a role in lipid metabolism and is involved in the binding and transportation of long-
chain fatty acids in adipocytes, heart and skeletal muscle (Febbraio, Hajjar and 
Silverstein 2001). It has been shown to aid in the clearance of apoptotic cells 
(Husemann et al. 2002, Stolzing and Grune 2004). Human macrophages deficient in 
CD36 secrete less TNF" and IL-1! with reduced NF-kB activation when stimulated with 
oxidized low-density lipoproteins, suggesting that the CD36 pathway might lead to 
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classical activation (Janabi et al. 2000, Husemann et al. 2002). It is expressed by both 
microglia and capillary endothelium in the brains of AD patients. CD36 also mediates 
adhesion to fibrillar A!, and induces ROS secretion upon binding (Coraci et al. 2002).   
 
3.1.3.3 BDNF 
BDNF is a 28kDa dimer that is expressed widely throughout the brain by both neuronal 
and non-neuronal cells, including DA neurons in the SN and ventral tegmental area, 
and to a lesser extent in the striatum (Zhang et al. 2007a). BDNF recruits microglia and 
induces proliferation and phagocytic activity. It also reduces MHCII expression 
(Neumann et al. 1998).  
BDNF levels are reduced in the SN of PD patients compared to controls (Mogi et al. 
1999). In AD patients, BDNF and trkB levels in the frontal and temporal cortices, basal 
forebrain, and pyramidal cells of the hippocampus and the granular cells of the dentate 
gyrus were also found to be lower than controls (Murer, Yan and Raisman-Vozari 
2001).  
BDNF stimulates survival of rat and human fetal DA neurons, as well as rat 
hippocampal neurons in cell cultures. It also mediates neuroprotection in rat 
hippocampal lesions and axotomy models (Zhou et al. 1994, Murer et al. 2001). It 
protects against the effects of MPP+ and 6-OHDA (Kirschner et al. 1996, Peterson and 
Nutt 2008). BDNF has a regulatory effect on dopamine release from DA neurons and 
increases DA uptake (Hyman et al. 1994, Blochl and Sirrenberg 1996). It also increases 
the average firing rate of SN, cortical and hippocampal neurons in rodents in vitro 
(Shen, Figurov and Lu 1997, Murer et al. 2001). Knockout of BDNF receptors trkB and 
trkC in mice resulted in lower number of SN DA neurons, and caused accumulation of 
"-syn in the remaining neurons (von Bohlen und Halbach, Minichiello and Unsicker 
2005). It exerts neuroprotection through enhancing calcium sequestration in vitro 
(Cheng and Mattson 1994). 
  
3.1.3.4 IL-10 
IL-10 is a major regulator of the immune response, and is expressed by lymphocytes 
and monocytes, including microglia. It is involved in inhibiting the development of T 
Helper 1 effector cells (Chabot et al. 1999), blocking MHCII expression (O'Keefe, 
Nguyen and Benveniste 1999), and suppressing pro-inflammatory cytokines expression 
(Moore et al. 2001). It also has a protective effect against cell death caused by 
glutamate excitotoxicity (Bachis et al. 2001), hypoxia (Grilli et al. 2000), and LPS 
(Molina-Holgado, Grencis and Rothwell 2001). This protective effect against LPS-
mediated neurotoxicity is executed via the suppression of NADPH oxidase activity 
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(Qian et al. 2006). IL-10 also coordinates its immuno-regulatory activity via heme-
oxygenase 1 (Lee and Chau 2002).   
Immunization of transgenic AD mice models with an altered myelin-derived peptide 
caused a shift in inflammatory profile, including a reduction in TNF", increase in IL-10, 
and diminished A! plaques and soluble A! (Koronyo-Hamaoui et al. 2009).  Increased 
levels of IL-10 mRNA have also been found in AD patients (Colton and Wilcock 2010).  
 
3.1.3.5 CD163 and CD14 
CD163 and CD14 both have functions relating to phagocytosis. CD163 acts as a 
scavenger receptor for haptoglobin-haemoglobin complexes (Hp-Hb). CD14 mediates 
the recognition of bacterial pathogens, apoptotic cells and fibrillar A!. However, while 
CD163 and CD14 induce an alternative activation state in microglia, CD14 can also 
induce a classical activation state. More details of these two markers will be covered in 
the later chapters.  
 
 
3.2 Aims 
The aim of this study was to characterize the phenotype of microglia in AD based on 
markers associated with both classical activation and alternative activation states. 
Based on the observed immunoreactivity and distribution of the microglia in AD, 
markers of interest were picked for analysis in all three neurological disorders- AD, 
Lewy Body disease (LBD), and TBI.  
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3.3 Materials and methods 
 
3.3.1 Case selection 
All AD cases were obtained from the Corsellis Archival Collection. Paraffin-embedded 
blocks from the frontal and occipital cortices, and hippocampus, were obtained from a 
total of 101 cases that were clinically diagnosed with senile dementia (ICD-10: F00). 
The aim was to find AD cases of Braak stages 5 or 6. Cases were also excluded based 
on their cause of death- systemic inflammation or other forms of neurological disorder 
or injury were not used in this study. 
These blocks were then sectioned at 7µm; neuropathological diagnosis was carried out 
by staining for 4G8 and AT8, which labels A! plaques and tau respectively. 4G8 against 
A! is able to stain a variety of A! plaques (fleecy, diffuse and cored), CAA, as well as 
intracellular A!- its detection of intracellular A! is assessed most consistently among a 
panel of antibodies against A! (Alafuzoff et al. 2008b). AT8 clone against tau 
specifically recognizes tau which are phosphorylated at serine residue 202 and 
threonine 205 (Goedert, Jakes and Vanmechelen 1995). AT8 has also been used as a 
diagnostic standard against phosphorylated tau in AD by both the Braak staging system 
and BrainNet Europe (Alafuzoff et al. 2006, Braak et al. 2006). 
Staging of AD was done by assessing neurofibrillary changes using the protocol from 
BNE (Alafuzoff et al. 2008a). A neuropathological diagnosis of AD was given on the 
basis of presence of NFT and neuritic plaques. Tau pathology at the peristriate/striate 
region indicated Braak stage 5 and 6 respectively. 31 cases were eventually selected 
from the initial cohort - 21 females and 10 males, age range 65-88, mean age at death 
76. (Table 2) 
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Table 2 - Age, gender and causes of death of AD cases  
Alzheimer’s Disease cases (Braak stages 5 or 6) 
Case no. Age at 
death 
Gender Cause of death 
1 70 F Other heart disease classified elsewhere 
2 65 F Pneumonia 
3 65 M Pneumonia 
4 71 F Pulmonary embolism 
5 71 F Pneumonia 
6 69 F Pneumonia 
7 67 F Intracerebral haemorrhage 
8 65 F Pulmonary embolism 
9 88 F Pneumonia 
10 74 M Pneumonia 
11 74 F Pneumonia 
12 71 F Pneumonia 
13 88 F Pneumonia 
14 75 F Pneumonia 
15 71 M Pneumonia 
16 76 F Pneumonia 
17 76 F Pneumonia 
18 76 M Pneumonia 
19 83 M Pneumonia 
20 80 F Peritonitis 
21 85 F Heart failure 
22 82 F Heart failure 
23 77 M Pneumonia 
24 78 F Malignant neoplasm of bronchus and lung 
25 85 M Pneumonia 
26 87 M Pneumonia 
27 81 F Acute myocardial infarction 
28 79 M Intracranial injury 
29 77 M Pneumonia 
30 79 F Pneumonia 
31 72 F Pneumonia 
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3.3.2 Immunohistochemistry 
IHC staining was done on sections from the frontal and occipital cortices, and the 
hippocampus region from 31 selected AD cases. A variety of antibodies against 
microglia markers was tried and tested using different pretreatments for optimum 
results. Antibodies that were successfully used in the IHC staining are listed in Table 3, 
while those that were not are listed in Table 4. Please refer to section 2.3 for the 
protocol on IHC procedure.  
 
3.3.3 Pretreatments 
Pretreatments used in this chapter include microwaving at 600W with citrate buffer at 
pH 6 (CA) or EDTA buffer at pH 8 (EDTA), incubation with proteinase K/ guanidine 
thiocyanate/ pepsin solution at 37OC for 10 minutes (PK, GT, Pep respectively), and 
soaking in 80% formic acid for an hour (FA). The best pretreatment was determined for 
each antibody based on intensity of staining and the pretreatment recommended by 
their respective companies.   
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Table 3: List of antibodies used for characterization of microglial phenotype 
Antibody Clone/type Epitope Dilution Pre-
treatment 
Source 
MHCII CR3/43, 
Mouse IgG1 
!-chain of the "! 
heterodimer of all 
products of the gene 
families DP, DQ and DR 
 
1: 200 CA Dako 
Iba1 Rabbit 
Polyclonal 
Synthetic peptide 
corresponding to C-
terminus of Iba1 
1:400 CA Wako 
MRC1 Rabbit 
Polyclonal 
Macrophage mannose 
receptor 1 precursor 
recombinant protein 
epitope signature tag 
(PrEST) 
1:1000 CA Prestige, 
Sigma-
Aldrich 
IL-1" Goat 
Polyclonal 
C-terminus of mouse IL-
1" 
1:400 CA Santa 
Cruz 
CD68 PG-M1, 
Mouse IgG3 
Fixative-resistant 
epitope on macrophage-
restricted form of CD68 
1: 500 CA Dako 
CD14 7, Mouse 
IgG2a 
External domain of 
CD14 
1:100 CA+ GT Novocastr
a 
 
CD163 10D6, Mouse 
IgG1 
Prokaryotic recombinant 
protein corresponding to 
domains 1-4 of N-
terminal region of 
CD163 
1:200 CA Novocastr
a 
Tau AT8, Mouse 
IgG1 
Tau phosphorylated at 
Ser-202/Thr-205 
1:800 None Autogen 
Bioclear 
Abeta 4G8, Mouse 
IgG2b 
a.a. 17-24 1:2000 FA Signet 
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Table 4: Additional antibodies and pretreatments tested for characterization 
Antibody Clone/type Epitope Titrations Pretreatment Control tissue Source 
Arg1 Rabbit 
Polyclonal 
Arg-1 recombinant protein 
epitope signature tag 
1:1000, 2000, 4000 FA, CA, PK Kidney, AD Prestige, Sigma-
Aldrich 
Arg2 Rabbit 
Polyclonal 
Arg-2, mitochondrial precursor 
recombinant protein epitope 
signature tag 
Neat, 1:150, 300, 600 FA, CA, PK Kidney, AD Prestige, Sigma-
Aldrich 
CD36 Rabbit 
Polyclonal 
Synthetic peptide corresponding 
to a region within amino acids 
(a.a.) 302 and 395 of CD36 
1:50, 100, 200, 500, 1000, 
2000 
None, CA, FA, EDTA Appendix, tonsil, 
brain infarct 
GeneTex 
TNF! Goat 
Polyclonal 
E. coli-derived recombinant 
human TNF-!. Val177-Leu233 
1:20, 50, 100, 200 None, CA, EDTA Tonsil, AD R&D systems 
BDNF Polyclonal 
Chicken IgY 
S. frugiperda insect ovarian cell 
line Sf 21-derived recombinant 
human BDNF. His129-Arg247 
Neat, 1:10, 20 None, CA, EDTA Tonsil, AD R&D systems 
IL-10 Goat 
Polyclonal 
S. frugiperda insect ovarian cell 
line Sf 21-derived recombinant 
human IL-10. Ser19-Asn178 
1:10, 20, 50, 100, 200 None, CA, EDTA Tonsil, AD R&D systems 
IL-1! Rabbit 
Polyclonal 
Recombinant human IL-1! 1:50, 100, 200, 400 CA, EDTA, Pep Brain infarct, AD Peprotech 
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3.4 Results  
 
3.4.1 Negative results using IHC on paraffin-embedded, formalin-fixed tissue  
Anti-Arg1 and Arg2 did not show immunoreactivity in AD brain tissue. Anti-Arg1 has 
been proven to work in paraffin-embedded, formalin-fixed lung tissue (Yan et al. 2010).  
Anti-IL-1! (Peprotech) did not show immunoreactivity in AD and brain infarct tissue. 
However, other papers have previously shown it to work in paraffin-embedded, 
formalin-fixed temporal lobe sections from epilepsy patients (Aboud et al. 2012), and 
AD brain tissue (Liu et al. 2011a). 
No immunoreactivity was observed for antibodies against cytokines TNF! and IL-10, 
and growth factor BDNF in AD and control brain tissues. This is most probably 
attributed to the labile nature of the antigens. However, other papers have previously 
shown for TNF! to work in paraffin-embedded, formalin-fixed mice ovarian tissue 
(Emmerson et al. 2009) and endoscopic biopsies specimens (Kuo et al. 2008). IL-10 
was found to work in paraffin-embedded, formalin-fixed human melanomas and 
metastases (Yaguchi et al. 2012, Itakura et al. 2011), lymphomas (Ogden et al. 2005), 
and lung tissue (Garantziotis et al. 2006). ELISA was used to investigate their 
expression levels and this is elaborated in Chapter 5.  
Antibodies used against Arg2, BDNF and CD36 also did not work well in the IHC 
experiments performed. Other laboratories have not tested them on paraffin-embeded, 
formalin-fixed tissues.  
 
3.4.2 Markers for identifying microglial activation are uniform within AD 
In order to identify microglial markers that would provide an insight into their varying 
activation states in the brain, MHCII, CD68, and Iba1 were utilized. While these three 
markers did not differentiate between classical or alternative activation, they gave 
information as to the degree of activation through intensity of staining and morphology.  
Iba1 immunostaining was done on a selection of AD cases. 20 slides were chosen at 
random from a range of cases and brain regions (frontal and occipital cortices, and 
hippocampus). Semi-ramified microglia – microglia with slight hypertrophy of their 
soma, but have yet to become fully amoeboid, with noticeable fine processes, were 
observed in both white and grey matter in most of these cases. (Figure 8)  
IHC was performed against MHCII on all AD and PD cases. Uniform immunoreactivity 
was observed throughout most brain regions in every case. Immunoreactivity was more 
prominent for MHCII than Iba1, suggesting that MHCII protein was upregulated more 
than Iba1 upon microglial activation. (Figure 9)  
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CD68 staining was carried out in three cases of AD as a proof-of-principle that 
microglial activation involved the upregulation of lysosomes and their ensuing 
phagocytic activity. CD68 immunoreactivity was seen in both amoeboid and ramified 
microglia. (Figure 10a, b) The staining was observed to be granular, ranging from large 
granules found in the soma to small particles found in both the soma and within 
microglial processes. Clusters of amoeboid microglia were also observed, almost 
certainly associated with A! plaques. (Figure 10c, d) 
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Figure 8: Iba1 as a pan-microglia marker 
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(A & B) Semi-ramified microglia reactive for Iba1 with a relatively even distribution in the occipital lobes 
of AD cases. Magnification x20 
(C & D) Clusters of Iba1-positive microglia in the (C) granular cell layer of the dentate gyrus and (D) 
entorhinal cortex of AD cases. Magnification x40 
!
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Figure 9: MHCII immunoreactivity in diseased brains 
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(A & B) Florid microglial activation immunoreactive for MHCII in the hippocampi of PD cases. Many of 
these microglia appeared more amoeboid than ramified. Distinction between density of microglia and 
level of microglial activation becomes difficult due to the intense upregulation of MHCII. Magnification 
x20 
!
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Figure 10: CD68 immunoreactivity in AD cases 
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(A) CD68 is expressed by microglia and PVM in the occipital cortex. Most of the microglia appeared 
ramified but still contain granules of late endosomes/ lysosomes. Magnification x20 
(B) A cluster of CD68 positive microglia in the occipital lobe that is most likely associated with an A! 
plaque. This implies that the microglial cells are active phagocytes. Magnification x20  
(C & D) Clusters of CD68 positive microglia around A! plaques in the occipital lobes. Magnification x40 
!
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3.4.3 Astrocytic labeling by IL-1!   
Immunostain using pro-inflammatory cytokine IL-1! antibody was performed on a 
random selection of AD and control cases. Staining was observed in astrocytes, instead 
of microglia. Protoplasmic and fibrous astrocytes were stained with IL-1!, in both AD 
cases and controls. (Figure 11a) The molecular layer of the cortex had a higher amount 
of astrocytic IL-1! stain. (Figure 11b) Clusters of astrocytes were also observed, and 
are clearly associated with A" plaques.  
 
 
 
Figure 11: Immunostaining of astrocytes by IL-1!  
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(A) Astrocytes immunoreactive for IL-1!. Aggregation of astrocytes around multiple neuritic A" 
plaques in the frontal lobe of an AD case. Magnification x20 
(B) Astrocytes found in the pons of a control case are also immunopositive for IL-1!. Protoplasmic 
and fibrous astrocytes are seen in the grey and white matter respectively. Magnification x20 
!
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3.4.4 Markers exclusive to perivascular macrophages are observed in the 
diseased brain parenchyma  
Studying the immunoreactivity of PVM markers in diseased brains is essential to gain 
insight into the influence of systemic inflammation and a possible breakdown in the 
blood-brain barrier (BBB) on microglial’s activation states and phenotypes. PVM are 
constitutively phagocytic, and investigating the function of phagocytosis in AD is 
especially relevant due to extracellular pathology like A! plaques and CAA. All three 
antibodies- MRC1, CD14 and CD163 were tested on a random selection of AD and 
control cases.  
MRC1 positivity in control and AD cases was restricted to PVM, meningeal (MM) and 
choroid plexus macrophages (CPM). (Figure 12) PVM were found around vessels in an 
elongated and flattened morphology, sandwiched between the end-feet of astrocytes 
forming the glial basement membranes and endothelial cells of the vessels. No MRC1 
immunoreactivity was observed in parenchymal microglia in control cases or AD cases.  
CD14 and CD163 positivity were mostly restricted to PVM, MM, and CPM in control 
cases. Staining for CD14 and CD163 in AD cases also labeled the three populations of 
macrophages, and revealed unexpected immunopositivity in parenchymal microglia. 
(Figure 13) 
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Figure 12: MRC1 immunoreactivity exclusive to brain macrophages  
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MRC1-immunopositive (A) MM and (B, C, D) PVM in the hippocampi of AD cases. Magnification x 
20 (A & B) and x40 (C & D) 
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Figure 13: CD14 and CD163 positivity in brain macrophages and parenchymal 
microglia  
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PVM and microglia were immunoreactive for (A) CD14 and (B) CD163 in the occipital and frontal 
lobes of AD cases respectively. Magnification x10 
!
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3.5 Discussion 
Characterizing the heterogeneous phenotypes of microglia using IHC requires the study 
of the several criteria, including the morphology, density, regional and localized 
distribution, and associations of each of these markers with one another and with 
pathology found in neurological diseases. Initial testing on a random selection of AD 
cases was done in order to identify markers that would immunostain sufficiently diverse 
in order to distinguish between separate microglial phenotypes.  
Novel antibodies that to our knowledge, have yet to be explored thoroughly in AD and 
PD were tested in this study. However, many of them did not show any positivity in 
human formalin-fixed, paraffin-embedded tissue (refer to table 4). This might be due to 
the destruction of antigens through fixation or IHC processing and harsh organic 
solvents. Residual water molecules that might have been trapped in the tissue by 
paraffin embedment will gradually cause degradation of antigens (Xie et al. 2011). 
Antigenic binding sites are not altered in frozen tissue sections as no chemical fixatives 
are used, and thus no harsh processing is required e.g. paraffin removal and antigen 
retrieval. These antibodies can be tested on frozen sections for future investigation. 
Levels of cytokines TNF! and IL-10, and neurotrophic factor BDNF will be assessed in 
PD cases using Western blotting (Chapter 5). 
Markers for nonspecific microglial activation were tested in this study. This included 
MHCII, CD68, and Iba1. MHCII is expressed by both classically activated and 
alternatively activated microglia (Taylor et al. 2005b). While it is not able to distinguish 
between activation states, MHCII can give an idea of the degree of activation. However, 
as observed in all AD and PD cases, a large majority of the cases consistently 
demonstrated extremely florid microglial activation, which excludes the use of this 
marker to differentiate between microglia phenotypes. This observation might be due to 
chronic microglial activation that was initiated early in the disease course (Croisier et al. 
2005), agonal state of the patient (Smith et al. 2012), or systemic inflammation (Perry 
2004).  Iba1 is a pan microglia marker and similar to MHCII, does not differentiate 
between microglia activation states (Ito et al. 2001). The intensity and density of Iba1 
immunoreactivity throughout the AD cases tested were rather consistent, excluding this 
marker for characterization purposes.  
CD68 immunoreactivity was upregulated by ramified and amoeboid microglia. While 
amoeboid microglia have always been associated with phagocytic activity, in actual fact 
microglial morphology tells us little about their phenotype or function (Colton and 
Wilcock 2010, Kettenmann et al. 2011). IHC staining in AD showed that late endosomal 
particles exist even in microglial processes, hence microglia do not need to take on an 
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amoeboid shape to carry out phagocytosis. Another way to view semi-ramified 
microglia immunoreactive for CD68 is a compromise in their ability to phagocytose, 
which provides an explanation for the incomplete clearance of A! plaques in the brains 
of AD patients.  
Another set of markers associated with microglia’s alternative activation state and 
phagocytic function was tested. The function of phagocytosis is intricately linked to 
microglia’s alternative activation/ acquired deactivation states (Colton 2009). PVM are 
extremely efficient phagocytes and are not restricted in their ability to engulf and digest 
cellular debris (Gate et al. 2010).  To this end, PVM markers involved in scavenging 
and uptake of foreign, waste or pathogenic material were used in the study.  
MRC1 is a mannose receptor involved in adhesion, pathogen recognition and 
clearance. Staining with MRC1, a PVM marker, remains restricted to perivascular 
spaces in AD. This is similar to other findings in which no other MRC1 expression was 
found in the parenchyma, despite acknowledged BBB damage e.g. in MS and models 
of excitotoxic damage and acute inflammation (Fabriek et al. 2005, Galea et al. 2005).   
CD14 has previously been used to distinguish between PVM and microglia, but later 
was found to be expressed by microglia in AD, HIV and HIV encephalitis (HIVE) 
(Cosenza et al. 2002, Liu et al. 2005). Our findings indeed show that microglia in AD 
cases were immunopositive for CD14 (CD14+), and the regional distribution of these 
microglia was patchy and uneven. CD14 has yet to be investigated in PD, and had only 
been tested in 9 cases of AD in another study (Liu et al. 2005). 
Previous investigation by our laboratory (investigator Lynn Christian) demonstrated 
CD163 immunoreactivity in microglia of TBI cases, providing incentive for testing this 
antibody in AD cases. CD163 is another PVM-specific marker (Fabriek et al. 2005, 
Borda et al. 2008) and its expression was restricted to PVM, MM and CPM in control 
cases. However we found CD163 immunopositive (CD163+) microglia in the 
parenchyma of AD cases. Foamy macrophages and microglia that are immunopositive 
for CD163 have been found in the parenchyma of HIVE (Roberts, Masliah and Fox 
2004), MS, and head injury cases (unpublished work). Profiling CD163 
immunoreactivity in AD and PD would be a novel study that can aid in the 
understanding of microglial alternative activation state and its phagocytic function.  
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Chapter 4: Characterization of CD14 immunoreactivity in AD 
and LBD 
 
4.1 Introduction 
 
4.1.1 Structure of CD14 
CD14 is a 55kDa glycosylphosphatidyl inositol-anchored protein found on the cell 
plasma membrane (Poussin et al. 1998). CD14 also exists in a soluble form. It is 
expressed by monocytes, macrophages and granulocytes, but is not found in neurons 
(Gregory 2000, Milatovic et al. 2004).   
CD14 takes on the shape of a bowed solenoid, made of up 11 turns, each containing 
leucine-rich repeats from amino acids 25-335. The convex side of the bent includes 5 
!-helices; the concave side contains a " sheet structure comprising 11 "-strands. This 
forms a large hydrophobic pocket at the N-terminus that probably functions as a binding 
site (Kelley et al. 2013).  
 
Figure 14: X-ray crystal structure of CD14 (human) 
                         
 
 
The structure is made up of human CD14 from a.a. 26-335. Locations of !-helices 1, 4, 5, 6 and 7, 
and "-strands 3-13 are indicated in the diagram. (Image taken from Kelley et al. 2013) 
!
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4.1.2 Functions of CD14 
Functions of CD14 include mediating immune responses to bacterial and microbial 
organisms through the recognition of PAMP. Both soluble and membrane-bound CD14 
are able to bind LPS, resulting in activation of myeloid and non-myeloid cells (Ulevitch 
and Tobias 1999). The activity associated with LPS interaction is mediated by the N-
terminal of CD14, which is kept intact in both the soluble and membrane-bound forms 
(Kelley et al. 2013). 
CD14 specifically interacts with TLR2 and TLR4 in response to bacterial pathogens to 
initiate downstream activation signaling, which brings about a pro-inflammatory 
response (Kielian 2006). It also plays a crucial role in the phagocytosis of apoptotic 
cells e.g. lymphocytes and erythrocytes (Schlegel et al. 1999). However, this initiates 
an anti-inflammatory response instead of a pro-inflammatory one. While the site of 
interaction on CD14 for the two respective targets are similar (Devitt et al. 1998), the 
difference in cellular response after binding of CD14 to either LPS or apoptotic cells is 
probably due to divergence of signaling pathways, either with the participation of a 
signaling partner e.g. LPS-binding protein, or additional accessory proteins (Gregory 
2000).  
 
4.1.3 Inflammatory roles of CD14 
While CD14 levels are reduced by IL-4, LPS or IFN! treatment (Becher, Fedorowicz 
and Antel 1996), they are increased with GM-CSF. Co-treatment with GM-CSF and IL-4 
resulted in the lowering of CD14 expression by microglia and monocytes, even after 
being stimulated with LPS. A decrease in phagocytic activity was also observed 
(Lambert et al. 2008). Soluble CD14 is also able to bind to and downregulate T cell 
responses (Rey Nores et al. 1999).  
 
4.1.4 Expression of CD14 
CD14 is expressed by both fetal and adult microglia in cell cultures, but at a lower level 
compared to monocytes. In the normal brain, CD14 immunoreactivity is only observed 
in monocytes/macrophages, not in microglia (Ulvestad et al. 1994). Hence, CD14 was 
initially used as a marker to distinguish between PVM and microglia in macaques 
(Williams et al. 2001). However, CD14+ parenchymal microglia have been found in HIV 
and HIVE, as well as AD cases (Cosenza et al. 2002, Liu et al. 2005). They were not 
observed in DLB patients (Letiembre et al. 2009).   
CD14 binds to fibrillar A! (Fassbender et al. 2004). CD14 is closely associated with 
fibrillar A! in AD cases, and CD14 greatly facilitates A! phagocytosis in vitro using 
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murine microglia, suggesting a role in the clearance of plaques in vivo (Liu et al. 2005). 
In vitro experiments also showed that when fibrillar A! is used as a stimulant, it leads to 
activation of NADPH oxidase and ROS production (Reed-Geaghan et al. 2009). CD14 
parenchymal microglia are more pronounced around diffuse than neuritic plaques 
(Letiembre et al. 2009).   
In a murine model of AD, CD14 knockout animals showed a reduced plaque burden, 
reduced number of microglia, and an alteration in microglia activation status with 
regards to A! plaques. This observation was not expected in the light of in vitro 
experiments where CD14 was essential for the phagocytosis of A! plaques. An 
increase in the mRNA of TNF", IFN!, and IL-10, and decrease in Fizz1 and Ym1 were 
also observed in these knockout animals. Specifically, IL-10 mRNA increase has been 
linked to reduced cerebral amyloidosis (Town et al. 2008, Reed-Geaghan et al. 2010).  
 
 
4.2 Aims 
The aim of this chapter was to investigate CD14 immunoreactive microglia and its 
spatial distribution in AD and PD. A possible temporal relationship between CD14 
immunoreactivity and the developmental stages of PD using Braak’s staging system 
was explored. Finally, the associations of CD14 immunoreactivity with clinical 
symptoms of PD and pathological hallmarks of AD and PD were studied. 
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4.3 Materials and Methods 
 
4.3.1 Case selection 
31 AD cases of Braak stages 5 and 6 obtained from the Corsellis Archival Collection 
were used in this study. (Refer to chapter 3 for selection criteria) Formalin-fixed, paraffin 
embedded samples from frontal cortex, hippocampus, and occipital cortex were used. 
The patient cohort comprised of 21 females and 10 males, age range 65-88, mean age 
at death 76. The information on age at death, gender, and cause of death are listed in 
Table 2.  
Using BNE’s staging protocol for !-syn pathology, 10 cases from Braak stage 6, and 6 
cases each from stages 4 and 5, and 5 cases from stage 3 were obtained from the 
UKPDSTB, making up a total of 27 cases of LBD. This was made up of PD and DLB 
cases (McKeith et al. 2005, Alafuzoff et al. 2009). Formalin-fixed, paraffin-embedded 
samples from the frontal cortex, cingulate cortex, striatum, basal forebrain, 
hippocampus, midbrain, pons, and medulla were used. Frozen sections from the frontal 
and cingulate cortices were obtained from 10 cases of LBD. The patient cohort 
comprised of 9 females and 18 males, age range 57-96, mean age of death 74. The 
age at death, gender, and cause of death for these cases are listed in Table 5.  
16 cases with no neurological or systemic disease were also selected as controls. 
These were classified as NPD (no psychiatric disease), and were obtained from both 
the Corsellis collection and the UKPDSTB. Formalin-fixed, paraffin-embedded samples 
from the frontal cortex, occipital cortex, cingulate cortex, striatum, basal forebrain, 
hippocampus, midbrain, pons, and medulla were used. The patient cohort comprised of 
8 females and 8 males, age range 59-81, mean age at death 70. Information on these 
cases is listed in Table 6. There were no significant differences in age at death between 
the AD, LBD and control group. 
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Table 5: Age, gender, causes of death and BNE !-synuclein staging of cases with 
LBD  
Parkinson’s disease (without dementia) 
Case 
no. 
Age at 
death 
Gender !-syn 
staging 
(Braak) 
Cause of death 
1 75 F 4 - 
2 81 M 4 Thrombosis histology 
3 80 F 4 “Old age” and Parkinson’s disease 
4 87 F 4 Gastrointestinal bleeding 
5 49 M 5 - 
6 75 M 5 Myocardial Infarction, Acute Renal Failure, 
Pneumonia 
7 72 M 4 Cardio-respiratory arrest; aspiration 
pneumonia, Parkinson’s disease 
8 77 F 5 End stage cardiac failure; moderate to 
severe LV dysfunction; Aortic & mitral valve 
disease; Colonic bleed, UTI 
9 79 M 5 Bronchopneumonia, Parkinson’s disease & 
GI Bleed 
10 66 M 4 - 
11 61 M 6 Bronchopneumonia 
12 86 M 6 Aspiration pneumonia and small bowel 
obstruction 
13 96 F 3 - 
14 74 M 6 Bronchopneumonia 
15 73 F 3 Progressive PD and recurrent CVA 
16 89 M 3 - 
17 57 M 5 Gastric cancer, liver and bone metastases 
Parkinson’s Disease with Dementia (PDD) 
1 80 F 6 Hypostatic pneumonia X 1 week; 
Parkinson’s disease; senile/presenile 
Dementia 
2 72 M 6 - 
3 66 M 6 Chest infection 
4 80 M 3 Dementia in Parkinson’s Disease: Lewy 
Body Dementia 
5 84 F 6 - 
6 78 F 6 Sepsis, pneumonia 
! ""#!
Dementia with Lewy Bodies 
1 61 M 3 Fall; upper cervical spinal cord damage 
2 70 M 5 Bronchopneumonia 
3 69 M 6 Dementia with Lewy bodies 
4 74 M 6 - 
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Table 6: Age, gender and causes of death of control cases  
Control cases 
Case no. Age at 
death 
Gender Cause of death 
1 M 59 Polyarteritis nodosa and related conditions 
2 F 59 Gastric ulcer 
3 M 62 Acute myocardial infarction 
4 M 63 Seropositive rheumatoid arthritis 
5 F 63 Chronic renal failure 
6 F 68 Crushing injury of thorax and traumatic amputation 
of part of thorax 
7 F 69 Acute myocardial infarction 
8 M 71 Chronic tubulo-interstitial nephritis 
9 M 71 Haemopericardium, Ruptured acute myocardial 
infarction 
10 F 72 Peptic ulcer 
11 M 74 Acute myocardial infarction 
12 M 75 Squamous cell carcinoma of the lung 
13 F 76 Pulmonary embolism 
14 M 78 Acute myocardial infarction 
15 F 80 Breast carcinoma with spinal metastasis; 
carcinosarcoma uterus 
16 F 81 Bronchial pneumonia, old age 
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4.3.2 Immunohistochemistry 
CD14 immunostaining was performed on all AD and LBD cases. Dilutions and 
pretreatments used are listed in Table 7. Frontal and occipital cortices, and the 
hippocampus region from AD cases, and frontal and cingulate cortices, striatum, basal 
forebrain, hippocampus, midbrain, pons, and medulla from the LBD cases were 
stained.  
 
 
Table 7: Primary antibodies used with CD14 in double immunofluorescence 
Antibody Clone/type Epitope Dilution Pretreat
ment 
Source 
CD14 7, Mouse 
IgG2a 
External domain of 
CD14 
1:100 CA+ GT Novocastra 
 
CD14 EPR3652, 
Rabbit 
Monoclonal 
IgG 
Synthetic peptide of 
human CD14 
1:500 CA Lifespan 
Biosciences 
!-
synuclein 
42, Mouse 
IgG1 
Rat !-syn a.a. 15-
123 
1:1000 FA Becton-
Dickinson 
Tau AT8, Mouse 
IgG1 
Tau phosphorylated 
at Ser-202/Thr-205 
1:800 None Autogen 
Bioclear 
Abeta 4G8, Mouse 
IgG2b 
a.a. 17-24 1:2000 FA Signet 
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4.3.3 Double Immunofluorescence 
Investigation into the relationship between CD14+ microglia and pathological hallmarks 
of AD and PD was carried out by double immunofluorescence (DIF). Antibodies against 
pathogenic A!, tau and !-syn (monoclonal mouse anti-human) were used together with 
CD14 (monoclonal rabbit anti-human). Pretreatments used are listed in Table 7. 
Antibody dilutions used for DIF are twice as concentrated as those used for IHC. When 
both antibodies used required different antigen unmasking, the pretreatments were 
done consecutively before addition of the primary antibodies concoction.  
Antibody clone 42 against !-syn was chosen due to its specificity and strong 
immunoreactivity towards a range of structures with !-syn inclusions (Croisier et al. 
2006).  
 
4.3.4 Semi-quantitative assessment of CD14+ microglia  
Rating of microglia’s CD14 positivity was carried out using subjective assessment of 
microglial abundance on all cases of AD, LBD and controls. This was based on a scale 
of 0-3- absent, mild, moderate and severe (refer to Figure 15 for an illustrative 
representation of the scale). Assessment was carried out in the frontal, cingulate and 
occipital lobes, caudate, internal capsule, putamen, nucleus basalis of Meynert (NBM), 
CA1-4, subiculum, entorhinal cortex, SN, LC and dorsal motor nucleus of the vagus 
(DMV). The region with the highest concentration of immunoreactive microglia was 
chosen for the ratings. All assessments were done at x10 magnification.  
Aside from the internal capsule, rating of microglia load was restricted to the grey 
matter in all brain region assessed. PVM were excluded during the assessment. Intra-
rater reliability gave a Cronbach’s alpha value of 0.977, indicating high internal 
consistency during assessment. Please refer to the appendix for CD14+ microglia 
ratings. 
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Figure 15: Figure legend of CD14+ microglia load 
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1- Extremely sparse ramified microglia throughout the brain region (! 3 per field) 
2- A slight increase in the number of microglia (! 10 per field) throughout the brain region, microglia 
display shortened and clumpy processes 
3- Dense concentrations of microglia with hypertrophy of cell bodies and retraction of processes, 
resulting in an apparent amoeboid morphology 
All images were taken at magnification x10.  
!
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4.3.5 Statistical analysis 
Statistical analysis was performed using SPSS version 20. Shapiro-Wilk test was used 
to assess normality for all comparisons. Kruskal-Wallis test followed by post hoc Dunn-
Bonferroni’s test for correction of multiple comparisons was used to assess the 
differences in ages at death in AD, LBD and control cases.  
Comparison of semi-quantitative assessment of CD14+ microglia load between AD and 
LBD, and association between CD14+ microglia load and gender, neuropsychiatric 
complications, or motor onset type were assessed using Mann Whitney U test. Any 
association between CD14+ microglia load and Braak staging of PD or tau pathology 
was assessed using either Mann Whitney U test, or Kruskal-Wallis test, followed by 
post hoc Dunn-Bonferroni’s test. Comparison across different brain regions within each 
disease was done using Friedman’s two-way ANOVA, followed by post hoc Dunn-
Bonferroni’s adjustment. Spearman correlation and partial correlation were used to 
detect the relationship between age of disease onset, age at death, and duration of 
disease with CD14+ microglia load. The criteria for all statistical significance was set at 
p<0.05.  
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4.4 Results 
 
4.4.1 Mild upregulation of CD14 immunoreactivity by parenchymal microglia in 
control cases 
CD14 immunoreactivity was observed in PVM, MM, and CPM as expected (Williams et 
al. 2001). (Figure 16a) Most of the 16 control cases used in this study also 
demonstrated CD14 immunoreactivity in microglia. These microglia took on a semi-
ramified morphology (Figure 16b), and had a patchy, irregular distribution. 4 cases did 
not demonstrate any parenchymal CD14 positivity (CD14+). This is in contrast to 
common understanding that microglia in control cases are negative for CD14 (Ulvestad 
et al. 1994).  
 
4.4.2 PVM and parenchymal microglia are CD14 immunopositive in AD and LBD 
PVM, MM and CPM were positive for CD14 in AD and LBD cases. CD14+ microglia 
were observed in all AD cases, and 23 out of 27 of the LBD cases. (Figure 16c- f) 4 of 
the LBD cases that did not demonstrate any CD14+ microglia consist of two DLB cases 
both of Braak stage 6, and two PD cases of Braak stages 4 and 5. These microglia 
appeared semi-ramified with an uneven distribution, similar to those observed in control 
cases. In addition, perivascular and sub-arachnoid macrophages of AD and PD also 
tend to display increased CD14 immunoreactivity. Blood vessels in close association 
with CD14+ amoeboid macrophages/microglia were rarely observed. (Figure 17) 
 
4.4.3 CD14 immunoreactivity is more extensive in AD than in LBD cases 
There was an increase in CD14+ microglia load in the frontal cortex (U= 182.00, 
p<0.001), CA1 (U= 126.50, p<0.005), subiculum (U= 148.00, p<0.005) and entorhinal 
cortex (U= 89.00, p<0.001) in AD compared to LBD cases. (Figure 18) The 
comparisons were carried out using Mann Whiney U tests.  
CD14 positivity in parenchymal microglia was compared within the available brain 
regions for each disease type using Friedman ANOVA, and brain regions with the area 
of highest CD14 load were noted. The frontal and occipital cortex of AD cases had the 
highest and second-highest CD14+ microglia load respectively (p<0.001), while in LBD 
cases, the highest area was the putamen, and a tie for the caudate and SN for the 
second highest CD14+ microglia load (p<0.001).  
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Figure 16: Immunoreactivity of CD14 in AD, PD, and control cases 
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(A) PVM are immunoreactive for CD14 in the frontal cortex of a control case. Magnification x10 
(B) CD14+ microglia in the occipital cortex of a control case. These are occasionally observed in control 
tissues and are usually semi-ramified. Magnification x10 
(C & E) CD14+ microglia in the parenchymal of the occipital cortex of two AD cases. Morphologies of 
microglia in AD range from semi-ramified to amoeboid. Magnification at x10 and x20 respectively  
(D & F) CD14+ microglia in the parenchyma of the (D) putamen and (F) frontal cortex of PD cases. The 
microglia immunoreactive for CD14 in PD cases appear to be lightly stained compared to AD cases, an 
indication perhaps that CD14 is upregulated to a greater extent in AD. This is most likely relevant to its 
function as a receptor for fibrillar A!. Magnification x10 and x20 respectively 
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Figure 17: Close association of CD14+ macrophages with blood vessels 
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CD14+ microglia/macrophages were observed in close proximity to blood vessels. Microglia density 
diminishes away from the vessels, suggesting there is an influx of macrophages/microglia from the periphery 
into the parenchyma. These were observed on rare occasions in cases of AD (A- roof of inferior horn of lateral 
ventricle & B- occipital) and PD (C- frontal). Magnification x10 
!
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Regions of AD and LBD cases with the highest CD14+ microglia load were compared 
using Mann Whitney U tests as well. Microglia load were higher in the frontal cortex of 
AD cases than in the putamen of LBD cases (U=241.50, p<0.005). They were also 
higher in the occipital cortex of AD cases than the SN or caudate of PD cases 
(U=127.00 for caudate, p<0.001. U=109.50 for SN, p<0.001). There was no difference 
between PD without dementia and PDD in any of the brain regions tested.  
 
4.4.4 Age at death correlates positively with immunoreactivity of CD14 in AD 
CD14+ microglia load in AD and PD cases were analysed for their associations with 
gender, age of onset, age at death and duration of disease. Using Spearman 
correlation, there was a statistically significant positive association between age at 
death and CD14 load in CA2 (!=0.508, p<0.05) and CA4 (!=0.576, p<0.01) of the 
hippocampus in AD. In PD and PDD cases, partial correlation did not find any 
association between gender, age of onset, age at death and duration of disease and 
CD14+ microglia load. When both AD and LBD cases were analysed together, the 
association between age at death and CD14+ microglia load in CA2 (!= 0.422, 
p<0.005) and CA4 (!= 0.444, p<0.005) remained significant. This relationship also 
became significant for CA3 (!= 0.355, p<0.05).  
  
4.4.5 Correlation between CD14 load and clinical and motor symptoms  
CD14+ parenchymal microglia load in all brain regions assessed in LBD did not show 
any association with neuropsychiatric dysfunctions (dementia, anxiety, depression, 
visual hallucinations, and psychosis), nor exhibit a temporal relationship with disease 
stages using Braak staging system (Alafuzoff et al. 2009).  However, a lower CD14+ 
microglia load was found to correlate with gait and balance impairment as a motor 
onset symptom. (U= 32.00, p<0.05) (Figure 19) 
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Figure 18: Comparison of CD14+ microglia load in various brain regions of AD and LBD cases 
!
CD14+ microglia load was assessed in all available brain regions in 31 AD cases and 27 LBD cases. Significant differences were observed from 
comparison of medians between the frontal lobe and hippocampal regions (CA1, subiculum and entorhinal cortex) of AD and LBD cases. Columns 
represent mean CD14+ microglia load in their respective brain regions in AD and LBD cases.  
!
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Figure 19: Boxplot showing CD14+ microglia load in the substantia nigra in 
relation to gait and balance impairment as a motor onset symptom in LBD 
patients 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CD14+ microglia load was compared between LBD cases (n=27) with and without gait and balance 
impairment as the initial motor onset type. Out of all the brain regions tested, the only region that 
displayed significant difference in CD14+ microglial load between these two groups was the 
substantia nigra. 
!
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4.4.6 CD14+ microglia are associated with A!  plaques and !-syn pathology, but 
not tau pathology 
DIF demonstrated co-localisation of CD14+ microglia with A! plaques in AD cases. The 
co-localisation was seen with both diffuse and neuritic plaques, but not with CAA. 
(Figure 20) Many of these microglia have taken on a more amoeboid shape.   
DIF was performed using anti-CD14 and anti-tau antibodies. NFT, NT and neuritic 
plaques were stained by AT8. (Figure 21) Similar to Lewy pathology, CD14+ microglia 
were also found within areas of intense tau pathology, but there was no obvious 
association between CD14+ microglia and NFT or NT.  
When DIF was performed with anti-CD14 and anti-!-syn, intracellular Lewy inclusions 
within CD14+ amoeboid microglia were observed. (Figure 22) CD14+ microglia were 
found at close proximity to other neurons containing Lewy inclusions e.g. LB or LN, but 
any associations cannot be confirmed with immunofluorescence microscopy alone.  
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(A-C) DIF for CD14 
(red) and A! (green) in 
the occipital cortex of 
AD cases. Amoeboid 
CD14+ microglia 
coincide with (A & C) 
diffuse and (B) neuritic 
A! plaques. A few 
microglia were seen 
around the amyloid 
laden vessel (arrow) in 
(C). Magnification x40 
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Figure 20: Double immunofluorescence of CD14 with A!  pathology 
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Figure 22: Double immunofluorescence of CD14 with !-synuclein pathology  
!
Figure 21: Double immunofluorescence of CD14 with tau pathology  
!
DIF for CD14 (red) and 
!-syn (green) in the 
hippocampus of a PD 
case. Amoeboid 
CD14+ microglia 
contained !-syn 
inclusions (arrow). 
Magnification x40  
!
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DIF for CD14 (red) and 
AT8 (green) in the 
occipital lobe of an AD 
case. CD14+ microglia 
are in close proximity 
with neuropil threads 
but no specific 
associations can be 
confirmed. 
Magnification x40  
!
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4.5 Discussion 
This chapter explored CD14 as a parenchymal microglial marker in AD, LBD and 
control cases. The results are in agreement with Letiembre et al. 2009 with respect to 
the presence of CD14+ microglia in AD. While other studies have demonstrated AD 
positivity, DLB were found negative for microglial CD14, and investigation has not been 
made in PD yet (Liu et al. 2005, Letiembre et al. 2009). This discrepancy might be due 
to the limited number of cases tested. Contrary to expectations, CD14 immunoreactivity 
in microglia was also observed in PD, DLB, and control cases, albeit to a lesser extent 
than in AD cases. Out of 4 DLB cases tested, two demonstrated CD14 positivity in 
microglia. CD14+ microglia load was most prominent in the striatum and SN of PD 
cases, coinciding with brain regions with the greatest loss of DA neurons.  
Using DIF, CD14+ microglia were shown to associate with A! plaques. CD14+ 
microglia is upregulated in AD, and this is probably due to the ability it confers to 
microglia i.e. to enable them to recognize and internalize fibrillar A!. Their phagocytic 
function is further substantiated by their amoeboid morphology. A greater number of 
microglia were observed to cluster around diffuse plaques compared to neuritic 
plaques (Figure 20). This is also observed in the study done by Letiembre et al. 2009. 
A greater attraction towards diffuse plaques could be due to several factors. Diffuse 
plaques might be most malleable to breakdown and phagocytosis compared to other 
plaque types. CD14+ microglia might also aid in the maturation of plaques, from diffuse 
to end-stage “burnt-out” plaques (Dickson and Vickers 2001).  
Qualitative assessment shows a huge discrepancy between the number of CD14+ 
microglia and the amount of A! plaques present in AD cases. The antibody against 
CD14 evidently highlights only a subset of microglia, compared to activated microglia 
stained against MHCII (Figure 9) or a pan-microglia stain against Iba1 (Figure 8). We 
hypothesize that only a certain population of microglia are equipped with the ability to 
phagocytose A! plaques; or due to the dystrophic nature of microglia in 
neurodegenerative diseases (Streit et al. 2009), most microglia are unable to effectively 
phagocytose A! plaques. This could explain the poor clearance of plaques in AD.  
CD14 is constitutively expressed on monocytes and macrophages. IHC experiments 
consistently showed PVM, MM and CPM immunoreactive for CD14 in diseased and 
control cases. On rare occasions, clusters of CD14+ macrophages were seen 
surrounding blood vessels, probably signifying a compromise in the vessel wall and an 
influx of macrophages into the brain parenchyma. Although CD14 is not usually 
expressed by microglia, results from the study support the idea that CD14+ microglia 
are not derived from the periphery, but instead upregulate CD14 expression in 
! "#$!
response for the increased need for phagocytosis. The lack of association between 
most vessels with CD14+ microglia, including vessels with CAA, substantiates this 
theory.  
In LBD cases, CD14+ microglia were found to coincide with !-syn Lewy inclusions. 
These microglia had an amoeboid morphology, an indication of their phagocytic ability. 
However, most LB and LN did not associate with CD14+ microglia. These inclusions 
within CD14+ microglia might be derived from the ingestion of extracellular LB.  
Microglia labeled with Iba1 has been shown to associate with NFT in a rat model of 
taupathy (Zilka et al. 2009), but this was not observed with CD14+ microglia, even 
though CD14+ microglia are in very close proximity to neurons containing NFT and NT. 
There is most likely an array of microglia subsets with diverse functions- different types 
of microglia are equipped to respond to an array of pathology. As NFT and NT are 
intracellular, the microglia interacting with affected neurons might respond by taking on 
a neurotrophic profile instead of a phagocytic one.   
CD14+ microglia load increases along with age at death in the CA2, 3, and 4 sectors of 
AD and LBD cases. CA2 and CA4 are not implicated in AD unlike CA1 and CA3, where 
significant neuronal loss is observed (Padurariu et al. 2012). In PD, the hippocampal 
region is also affected, the most vulnerable site being CA2 (Pereira et al. 2013). The 
susceptibility of the hippocampus towards pathological changes might stimulate the 
upregulation of CD14 in microglia.  
The correlation between gait and balance impairment as a motor onset symptom and 
lower amounts of CD14+ microglia in the SN might support the idea that these 
microglia are neuroprotective. PIGD-dominant PD patients exhibit a faster cognitive 
decline compared to tremor-dominant patients (Alves et al. 2006). Nigral NFT relate 
positively with gait impairment (Schneider et al. 2006), but no correlation between tau 
pathology in SN and CD14+ microglia was found in our study. 
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Chapter 5: Characterization of CD163 immunoreactivity in AD 
and LBD 
 
5.1 Introduction 
 
5.1.1 Structure of CD163 
CD163, also known as M130, RM3/1, or p155 is a 130 kDa transmembrane 
glycoprotein found on monocytes and macrophages. It belongs to a subfamily of 
scavenger receptor cysteine-rich (SRCR) domain proteins, which are characterized by 
having a short cytoplasmic tail, a transmembrane segment and an extracellular part 
formed from 9-SRCR domains (Figure 23). 4 splice variants that differ in the 
cytoplasmic tail have been reported (Hogger et al. 1998, Van den Heuvel et al. 1999, 
Graversen, Madsen and Moestrup 2002).  
The SRCR domain is made up of around 100 amino acids. CD163’s SRCR domains 
belong to class B, which are found only in vertebrates and is encoded by a single exon. 
Its conformation in 3D probably resembles a six-stranded !-sheet cradling a single "-
helix, similar to a class A SRCR domain. The interaction site is made of highly variable 
residues located on a long loop of amino acids between !-strands 5 and 6 of the SRCR 
domain, of which several come together to form an ideal ligand binding site (Graversen 
et al. 2002).  
The splice variants of CD163 differ mainly in the lengths of their cytoplasmic tails, 
ranging from 49 amino acids (more abundant isoform) to 84 and 89 amino acids. The 
first 42 amino acids after the membrane-spanning segment containing consensus 
sequences for internalization and phosphorylation with protein kinase C and creatine 
kinase are retained among the isoforms (Graversen et al. 2002). Their varying 
subcellular localization, i.e. shorter tail variant is mainly localized to the cell surface, 
while longer tail variants are more often found in the trans-golgi network and 
endosomes, and might indicate different functionalities of the isoforms (Akila et al. 
2012).  
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Figure 23: Schematic representation of the structure and domain organization of 
membrane-bound CD163  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD163 consists of a 1003 amino acid extracellular portion with 9 class B SRCR domains, with 
domains 6 and 7 separated by a 31 amino acid linker. This linker is composed of many proline, 
serine and threonine residues (PST). Another PST linker connects the last SRCR domain to the 
transmembrane segment, which is made up of 24 amino acids. The intracellular cytoplasmic domain 
ranges from 49 to 89 amino acids that contain consensus sequences for phosphorylation and 
internalization   
!
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5.1.2 Functions of CD163 
CD163 functions as a hemoglobin (Hb) scavenger by binding and internalizing 
haptoglobin-hemoglobin (Hp-Hb) complexes from the blood (Kristiansen et al. 2001, 
Nguyen et al. 2005). After Hp-Hb complexes are endocytosed, the globin undergoes 
lysosomal proteolysis, while the heme gets broken down into iron and bilirbin; around 
10% of all Hb is cleared by this method (Graversen et al. 2002).   
CD163 might have a role in host defense, as it is able to recognize and bind both 
Gram-negative and Gram-positive bacteria. This causes production of pro-inflammatory 
cytokines in monocytes, which leads to elimination of bacterial infection, though 
phagocytosis was not observed (Fabriek et al. 2009).   
 
5.1.3 Inflammatory roles of CD163 
CD163 expression is induced/ enhanced by IL- 6, IL-10, macrophage colony 
stimulating factor (M-CSF), and glucocorticoids (Zwadlo-Klarwasser et al. 1990, 
Wenzel, Roth and Sorg 1996, Hogger et al. 1998, Van den Heuvel et al. 1999). The 
promoter region of the gene contains potential binding sites for glucocorticoid receptor 
and transcription factors for myeloid differentiaton (Ritter et al. 1999). Production of IL-6 
and IL-10 actually occurs simultaneously with upregulation of CD163, and act as 
intermediates in boosting CD163 expression (Weaver et al. 2007). Though touted as 
an anti-inflammatory marker, it is not induced by IL-4 nor IL-13. It is downregulated by 
LPS, TNF-!, TGF" and IFN-# (Buechler et al. 2000, Sulahian et al. 2000, Pioli et al. 
2004).   
 
5.1.4 Expression of CD163 
CD163 expression is observed on monocytes and macrophages (Zwadlo et al. 1987, 
Pulford et al. 1992, Lau, Chu and Weiss 2004, Nguyen et al. 2005, Fabriek et al. 2009). 
CD163 expression has been hypothesized to occur only on macrophages at certain 
stages of differentiation, or activation state (Lau et al. 2004). Augmented expression of 
CD163 on phagocytic macrophages e.g. in liver and spleen, as compared to 
monocytes, might point to the result of a maturation process (Pulford et al. 1992, 
Sanchez et al. 1999, Schaer, Alayash and Buehler 2007). It can be induced on 
microglia in vitro by stimulation with Hp-Hb (Borda et al. 2008).  
CD163 expression has been observed in different diseases. In SIVE and HIVE cases, 
CD163 expression is highly upregulated in the microglia found within the grey matter. 
The reason for this observation was the presence of Hb-Hp complex in the tissue due 
to vascular compromise (Roberts et al. 2004, Borda et al. 2008). Both foamy 
macrophages and microglia were found to express CD163 in MS near to or within the 
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lesions. Some of the macrophages contained myelin debris instead of Hb-Hp 
complexes (Fabriek et al. 2005). In SIV, AD, systemic sepsis and AIDS, expression 
was restricted to PVM (Roberts et al. 2004, Borda et al. 2008).   
 
 
5.2 Aims 
The aim of this chapter was to investigate CD163 immunoreactive microglia and its 
spatial distribution in AD, PD and TBI. A possible temporal relationship between CD163 
immunoreactivity and the developmental stages of PD using Braak’s staging system 
was explored. A comparison of consistency and reliability between assessment 
methods of microglia load was carried out using semi-quantitative measurements on 
IHC stains and Western blot. 
The associations between CD163 immunoreactivity and pathological hallmarks of AD 
and PD were studied. The association between level of CD163 immunopositivity and 
clinical symptoms of PD were also analysed. Finally, the relationships between level of 
CD163 immunopositivity and levels of TNF!, BDNF, and IL-10 were investigated using 
ELISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! "#$!
5.3 Materials and methods 
 
5.3.1 Case selection  
For IHC, AD, LBD, TBI, and control cases were used. All cases other than TBI were 
previously used in chapters 3 and 4. Please refer to chapter 3.2.1 and 4.2.1 for 
selection criteria. 41 cases of TBI were obtained from the tissue archive in the 
Department of Neuropathology, Southern General Hospital at the University of 
Glasgow. (Table 8) All cases were assessed by Professor Gentleman and exhibited 
TAI. A single slide from various regions of the cortex was obtained for all cases. In 
addition, cingulate cortices were obtained for 8 of these cases.  
For Western blotting and ELISA, 18 samples consisting of frontal and cingulate cortices 
were obtained across 10 cases of LBD from the UKPDSTB. Grey matter was obtained 
from the frontal cortices. A mixture of grey and white matter was obtained from the 
cingulate cortices due to tissue availability and orientation. CD163+ microglia load in 
these brain regions were assessed previously and ranged from mild to severe. 
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Table 8: List of traumatic brain injury cases  
Case no. Age at death Survival time 
(days) 
A!  plaques 
1 45 13 1 
2 46 10 1 
3 24 4 0 
4 20 7 0 
5 20 5 0 
6 47 0 0 
7 0.58 0 0 
8 56 3 0 
9 20 2 0 
10 26 3 0 
11 52 4 0 
12 18 2 0 
13 22 13 0 
14 47 1 0 
15 65 1 1 
16 20 5 0 
17 46 10 0 
18 21 1 0 
19 17 7 0 
20 29 12 0 
21 26 1 0 
22 37 2 0 
23 9 2 0 
24 27 1 0 
25 9 5 0 
26 25 0 0 
27 62 1 1 
28 32 3 0 
29 28 1 1 
30 16 2 1 
31 14 0 0 
32 16 2 0 
33 5 9 0 
34 62 11 0 
35 32 5 0 
36 17 4 0 
! "#$!
37 21 8 0 
38 75 3 0 
39 56 4 1 
40 43 11 0 
41 59 4 1 
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5.3.2 Immunohistochemistry 
CD163 immunostaining was performed on all AD, LBD, and TBI cases. Dilution and 
pretreatment used are listed in Table 9. Brain regions analysed for AD and LBD were 
similar to those used in Chapter 4.  
 
5.3.3 Double Immunofluorescence 
DIF was used to investigate the relationship between CD163+ microglia and 
pathological hallmarks of AD and PD. Antibodies against pathogenic A!, tau and !-syn 
(polyclonal rabbit anti-human) were used together with CD163. Staining against CD68 
was carried out to ascertain the phagocytic ability of CD163+ microglia. Antibodies 
against MRC1, Iba1 and fibrinogen were examined together with CD163 to learn the 
source of CD163+ microglia.  
Pretreatments used are listed in Table 9. Antibody dilutions used for DIF are twice as 
concentrated as those used for IHC (refer to table 9). When both antibodies used 
required different antigen unmasking, the pretreatments were done consecutively 
before addition of the primary antibodies concoction.  
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Table 9: Primary antibodies used with CD163 in double immunofluorescence 
Antibody Clone/ 
type 
Epitope Dilution Pretreat-
ment 
Source 
CD163 10D6, 
Mouse 
IgG1 
Prokaryotic 
recombinant protein 
corresponding to 
domains 1-4 of N-
terminal region of 
CD163 
1:200 CA Novocastra 
!-synuclein Rabbit 
Polyclonal 
a.a. 111-131 1:2000 FA Millipore 
Tau Rabbit 
Polyclonal 
C terminal a.a. 243-
441 
1: 
20000 
None Dako 
Abeta Rabbit 
Polyclonal 
Synthetic peptide 
corresponding to a.a. 
1-16 of A! peptides 
38, 40, and 42 
1:500 FA Synaptic 
Systems 
MRC1 Rabbit 
Polyclonal 
Macrophage mannose 
receptor 1 precursor 
recombinant protein 
epitope signature tag 
(PrEST) 
1:1000 CA Prestige 
Antibodies 
Iba1 Rabbit 
Polyclonal 
Synthetic peptide 
corresponding to C-
terminus of Iba1 
1:400 CA Wako 
CD68 PG-M1, 
Mouse 
IgG3 
Fixative-resistant 
epitope on 
macrophage-restricted 
form of CD68 
1:500 CA Dako 
Fibrinogen Rabbit 
Polyclonal 
Fibrinogen isolated 
from human plasma 
1:5000 CA Dako 
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5.3.4 Semi-quantitative assessments of CD163+ microglia  
CD163 immunoreactivity in parenchymal microglia was measured using two semi-
quantitative approaches. The first was carried out using subjective assessment of 
microglia abundance based on a scale (CD163+ microglia load) identical to the one 
used in chapter 4. Please refer to figure 15 for a pictorial representation of the scale. 
CD163+ microglia in the cingulate cortex, entorhinal cortex, and LC of PD cases, and 
TBI cases were quantified using microglia load.  
The second semi-quantitative assessment method involves percentage area (%area) 
measurement of detected cells in the region with the highest density of microglia cells. 
Assessment was carried out on all AD, LBD and control cases. CD163+ microglia from 
the frontal and occipital lobes, as well as the entorhinal cortex of AD and control cases 
were quantified using %area. Those in the frontal, cingulate and occipital lobes, 
caudate, internal capsule, putamen, NBM, CA1-4, subiculum, entorhinal cortex, SN, LC 
and DMV of PD and the remaining control cases were also quantified with %area. 
For each brain region, the area with the highest amount of CD163+ parenchymal 
microglia was determined by eye and examined at x10 magnification with a field area 
of 0.153mm2. On the occasion that the rater is unable to pick out the region with the 
highest microglia density, multiple regions in the same tissue section were measured. 
Similar to microglia load assessment, measurement of %area was restricted to grey 
matter for all brain regions assessed other than the internal capsule.  Image Pro Plus 
software was used to assess the area occupied by parenchymal microglia within the 
image generated. The software measures the areas of immunoreaction using a 
process called segmentation, which allows the isolation of color components in the 
image based on a color threshold. This measures the number of pixels occupied by 
immunoreactive microglia. As DAB produces a brown precipitate, segmentation was 
performed using the blue component of the image as this enhances the brown of the 
immunolabelled microglial cells. Thresholding was performed individually for each slide 
as the intensity of immunostaining might differ with each experimental batch. In order to 
prevent CD163+ PVM from influencing the measurement of CD163+ microglial cells in 
the parenchyma, all PVM were manually deselected from images. Intra-rater reliability 
gave a Cronbach’s alpha value of 0.973, indicating high internal consistency during 
assessment. Please refer to the appendix for CD163+ microglia ratings. 
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5.3.5 Western Blot  
Refer to section 2.6 and 2.7 for protein extraction and quantification, complete protocol 
of Western blotting and !-actin normalization. Primary antibody rabbit polyclonal IgG 
against CD163 (Santa Cruz, USA) recognizing the C-terminal of CD163 amino acid. 
1027-1156 was used at 1:200. Secondary antibody HRP-conjugated goat anti-rabbit 
IgG (Sigma, UK) was used at 1:5000.  
 
5.3.6 ELISA 
ELISA was carried out following the instructions from the respective antibody kits. 
TNF" and IL-10 ELISA Development kit from Peprotech (UK) and BDNF Emax 
Immunoassay system from Promega (UK) were used in this study. Please refer to 
section 2.8 for experimental details.  
 
5.3.7 Statistical analysis 
Statistical analysis was performed using SPSS version 20. Shapiro-Wilk test was used 
to assess normality for all comparisons. Comparison of CD163 %area between AD and 
LBD, and association between CD163 %area and gender, neuropsychiatric 
complications, or motor onset type was assessed using Mann Whitney U test. Any 
association between CD163+ microglia load and Braak staging of PD was assessed 
using either Mann Whitney U test, or Kruskal-Wallis test, followed by post hoc Dunn-
Bonferroni’s test. Comparison across different brain regions within AD and LBD was 
done using Friedman’s two-way ANOVA, followed by post hoc Dunn-Bonferroni’s 
adjustment. Spearman correlation and partial correlation were used to detect the 
relationship between CD163 %area and age of disease onset, age at death, and 
duration of disease for AD and LBD.  
Pearson and Spearman correlations were used to correlate measurements of CD163 
expression (Western blot) with %area, and %area with CD163+ microglia load (scale 0-
3). Spearman correlation was used to study the correlation between CD163 %area and 
expression levels of TNF", IL-10 and BDNF detected by ELISA. The criteria for all 
statistical significance was set at p<0.05.  
Kruskal-Wallis tests followed by Dunn-Bonferroni correction, Jonckheere-Terpstra tests 
and partial correlations were used to study the association of CD163+ microglia load 
with the age at death and survival times of TBI cases. Presence of A! plaques was 
correlated with age at death, survival times, and CD163+ microglia load using Mann 
Whitney U tests.  
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5.4 Results  
 
5.4.1 CD163 immunoreactivity is restricted to PVM in majority of control cases  
In 12 out of 16 control cases, the only CD163 positivity seen was in PVM, MM and 
CPM. (Figure 24a) Little or no CD163 immunostaining was observed in parenchymal 
microglia. This observation is in agreement with the concept that CD163 is a marker 
specific for monocytes (Fabriek et al. 2005, Kim et al. 2006, Borda et al. 2008).  
 
5.4.2 PVM and parenchymal microglia are CD163 immunopositive in AD and LBD 
CD163+ microglia in the parenchyma was found in all cases of AD and LBD, in addition 
to CD163+ PVM, CPM and MM. These microglia typically took on a semi-ramified 
morphology (Figure 24b), were distributed in a patchy pattern and tended to be close to 
the meninges (Figure 24c). CD163 immunoreactivity in both AD and LBD cases ranged 
from mild to severe. (Figure 25) This finding is different from other reports (Roberts et 
al. 2004) whereby CD163+ microglia were mostly restricted to perivascular and sub-
arachnoid spaces; once again, this observation might be due to the limited number of 
cases tested in previous studies.  
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Figure 24: IHC detection of CD163  
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(A) PVM expressing CD163 in the frontal cortex of a control case. Magnification x20  
(B) Parenchymal microglia expressing CD163 in the frontal cortex of an AD case. Magnification x 40  
(C) Microglia expressing CD163 in close proximity to meningeal spaces in the occipital cortex of an AD case. 
Magnification x20  
!
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(A) mild upregulation in the frontal cortex (B) moderate upregulation in the occipital cortex (C) severe 
upregulation in the frontal cortex. Magnification x10 
!
 
Figure 25: Range of CD163 immunoreactivity in microglia of AD cases  
!
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5.4.3 CD163 immunoreactivity is more extensive in AD than in LBD cases 
There was a significant increase in CD163+ microglia load in the frontal cortex (U= 
105.00, p<0.001), CA1 (U= 135.00, p<0.005), CA3 (U= 190.50, p<0.05), CA4 (U= 
177.00, p<0.05), subiculum (U= 94.00, p<0.001) and entorhinal cortex (U= 141.00, 
p<0.005) of AD compared to LBD cases. (Figure 26) Qualitative assessment of PVM 
also showed them to be more numerous and prominently stained in AD than LBD.   
%area of CD163 positivity in parenchymal microglia was compared within the available 
brain regions for each disease type using Friedman ANOVA and brain regions with the 
area of highest CD163 load were noted.  The frontal and occipital cortex of AD cases 
had the highest and second-highest %area occupied by CD163+ microglia respectively 
(p<0.001), while in LBD cases this was observed in the SN and DMV respectively 
(p<0.001).  
Regions of AD and LBD cases with the highest %area occupied by CD163+ microglia 
were compared using Mann Whitney U tests, with median (Mdn) given as a reference 
point. %area measurements were significantly higher in the frontal cortex (Mdn= 
1.19%) of AD cases than SN (Mdn= 0.70%) in LBD cases (U=254.00, p<0.01). They 
were also significantly higher in the occipital cortex (Mdn= 1.62%) of AD cases than 
DMV (Mdn= 0.43%) of LBD cases (U=194.00, p<0.001). There was no difference 
between PD without dementia and PDD in any of the brain regions tested.  
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%area of CD163+ microglia was assessed in all available brain regions in 31 AD cases and 27 LBD cases. Significant differences were observed from comparison of 
the median between the frontal lobe and hippocampal regions (CA1, CA3, CA4, subiculum and entorhinal cortex) of AD and LBD cases. Columns represent mean 
%area of CD163+ microglia in their respective brain regions for AD and LBD cases.  
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Figure 26: Comparison of percentage area of CD163+ microglia in various brain regions of AD and LBD cases 
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5.4.4 Do CD163 parenchymal microglia originate from the periphery? 
DIF was carried out with Iba1 and MRC1 to explore the similarities between CD163+ 
microglia and PVM. Iba1 is a pan-microglia marker that does not label PVM, while 
MRC1 is a PVM specific marker. Association with either Iba1 or MRC1 may shed light 
on whether the CD163+ microglia originated from the periphery, or are resident to the 
CNS. Fibrinogen was also used to test for damage to the integrity of the BBB.   
While it was expected that all CD163+ microglia would co-stain with Iba1, absence of 
Iba1 was observed in many of them. (Figure 27a, b) It was found that MRC1 positivity 
was strictly limited to PVM (Figure 27c). Staining for fibrinogen revealed perivascular 
leakage around small to medium sized vessels and around pial vessels in both AD 
and PD cases. (Figure 28) This was seen as a diffuse pattern that remained in a halo 
around the compromised vessels. Most vessels in both AD and PD were spared from 
BBB breakdown, as surmised from the presence of fibrinogen only within the blood 
vessel lumen. DIF showed CD163+ microglia had a tendency to be found in close 
proximity to sites of BBB damage.  (Figure 29) These blood vessels with fibrinogen 
leakage were not associated with CAA, neither did CAA show any association with 
CD163+ microglia. (Figure 30) 
 
5.4.5 Correlation between CD163 %area and clinical symptoms of LBD cases  
Negative correlation was found between anxiety and CD163 %area in the cingulate 
cortex (U= 27.0, p<0.05), entorhinal cortex (U= 36.0, p<0.05), and LC (U= 30.0, 
p<0.05) in LBD cases. (Figure 31) These correlations remained statistically significant 
whether or not DLB cases were included in the statistical tests.  
No correlation was found between CD163 %area and motor onset symptoms (tremor, 
rigidity, gait and balance impairment). There was also no correlation between Braak 
stages of PD and CD163 %area, and CD163 %area with age at death, disease onset 
age and duration of disease in both AD and LBD cases tested.     
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(A & B) DIF for CD163 (red) and 
Iba1 (green) in the occipital cortex 
of AD cases. Not all CD163+ 
microglia stained for Iba1 
(centerfield), a marker highly 
specific for microglia. This suggests 
that CD163+ parenchyma microglia 
might originate from systemic cells 
that have yet to obtain an Iba1+ 
profile. The presence of Iba+ 
CD163+ microglia also indicates 
that resident microglia might be 
able to express CD163 with 
stimulation from the periphery. 
Magnification x40 
(C) DIF for CD163 (red) and MRC1 
(green) in the occipital cortex of an 
AD case. CD163 co-stains PVM 
with MRC1. MRC1 expression is 
limited to PVM. This is in 
concordance with findings that 
MRC1 is restricted to PVM despite 
a clear BBB breakdown. 
Magnification x40  
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Figure 27: Double immunofluorescence of CD163 with microglia/macrophage markers Iba1 and MRC1 
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Figure 28: Immunofluorescence staining against fibrinogen 
!
Fibrinogen was found to exude from compromised blood vessels in both AD and PD cases, but to a lesser extent in the PD cases. (A) occipital cortex of an AD case. 
Magnification x20.  (B) cingulate cortex of a PD case. Magnification x40 
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Figure 29: Double immunofluorescence of CD163 with fibrinogen 
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DIF for CD163 (red) and 
fibrinogen (green) in the (A) 
frontal and (B) occipital cortex 
of AD cases. CD163+ microglia 
were seen at close proximity to 
areas of fibrinogen leakage in 
the parenchyma. This raises the 
possibility that CD163+ 
microglia are a result of 
migration from the periphery. 
Astrocytes were also found to 
have fibrinogen 
immunoreactivity. Magnification 
x20 
!
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Figure 30: Double immunofluorescence detection of CD163 with CAA 
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Neither CD163+ PVM nor 
microglia appear to be overtly 
reacting to CAA in the occipital 
lobes of an AD case. A! 
plaques are observed in the 
vicinity of these vessels and 
clearly associated with CD163+ 
microglia. Magnification x40!
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Figure 31: Level of CD163 immunoreactivity in LBD patients with anxiety 
symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Columns represent the mean %area of CD163+ microglia in the cingulate cortex (blue), entorhinal cortex 
(green), and locus coerulus (beige) of LBD cases (n=27). Out of all brain regions tested for LBD, 
associations between CD163 %area and presence of anxiety were found to be statistically significant in 
these three regions.  
!
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5.4.6 CD163+ microglia are associated with A!  plaques, but not NFT or !-syn 
pathology 
Using DIF, CD163+ microglia were found to co-localise with A! plaques. Microglia 
clusters were seen within plaques with most of them found in the core of neuritic 
plaques (Figure 32), and fewer of them within diffuse plaques. While many of these 
microglia retained their ramifications, some of them seemed to have taken on a more 
amoeboid shape, indicating phagocytosis. This was observed in AD, LBD and control 
cases. DIF was also performed using antibodies against CD68 and CD163, to confirm 
the phagocytic nature of CD163+ microglia. Many of the CD163+ microglia were 
positive for CD68, particularly those with a more amoeboid shape. (Figure 33a) 
DIF was performed using antibodies to CD163 and NFT or !-syn, there was no visible 
signs of interaction between CD163+ microglia and intracellular NFT (Figure 33b) or 
!-syn. However, in rare cases, microglia were found to associate with extracellular !-
syn. (Figure 33c)  
 
5.4.7 Cytokines and neurotrophin levels do not correlate with CD163+ microglia 
load 
Expression levels of TNF", IL-10 and BDNF detected using ELISA did not 
demonstrate statistically significant results with both the expression levels of CD163 
as measured by Western blotting, and CD163 %area assessment on DAB-stained 
sections. However, a correlation between TNF" and IL-10 expression levels was 
observed (#= 0.676, p<0.005). (Figure 34) 
 
5.4.8 Comparison between different methodologies of assessing CD163 
immunoreactivity 
Assessments of microglia immunoreactivity were carried out in the cingulate and 
entorhinal cortex of LBD cases. Using Pearson correlation, measurement of CD163 
microglial immunoreactivity using microglia load (using scale 0-3) and %area yielded 
significant positive correlation in both the cingulate cortex (r=0.779, p<0.001) and the 
entorhinal cortex (r=0.831, p<0.001).  
No statistically significant relationship was found between expression of CD163 
(Western blot, refer to figure 35) and CD163 %area using Pearson correlation. Instead 
using Spearman correlation produced a statistically significant positive relationship (#= 
0.471, p<0.05).  
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Figure 32: Double immunofluorescence of CD163 with A!  pathology  
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DIF for CD163 (red) and A! (green) in the (A) occipital cortex of an AD case, and the (B) frontal cortex of a PD case. CD163+ microglia 
were observed to cluster around neuritic plaques. Magnification at x40 and x20 respectively 
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Figure 33: Double immunofluorescence of CD163 with CD68, tau and !-synuclein pathology!
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(A) DIF for CD163 (red) and 
CD68 (green) in the frontal 
cortex of an AD case. CD68 is a 
marker for lysosomes; co-
localisation indicates phagocytic 
properties of CD163+ microglia, 
confirming its role as a 
scavenger receptor.  
(B) DIF for CD163 (red) and 
AT8 (green) in the hippocampus 
of an AD case. CD163+ 
microglia are in close proximity 
with neuropil thread but with no 
specific associations.  
(C) DIF for CD163 (red) and !-
syn (green) in the frontal cortex 
of a PD case. CD163+ microglia 
cluster around extracellular LBs. 
Most of the LB were intracellular 
and did not coincide with 
CD163+ microglia. It is 
predictable that these microglia 
would react with abnormal 
aggregates of protein found 
extracellularly, not 
intracellularly. Magnification x40 
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Figure 34: Scatter plot of expression levels of IL-10 against TNF!  in LBD cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression levels of TNF! and IL-10 were measured in the frontal and cingulate cortices of LBD patients 
(n=10) using ELISA. Significant positive correlation between their expression levels was observed.   
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Figure 35: CD163 quantification using Western blot 
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A representative western blot of 6 different PD cases chosen based on their CD163 microglial load (1, 2, 
3). Two samples were used for each microglial load, totaling 6 samples per blot.  
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5.4.9 Co-localisation of CD163 and CD14 immunoreactivities within the same 
microglial cells 
CD163 and CD14 both represent phagocytic functions of macrophages/microglia, and 
DIF with both markers found that they co-localised within the same microglial cells. 
(Figure 36a,b) However, microglia immunoreactive for only one marker are also seen. 
CD14+ only microglia tend to take on a more ramified morphology, while CD163+ only 
microglia tend to be more amoeboid. PVM were immunopositive for both CD163 and 
CD14. (Figure 36c) 
 
5.4.10 CD163 immunoreactivity in the parenchyma of a haemorrhage  
Staining against CD163 labeled both microglia and macrophages in TBI. At the sites of 
lesion, intense amounts of peripheral macrophages immunoreactive for CD163 were 
observed. (Figure 37a, b) A gradient of morphological change was observed away from 
the lesion. Macrophages were usually found in close proximity to lesions, representing 
an influx from the periphery. At peri-contusional sites, ramified microglia increased in 
numbers while amoeboid macrophages/microglia decreased. (Figure 37c, d)   
 
5.4.11 CD163+ microglia in non-lesional sites of TBI 
Away from lesions and haemorrhages in the parenchyma, CD163+ microglia and 
macrophages were also observed in the parenchyma. (Figure 38a, b) The morphology 
of these microglia ranged from ramified to amoeboid, and they were upregulated in 
varying degrees ranging from mild to intense immunoreactivity.  
PVM strongly immunoreactive for CD163 were observed in vessels of all sizes. (Figure 
38c) CD163+ microglia were also found close to meninges, where subpial 
macrophages exhibited intense upregulation of CD163. (Figure 38d)  
 
5.4.12 Presence of !-amyloid protein in TBI cases relates to increasing age at 
death  
There was a statistically significant positive correlation between the increasing age at 
death and the presence of A! plaques. (U= 204.0, p< 0.05) (Figure 39) This finding is 
not unexpected as A! plaques are observed in subjects of advanced age (Arsene and 
Ardeleanu 2010), however this was also observed in young TBI patients in our cohort 
(Gentleman et al. 1997), with the youngest one at age 16.  
No correlation was found between CD163+ microglia load and presence of A! plaques. 
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DIF against CD163 (red) and 
CD14 (green) show co-
localisation in the same cells. 
Ramified and amoeboid 
microglia were immunopositive 
for CD163 and CD14. 
Occasional microglia were seen 
immunopositive for only one 
marker (arrows). In (C), PVM 
were immunoreactive for both 
markers. All images were taken 
in the occipital cortex of an AD 
case. Magnification x40 
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Figure 36: Double immunofluorescence of CD163 and CD14 
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Figure 37: CD163 immunoreactivity in a haemorrhage 
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(A & B) Amoeboid macrophages immunoreactive for CD163 in a haemorrhagic lesion in the frontal 
cortex of a TBI case. Magnification x10 and x40 respectively 
(C & D) Peri-contusional areas displaying the perimeter of the macrophage influx into the brain 
parenchyma in the frontal cortex of a TBI case. As distance increases from the lesion, a change in 
morphology (from amoeboid to ramified) and/or cell type (macrophage to microglia) is evident. 
Magnification x40 
!
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Figure 38: CD163 immunoreactivity in non-lesional areas of TBI 
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(A & B) CD163+ microglia were observed even in regions of the brain cortex spared from lesions 
and haemorrhages. These microglia appeared in a range of morphologies, from semi-ramified (A) to 
amoeboid (B). Magnification x10 
(C) PVM in the vessels of non-lesional areas were rounded and stained strongly for CD163. This is 
usually accompanied by CD163+ microglia and macrophages in the vicinity of the vessels, as seen 
in the cingulate cortex of a TBI case. Magnification x20 
(D) Sub-pial and sub-arachnoid macrophages displayed strong immunostaining for CD163. 
Microglia/ macrophages were also observed close to the meninges, seen in the cortex of a TBI 
case. Magnification x10 
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Figure 39: Boxplot showing the association between the presence of A!  plaques 
and age at death of TBI patients   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of A! plaques was compared against the age at death of TBI cases (n=41), using a single 
brain region from each case. The cases with A! plaques had a later age at death compared to those 
without A! plaques.  
!
! "#$!
5.4.13 Survival times and age at death correlate with CD163+ microglia load in 
TBI cases 
CD163+ microglia load correlated positively with age at death (H= 8.218, p<0.05) and 
survival times (H= 13.817, p<0.005) of TBI patients. When controlled for survival time, 
the relationship between age at death and CD163+ microglia load lost its significance. 
However, when controlled for age at death, survival time continue to show significant 
correlation with CD163+ microglia load (p<0.007).   
Jonckheere’s test revealed a significant trend (J= 424.00, p<0.005) with regards to 
survival time only: CD163+ microglia load increases along with survival times. (Figure 
40) 
 
Figure 40: Boxplot showing the association between survival time and CD163+ 
microglia load in the cortices of TBI patients  
 
 
 
 
 
 
 
The survival times was compared against CD163+ microglia load in TBI cases (n=41). CD163+ 
microglia load was found to increase with survival times.  
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5.5 Discussion 
CD163 is generally considered to be a specific PVM marker (Fabriek et al. 2005, Borda 
et al. 2008) and indeed in this study its expression was restricted to PVM in the 
majority of control cases. However we found that in AD and PD, in addition to a more 
intense staining of PVM, it was also expressed by microglia in the parenchyma. Foamy 
macrophages and microglia in the brain parenchyma have previously been found to 
express CD163 in HIVE (Roberts et al. 2004), MS, and head injury tissue (Gentleman 
et al. 2004).  In concordance with general consensus, these are inflammatory 
disorders, and the observation can be attributed to breakdown of the BBB and 
infiltration of peripheral monocytes (Fabriek et al. 2005, Kim et al. 2006, Borda et al. 
2008). Therefore the reason for significant increases of CD163+ parenchymal microglia 
in AD could be an immune response to the pathology specific to AD (D'Andrea, Cole 
and Ard 2004, El Khoury and Luster 2008). We also observed CD163+ microglia in PD, 
although the number of microglia stained and intensity of staining did not reach the 
levels seen in AD. CD163+ microglia were most prominent in the brainstem of PD 
cases, coinciding with the regions affected in the earlier stages of the disease. While 
some of the CD163+ microglia coincided with plaques both in AD and PD, focal 
aggregations were also seen in the absence of plaques. Such an observation might 
suggest that CD163 can react to both neuronal debris and extracellular abnormal 
aggregates of protein, including A! plaques and occasional Lewy bodies.  
Much interest has been shown in A! and its removal from the brain via natural methods 
or vaccination (Holmes et al. 2008). Microglia are capable of phagocytosis through 
immunization with A!42 peptides in the Elan clinical trials. In these patients, microglia 
were found to increase their expression of CD68 and A! was found within lysosomes 
(Zotova et al. 2011). In this study, the observation that CD163+ microglia cluster 
around A! plaques supports the idea that they might serve a similar purpose. Co-
localisation with CD68 indicates the possibility for a phagocytic function, that 
phagocytosis of A! takes place naturally in AD, and A! is a stimulant for microglia.  As 
seen in our study, CD163+ microglia did not react with NFT or intracellular LB, only 
extracellular LB- further supporting a role in phagocytosis. In spite of this, most of them 
remain in a ramified state, albeit with shortened and thickened processes, which raises 
doubt with regards to their phagocytic function. One possibility might be that they are 
influenced by the chronic state of the disease and the persistent generation of A! 
plaques (in AD) (Hickman, Allison and El Khoury 2008).   
Staining with MRC1 remains restricted to the perivascular spaces in AD and PD. MRC1 
is a mannose receptor involved in adhesion, pathogen recognition and clearance, and 
a marker for PVM (Galea et al. 2005). This is similar to other findings that no other 
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MRC1 expression was found in the parenchyma, despite acknowledged BBB damage 
e.g. in MS; and also in excitotoxic damage, acute inflammation and other chronic 
neurodegeneration models (Fabriek et al. 2005, Galea et al. 2005). It demonstrates 
that although they might serve similar phagocytic functions, CD163 and MRC1 
expression and consequently their targets might be different e.g. MRC1 is involved in 
the recognition and endocytosis of foreign pathogens (Musiani and Battelli 2003, Galea 
et al. 2005).  
There has been doubt as to whether the BBB is intact in AD (Eikelenboom et al. 2006, 
El Khoury and Luster 2008). In this study most of the microglia were found near the 
meninges, which might indicate infiltration of PVM from the periphery. Furthermore, 
some of these microglia were found to coincide with fibrinogen leakage around vessel 
walls, an indication that there is a breakdown in BBB. Migration of CD163+ 
macrophages from the periphery into the parenchyma might stem from vasculature 
compromise. This theory corresponds with the observation that most of the CD163 
microglia were not positive for Iba1. Iba1 is a calcium binding protein expressed in 
macrophages/microglia (Ito et al. 2001, Kanazawa et al. 2002), which labels all 
microglia and only certain types of PVM (Ahmed et al. 2007, Xu et al. 2007, Hawkes 
and McLaurin 2009, Mendes-Jorge et al. 2009). Signaling or infiltration through the 
BBB could strengthen the idea that systemic inflammation plays a part in the pathology 
of AD and PD (Perry 2004, Whitton 2007, Tansey and Goldberg 2010), and might 
explain the variations in CD163+ microglia load within each disease. Presence of 
microglia double positive for Iba1 and CD163 can be explained by the capability of 
resident parenchymal microglia to upregulate CD163, induced by signaling from the 
periphery. Vascular risk factors that are associated with an increased chance of 
developing AD might result in either an infiltration of peripheral macrophages into the 
brain, or increased signaling through the BBB to cause an abnormality in protein 
expression and upregulation.  
With regards to histological techniques, there has been no marker singularly capable of 
distinguishing between blood derived macrophages and resident brain microglia. If 
these CD163+ microglia are indeed derived from the blood, it would be interesting to 
further confirm their origin using markers specific for systemic macrophages. Animal 
models can also be used to track CD163+ peripheral macrophages and their probable 
entry into the brain parenchyma with or without a breach of the BBB. More experiments 
can be done to delve deeper into the presence and function of CD163 in AD and PD, 
and the subset of microglia/macrophages that express CD163 in these diseases.   
In TBI cases, macrophages that constitutively express CD163 were observed in 
parenchymal hemorrhagic lesions. This is especially relevant to the function of CD163, 
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which serves as a Hb scavenger. During hemolysis, Hb is freed, which can cause 
toxicity via oxidative damage through the production of ROS and oxidization of low-
density lipoproteins, as well as inducing pro-inflammatory reactions in endothelial cells 
(Schaer et al. 2007, Weaver et al. 2007). The expression level of CD163 on human 
macrophages is directly proportionate to their uptake of Hp-Hb complexes (Schaer et 
al. 2002). On microglia, CD163 expression in microglia is very low under normal culture 
conditions, and only detectable by immunoprecipitation/ Western blotting. However 
treatment with Hp-Hb complexes causes upregulation of CD163 to levels detectable by 
IHC (Borda et al. 2008).   
At peri-contusional sites, both amoeboid macrophages and activated microglia (albeit 
with ramifications) were observed. As distance increased away from lesions, the 
number of macrophages decreased and activated microglia increased. These findings 
present a possibility that peripheral macrophages are able to change their phenotype 
and structure to resemble microglia. Similar to AD, brain-resident microglia in TBI might 
also have upregulated CD163. The ability to upregulate a marker originally exclusive to 
PVM via signaling from peripheral macrophages might explain the spread of CD163 
microglia immunoreactivity to brain regions remote from lesions. CD163 expressed by 
microglia/macrophages remote from haemorrhages most likely serve purposes other 
than the scavenging of hemoglobin. A confirmation of CD163+ microglia’s phagocytic 
function can be carried out via double immunofluorescence with CD68.  
A positive correlation was found between CD163+ microglia load and survival timing of 
TBI patients. These microglia were not associated with lesions and were found 
throughout the uninjured parenchyma of the neocortex. CD163 could potentially be 
used as a marker specific for labeling activated microglia in TBI cases.   
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Chapter 6: General discussion 
The hypothesis of this project states that microglial phenotype differs in chronic 
neurodegenerative diseases AD and PD, as well as in acute brain disorder TBI. To 
carry out this investigation, a range of microglial markers was utilised. Many of these 
markers were characteristic of a particular microglial activation state i.e. classical or 
alternative activation, while some were of a more ambiguous nature. They were initially 
tested in AD cases in order to assess their usability in formalin-fixed, paraffin-
embedded sections. Many of these markers did not work in brain tissue despite testing 
at a range of antibody concentrations and using a variety of pretreatments; either a lack 
of immunopositivity, or a very high background was observed.  
Immunopositivity of CD14 and CD163 in parenchymal microglia proved to be intriguing 
as both markers were thought to be exclusive to PVM; this project sought to 
characterize them extensively in AD, PD and TBI. While these two markers are not as 
reliable at revealing the type of microglial activation state, they give an indication of 
phagocytic function. Their spatial and temporal distribution, and associations with 
pathological hallmarks were clearly varied in the disorders, which affirms the 
hypothesis that microglial phenotype differs between these three disorders.  
There was consistently higher CD14 and CD163 immunoreactivity in AD than in PD, 
which might be attributed to the presence of CAA in AD that cause weakened vessel 
walls, a subsequent disruption of BBB and influx of peripheral macrophages into the 
brain parenchyma. Higher amount of extracellular protein aggregates i.e. A! plaques, 
might also serve as a stimulant for upregulation of CD14 and CD163 in AD, as 
compared to intracellular Lewy Bodies in PD. Similar to AD cases, TBI cases also 
exhibited increased CD163 immunoreactivity in parenchymal microglia even in brain 
regions remote from lesions.  
Correlation between CD14 and CD163 microglia immunoreactivity and clinical 
symptoms in LBD cases, co-localisation with extracellular pathology, and upregulation 
in non-lesional areas of TBI cases indicate that the functions of these microglia are 
varied and diverse, and extend beyond phagocytosis. 
 
6.1 Evaluation of microglia quantification methods 
In chapter 4 and 5, two different methodologies were used to quantify CD14 and 
CD163 immunoreactivity in parenchymal microglia. CD14+ microglia were rated semi-
quantitatively on the entire tissue section based on an impression scale of 0-3, while 
CD163+ microglia were rated using %area.  
Both quantification methods produced consistently reliable results- significant 
correlation (Pearson r=0.779 and 0.831) was found. This was further confirmed when 
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the data on CD163 immunoreactivity obtained from both methods were correlated with 
clinical symptoms. CD163 immunoreactivity in the cingulate and entorhinal cortices 
was positively associated with anxiety symptoms in LBD patients using both methods.  
The reliability of the semi-quantification methods was further ascertained with the 
usage of western blot. Using Spearman correlation, a statistically significant positive 
monotonic relationship was found between CD163 %area and protein expression. 
However, Pearson correlation did not find a significant linear relationship between the 
quantification methods. This might be due to the presence of PVM and microglia in the 
white matter, both of which are omitted during assessment on stained sections.  
Quantifying microglia has always been a challenge especially when they are distributed 
in a non-homogenous fashion. Various methods exist to quantify microglia, including 
assessing %area of staining, manual counting, and measurement of intersections using 
a grid (Blackbeard et al. 2007). Counting the number of cells per field does not give 
information about the morphology or level of activation of these microglial cells, while 
grid method allows for horizontal or vertical intersections with cell processes that 
indicate morphological changes.  Most studies have utilized %area as a quantification 
method for microglia protein load (Reinacher et al. 1999, Ryu and McLarnon 2009, 
Simpson et al. 2007, Zotova et al. 2011). Semi-quantitative assessment of microglia 
load based on a scale of mild, moderate, and high frequency (microglia load) correlates 
well with %area measurements and can therefore be used in its place. This finding is in 
agreement with that of Blackbeard et al 2007. Microglia load assessment provides a 
less time-consuming method for rating microglial immunoreactivity, and is more 
practical when a large number of cases have to be analysed.  
 
6.2 Functions and inflammatory states of CD163 and CD14 
immunoreactive microglia  
In relation to aims 1 and 2, microglial markers including MHCII, Iba1, MRC1, IL-1!, 
CD68, Arg1 and 2, CD36, CD14, CD163, TNF!, BDNF and IL-10 were investigated in 
human brain tissue. Some markers did not work in paraffin-embedded tissue. Among 
the markers that worked successfully, immunostaining against CD14 and CD163 
revealed interesting and novel upregulation in microglia of AD and LBD. Detailed 
analysis of the immunoreactivity of CD14 and CD163 in parenchymal microglia and 
their distribution was carried out to shed light on the alternative activation profile of 
microglia in two of the most common neurodegenerative diseases- AD and LBD, as 
well as in an acute disorder- TBI, which could possibly shed light on microglial 
phenotype during the early stages of disease development (AD or CTE).  
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Microglia are thought to be classically activated in both AD and LBD. Many studies 
utilising human postmortem tissue, transgenic animals and in vitro cell cultures point to 
A! plaques as the main culprit in inciting pro-inflammatory reactions (Lue et al. 2001, 
Lau et al. 2004, Fan et al. 2007, El Khoury and Luster 2008, Fabriek et al. 2009). Pro-
inflammatory conditions are prolific in LBD too, with the spotlight on destruction of DA 
neurons in the SN and striatum, although widespread microglia activation is observed 
throughout the brain (Croisier et al. 2005, Ouchi et al. 2009, Qian and Flood 2008). 
Recently, the alternative activation state of microglia in AD has garnered attention. 
Colton et al. demonstrated the presence of mRNAs of alternative activation genes in 
postmortem specimens and cell cultures and transgenic mice models, although Walker 
et al. 2009 did not detect the mRNA of IL-4 and IL-13 in most of the brain samples 
examined. Phagocytosis is a function most fundamental to microglial alternative 
activation and/or acquired deactivation states.  
CD14 and CD163 function as receptors that mediate phagocytosis- CD14 recognises 
microbial pathogens (Ulevitch and Tobias 1999), apoptotic cells (Schlegel et al. 1999), 
and fibrillar A! (Fassbender et al. 2004, Liu et al. 2005), while CD163 functions as a 
scavenger receptor for hemoglobin (Kristiansen et al. 2001), and also recognises and 
binds bacteria (Fabriek et al. 2009). CD14 is essential for the binding and clearance of 
A! plaques (Liu et al. 2005), and although phagocytosis is generally associated with an 
alternative activation state, the uptake of fibrillar A! via CD14 in culture conditions 
leads to the release of free radicals and ROS (Reed-Geaghan et al. 2009). 
Unexpectedly, CD14 knockout animal models show a reduced plaque burden (Reed-
Geaghan et al. 2010). Inactivating mutations in TLR4, which forms a complex with 
CD14, also results in a decreased risk for AD (Minoretti et al. 2006). As CD14 mediates 
a pro-inflammatory reaction towards bacterial pathogens (Kielian 2006), sustained 
inflammation throughout life e.g. repeated infections resulting in peripheral or systemic 
inflammatory responses, predisposes both humans and animals towards neuronal 
dysfunction and the development of AD or AD-like symptoms (Sheng et al. 2003). 
CD14 knockout animals are spared from repeated bouts of inflammation, resulting in a 
neuroprotective outcome. 
The specific molecular interactions between CD163 and A! or !-syn, and subsequent 
downstream signaling pathways have yet to be investigated. Whether the stimulation of 
CD163 results in a pro-inflammatory or anti-inflammatory reaction is also a matter for 
debate. CD163 levels are increased in wound healing and in late phases of acute and 
chronic inflammation e.g. experimental gingivitis (Topoll et al. 1989), indicating its role 
in the resolution of inflammation (Zwadlo et al. 1987, Zwadlo-Klarwasser et al. 1990, 
Sulahian et al. 2000, Roberts et al. 2004). It may also exert protective functions through 
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the removal of toxic Hb, and the subsequent stimulation of IL-10 release (Schaer et al. 
2002, Zhang et al. 2012). CD163 has also been shown to bind and scavenge TWEAK 
(TNF-like weak inducer of apoptosis), which has been found to induce apoptosis and 
compromise the neurovascular unit (Bover et al. 2007, Zhang et al. 2007b). However 
when CD163 is activated/ cross-linked by Hp-Hb complexes or antibodies, it can also 
stimulate the production of inflammatory cytokines e.g. IL-1!, IL-6, GM-CSF and IL-10 
(Van den Heuvel et al. 1999, Kristiansen et al. 2001, Ritter et al. 2001).  
With respect to the 3rd aim, double immunofluorescence was carried out with to detect 
associations between CD14+ and CD163+ microglia with pathologies of AD and PD i.e. 
A! plaques, LB, NFT and NT pathology. Co-localisation of A! plaques and !-syn/ 
extracellular Lewy bodies with CD14 and CD163+ microglia might be due to the 
phagocytic nature of these microglia. Many of these microglia had a semi-ramified 
morphology- less ramified than a resting microglia with hypertrophied soma. The 
morphology of microglia provides less than adequate information about its activation 
state and function (Boche, Perry and Nicoll 2013). If these microglia were indeed 
phagocytosing plaques/ !-syn, why have they not taken on a more amoeboid 
morphology? 
One possible reason for these microglia to appear semi-ramified is due to the 
resistance of fibrillar A! towards degradation. It is known that microglia are extremely 
inefficient at phagocytosing fibrillar A! and breaking them down (Koenigsknecht-Talboo 
and Landreth 2005, Kawahara et al. 2012). Diffuse A! plaques are more susceptible to 
degradation (Wilcock et al. 2003), which could justify the observation that a greater 
number of CD14+ microglia were co-localised with diffuse plaques instead of neuritic 
plaques.  
As AD progresses through its stages, it is likely that microglia which have been 
chronically activated gradually lose their phagocytic ability. This is observed in APP 
transgenic mice models where microglia continue to produce pro-inflammatory 
cytokines but lose their A!-clearing ability. An overall downregulation in the expression 
of scavenger receptors e.g. scavenger receptor A and CD36 are observed in these 
mice (Hickman et al. 2008). Blood-derived monocytes and macrophages isolated from 
AD patients are unable to degrade A! and are susceptible to apoptosis (Fiala et al. 
2005). Following the hypothesis that microglia in diseased patients are defective in 
their phagocytic capabilities, a change in morphology may follow suit. 
Although CD163 is upregulated by IL-10 and downregulated by TNF", no correlation 
was found between CD163 expression and cytokine expression. It is hypothesized that 
the aged brain has an impaired response towards IL-10; microglia from aged mice do 
not express high levels of IL-10 receptor (Fenn et al. 2012, Norden and Godbout 2013). 
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Failure of microglia to respond properly to IL-10 might explain the patchy distribution 
and weak upregulation of CD163 instead of a strong immunoreactivity and 
homogenous distribution as seen with other microglial activation markers e.g. MHCII.  
 
6.3 Heterogeneity of microglial phenotype 
The diversity of microglial phenotype is demonstrated with double staining against 
CD163 and CD14. Although both markers represent a phagocytic function, some 
microglia were immunopositive for both, while others were singly immunopositive for 
CD163 or CD14. The variation in their marker profile is probably not due to different 
stimuli as these microglia were observed in close proximity, but due to their innate 
differences e.g. the existence of subsets of microglia (Colton et al. 2006, Colton and 
Wilcock 2010), pre-conditioning or priming of microglia (Norden and Godbout 2013), or 
their sources- peripheral derived vs brain resident (Simard et al. 2006, Soulet and 
Rivest 2008, Gate et al. 2010). The functions and inflammatory cytokine profiles of 
these microglia are not known.  
 
6.4 Origin of CD14 and CD163 immunoreactive microglia 
CD14+ and CD163+ microglia, but especially CD163+ microglia, were found in higher 
densities around the meninges, and occasionally, compromised blood vessels. As 
discussed in the previous result chapters, the population of CD163+ microglia in AD 
and LBD are probably made up of resident microglia and peripheral macrophages. It is 
most likely the same for CD14+ microglia.  
Work done on TBI cases gives additional insight into the origins of CD163+ microglia. 
The gradation of microglia morphology from lesions to peri-lesional areas, and the 
presence of CD163+ microglia in areas remote from the lesions, both point to the ability 
of brain-resident microglia to upregulate CD163. This upregulation might be stimulated 
via signaling from the periphery aggravated by a compromise in the BBB. Activated 
microglia are found in long-term survivors of TBI, and are thought to contribute to 
chronic neurodegeneration and development of AD (Fleminger et al. 2003) and CTE 
(McKee et al. 2009). Phagocytic microglia/macrophages have been found in the corpus 
callosum of TBI cases up to 18 years after injury (Johnson et al. 2013). The association 
between survival times and CD163+ microglia load provides evidence for the chronic 
inflammatory response that arises after the initial injury, which is thought to predispose 
long-term TBI survivors to neurodegeneration and subsequent neurological diseases 
(Smith 2013). While the longest survival period after injury used in this study is 13 
days, CD163 upregulation by microglia throughout various brain regions is most likely 
to persist beyond this period.  
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6.5 Distribution of CD14 and CD163 immunoreactive microglia in AD, LBD 
and TBI 
Aside from the obvious breakdown of the BBB in TBI cases, compromise of the BBB 
has also been shown in AD and a rat model of LBD, which was correlated with 
neuronal death (Rite et al. 2007, Popescu et al. 2009). This coincides with our findings 
that the highest amount of CD14+ and CD163+ microglia were found in brain regions 
most affected in AD and LBD, including the frontal and occipital lobes in AD, and SN, 
DMV, and striatum in LBD. The breakdown of BBB in these brain regions might explain 
the upregulation of CD14 and CD163 that are usually restricted to perivascular 
macrophages. Our observation of CD14 and CD163 positivity in the parenchyma gives 
an example of how systemic inflammation could affect the brain and aggravate disease 
progression (Holmes et al. 2008, Perry 2004).  
 
6.6 CD163 immunoreactive microglia associated with anxiety symptoms in 
LBD patients 
With regards to the 4th aim, upregulation of CD163+ microglia in the cingulate cortex, 
entorhinal cortex and LC of LBD cases were found to associate with an absence of 
anxiety symptoms. DA receptor polymorphisms have been linked to social anxiety 
disorder and obsessive-compulsive personality disorder, both of which are anxiety 
disorders (Light et al. 2006, Sareen et al. 2007). High frequency of anxiety symptoms in 
the premotor phase of LBD can be explained by the loss of noradrenergic neurons in 
the LC that precedes degeneration of DA neurons in the SN (Braak et al. 2006). This 
coincides with the significant association we found between anxiety symptoms and the 
presence of CD163+ microglia in the LC. In patients who are clinically anxious, or 
those diagnosed with social anxiety disorder, both the anterior cingulate cortex and the 
entorhinal cortex are affected (Hattingh et al. 2012, Klumpp et al. 2013), confirming the 
involvement of neurotransmitter systems in these brain regions with fear and anxiety 
regulation.  
A study into the cytokine profile of CD163+ microglia and their interactions with 
common pathological protein aggregates e.g. tau, A! or !-syn in these brain regions 
might help to shed light on the cause of neuronal dysfunction resulting in anxiety. This 
finding is significant as it directly links inflammation to the clinical aspects of 
neurological diseases. Upregulation of microglia markers can also be useful in the 
mapping of clinical symptoms to specific brain regions. 
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6.7 Future studies 
To bring the investigation forward on characterization of microglial alternative activation 
state in patients afflicted with neurological diseases, it is essential to continue to test for 
new markers that can help characterize the diverse microglia phenotypes in the brain. 
As many of these markers target antigens that are too labile or in low quantities, 
experiments can be carried out with frozen, unfixed tissue using IHC, ELISA or capture 
protein microarray.    
Double staining experiments have been carried out with CD163 antibody were not 
done with CD14 antibody. A confirmation of the phagocytic capacity of CD14+ 
microglia in AD, PD and TBI cases can be tested using a double stain against CD14 
and CD68. Antibodies highlighting BBB damage e.g. fibrinogen, occludin or von 
Willebrand factor can also be used in double staining experiments to look into the 
origins of these microglia. 
 While double immunofluorescence detects association between microglial cells and 
pathology, it does not provide information regarding the type of interaction. This 
problem can be solved with confocal microscopy, which can help in the visualization of 
internalized pathological protein within microglial cells. To confirm interaction between 
microglial markers and protein pathology, immunoprecipitation followed by Western 
blotting can be done to assess binding affinities.  
No experiments have been done in AD, LBD, or TBI patients investigating the release 
of pro or anti-inflammatory cytokines via interactions between CD163 and CD14 and 
pathological protein aggregates (Gentleman 2013). Studying the cytokine expression in 
paraffin-embedded sections using IHC, or in frozen fresh tissue using Western blot 
have always proven difficult due to the cytokines’ small quantity, low molecular weight 
and labile nature (Boche et al. 2013).  A new technique using immunolaser capture 
microdissection in conjunction with microarray can be used to target a specific 
microglia subset from a heterogenous population, thus providing a way for 
transcriptome profiling (Waller et al. 2012) and a thorough characterization of 
microglia’s specific responses to different types of pathology.  
With regards to TBI cases, cases with survival period up to several years should be 
included in the testing as the cohort used in this study represents only the acute injury 
phase. A decrease in CD68 and CR3/43 immunoreactivity was found in those who 
survived more than a year after injury (Smith et al. 2012). Exploring a variety of 
microglial activation markers can help to define the evolution of microglial phenotype 
prior to the onset of AD or CTE.  
Current PET assessment of microglial activation using [11C](R)-PK11195 lacks 
accuracy as it measures the activation of both microglia and astrocytes. Our finding 
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that CD163 is upregulated by microglia in AD, PD and TBI cases could provide an 
alternative to the usage of mitochondrial translocator protein as a ligand for PET 
imaging.  
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Appendix I 
  
Buffers and Solutions 
 
2.6.1 Protein extraction  
• Lysis buffer  
PBS 
0.1% Triton X 
Roche complete protease inhibitor cocktail 
 
2.7.1 Gel preparation 
• 1 x 8% running gel 
2ml of acrylamide 
2.5ml of 1.5M Tris-HCl pH 8.8 
100µl of 10% SDS 
10µl TEMED (Tetramethylethylenediamine) 
50µl APS (10% Ammonium persulfate) 
5.34ml of ddH2O (double distilled) 
 
• Stacking gel 
250µl of acrylamide 
315µl of 1.5M Tris-HCl pH 6.8 
25µl of 10% SDS 
2.5ml TEMED (Tetramethylethylenediamine) 
12.5µl APS (10% Ammonium persulfate) 
1.9ml of ddH2O 
 
2.7.2 SDS-PAGE gel electrophoresis 
• Sample buffer 
3ml of 20% SDS 
3ml of glycerol 
2.4ml of 1M Tris pH 6.8 
1.5ml of !-mercaptoethanol 
a pinch of Bromo-phonol-blue 
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• Running buffer 
14.3g of glycine 
3g of Tris base 
1g of SDS 
1 litre of ddH2O 
 
2.7.3 Transfer and Detection 
• Tris-Buffered Saline with Tween 20 (TBST) 
6.05g of Tris base 
8.76g of NaCl 
1ml of Tween 20 
1 liter of ddH2O 
pH adjusted to 7.5 with HCl 
 
• Transfer buffer 
200ml of methanol 
28.8g of glycine 
6.05g of Tris base 
1.6 liter of ddH2O 
 
3.3.3 Pretreatments 
• Proteinase K solution 
50mM Tris-HCl buffer pH 8 
20 ug/ml Proteinase K 
 
• 4M Guanidine thiocyanate solution 
472.64 g of guanidine thiocyanate 
1 litre of ddH2O 
 
• 0.4% Pepsin solution 
4mg of pepsin 
1ml of 10mM HCl at pH 2.0 
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Appendix II 
CD163 %area assessment in AD cases 
Hippocampus AD cases Frontal cortex Occipital cortex 
CA1 CA2 CA3 CA4 Subiculum Entorhinal cortex 
1 0.925 1.126 - - - - - - 
2 2.946 1.466 0.548 0.238 0 0.22 0.181 0 
3 1.049 8.015 - - - - - - 
4 8.562 6.429 3.128 1.154 0.863 2.978 3.128 3.433 
5 5.107 3.245 0.701 0 0.288 1.085 2.478 4.93 
6 4.068 1.624 0.663 0.384 0 0.06 0.052 0.063 
7 3.279 1.243 0 0 0.011 0.032 0.512 0.115 
8 1.143 1.8 0.204 0.055 0 0.054 0.095 0.376 
9 0.7 1.911 0.749 0.659 0.167 0.715 1.565 2.384 
10 1.135 1.439 0.557 0.254 0.455 0.497 2.203 2.194 
11 3.538 1.308 - - - - - - 
12 1.227 1.331 0.318 0 0.089 0.207 1.041 4.186 
13 2.575 3.488 - - - - - - 
14 2.771 2.071 1.741 0.205 0.187 0.11 1.47 1.479 
15 0.692 1.141 1.891 0 0.456 0.191 1.335 0.43 
16 2.623 5.077 - - - - - - 
17 0.55 0.231 0.094 0 0 0 0.042 0 
18 1.021 1.676 0.455 0 0.198 0.256 0.528 0.808 
19 2.711 1.68 - - - - - - 
20 4.037 4.048 1.265 0.459 0.309 0.433 1.181 0.719 
21 0.38 0.176 0.203 0.294 0.337 0.247 1.634 0.3 
22 0.437 0.184 0.242 0 0 0.388 0.194 0.67 
23 1.893 1.602 0.094 0 0.151 0.158 0.206 2.133 
24 1.192 1.056 - - - - - - 
25 1.323 2.143 0.674 0.129 0.257 0.73 1.075 0.573 
26 0.866 1.911 - - - - - - 
27 0.406 0.973 - - - - - - 
28 0.177 0.355 - - - - - - 
29 0.067 0.374 0 2.231 0 0 0.305 2.238 
30 1.615 2.099 0.658 0.437 0.38 0.421 1.025 2.219 
31 0.943 2.03 0.192 0 0 0.217 0.588 0.156 
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CD14+ microglia load assessment in AD cases 
Hippocampus AD cases Frontal cortex Occipital cortex 
CA1 CA2 CA3 CA4 Subiculum Entorhinal cortex 
1 1 2 - - - - - - 
2 2 2 2 0 0 0 1 2 
3 2 3 - - - - - - 
4 1 3 3 2 3 3 3 3 
5 2 2 2 0 0 0 1 1 
6 1 2 0 0 0 0 0 1 
7 2 2 1 0 0 0 1 1 
8 1 1 1 0 0 0 1 1 
9 3 3 3 2 0 2 2 3 
10 1 2 1 0 0 0 1 - 
11 2 1 - - - - - - 
12 2 3 1 0 0 0 1 2 
13 2 3 - - - - - - 
14 3 3 3 1 0 1 2 3 
15 1 2 1 0 0 0 1 0 
16 1 2 - - - - - - 
17 1 1 1 0 0 0 1 1 
18 2 2 1 0 0 1 1 1 
19 2 2 - - - - - - 
20 2 3 1 0 0 1 1 3 
21 1 2 2 1 1 2 2 2 
22 1 1 0 0 0 0 0 0 
23 2 2 1 0 0 1 1 2 
24 1 2 - - - - - - 
25 3 3 3 2 2 2 2 2 
26 2 2 - - - - - - 
27 1 1 - - - - - - 
28 0 2 - - - - - - 
29 0 1 0 2 1 0 0 1 
30 2 3 1 1 1 1 0 2 
31 1 2 1 0 0 1 0 1 
 
 
! "#"!
Appendix III 
Clinical data for LBD patients 
Clinical symptoms Motor onset symptoms PD case Gender Clinical 
Diagnosis 
!-syn 
Braak 
staging 
Age of 
disease 
onset 
Age at 
death 
Disease 
duration Anxiety Depression Visual 
Hallucinations 
Psychosis Tremor Rigidity Gait/ 
Balance 
1 F PD 4 65 75 10 N N N N Y N N 
2 M PD 4 67 81 15 N N Y N Y N N 
3 F PD 4 67 80 13 N N Y N Y Y N 
4 F PD 4 77 87 9 N N N N Y Y N 
5 M PD 5 48 49 1 Y Y N N Y Y Y 
6 M PD 5 67 75 8 N N N N N Y N 
7 M PD 4 66 72 6 Y Y Y N Y Y N 
8 F PD 5 61 77 16 N Y Y N N Y Y 
9 M PD 5 69 79 10 N Y Y N Y Y N 
10 M PD 4 40 66 26 Y N Y N Y N N 
11 M PD 3 52 61 9 N N Y N Y N N 
12 M PD 6 80 86 6 N N Y N Y N Y 
13 F PD 3 78 96 18 Y Y Y N Y N N 
14 M PD 6 72 74 3 N N N N Y N N 
15 F PD 3 67 73 6 9 9 9 9 N Y N 
16 M PD 3 86 89 3 N N N N N N Y 
17 M PD 5 43 57 14 Y Y N N Y N N 
18 F PDD 6 66 80 14 Y Y Y Y Y N N 
19 M PDD 6 46 72 26 N N N N Y N N 
20 M PDD 6 58 66 8 N N Y Y Y Y Y 
21 M PDD 3 72 80 8 N N Y 9 N N Y 
22 F PDD 6 64 84 20 N N Y N N Y N 
23 F PDD 6 68 78 10 N Y Y N Y N N 
24 M DLB 6 47 61 14 N Y Y Y Y Y N 
25 M DLB 5 69 70 1 Y Y Y Y Y N Y 
26 M DLB 6 61 69 8 N N Y N Y N N 
27 M DLB 6 64 74 10 Y Y Y N Y N N 
 
 
 
! "##!
CD163 %area assessment in LBD cases 
Hippocampus PD 
cases 
Frontal 
cortex 
Cingulate 
cortex 
Caudate 
nucleus 
Internal 
capsule 
Putamen NBM 
CA1 CA2 CA3 CA4 Subiculum Entorhinal 
cortex 
SN LC DMV 
1 0.02 0.04 0.09 0.04 0.24 0 0 0 0 0.34 0 0.02 0.52 1.07 0.61 
2 0.21 0.09 0.08 1.41 0.16 0.38 0.08 0 0.01 0.09 0 1.09 1.09 0.14 1.43 
3 0.1 0.05 0.13 0.04 0.08 0.23 0 0 0 0 0.03 0.3 0.84 0.49 0.9 
4 0 0 0 0 0.05 0.34 1.82 0 0 0 0 0.2 0.78 0.2 0.53 
5 0 0 0 0 0 0 0 0 0 0 0 0 0.11 0.1 0.06 
6 0.19 1.06 0.18 3.65 2.31 1.26 0.93 0 0 0.05 0.32 1.03 0.76 0.91 2.78 
7 0.19 0 0 0 0 0.17 0 0.16 0 0.04 0 0.12 0.45 0.24 0.42 
8 0.07 0 0 0 0.67 0.16 0 0 0 0 0 0.26 0.46 0.14 0.28 
9 1.55 0.37 0 1.07 1.55 0.23 0.81 0.34 0.56 0.2 1.57 0.53 1.57 0.19 0.16 
10 0 0 0 0 0 0.12 0 0 0 0 0 0 0 0.07 0 
11 0 0 0 0 0 1.9 0 0.24 0.12 0.33 0 0 0.12 - 0 
12 1.2 1.8 0.27 0.95 0.49 2.48 0.71 0.63 1.14 1.57 0.89 1.43 1.86 3.86 2.31 
13 0.27 0 0 0 0 0.04 0 0 0.02 0.1 0.12 0 0.58 0.44 1.5 
14 0.42 1.26 1.65 2.8 3.87 0.41 0.84 0.49 0 0.09 0.41 0.67 2.27 1.84 3.69 
15 0.47 0.14 0 0.65 0 0.57 0.18 0.03 0.07 0.69 0.26 0.22 1.87 0 1.04 
16 0.28 0.8 0.54 0.27 0.13 0.38 0 0 0 0.1 0 0 1.27 0.46 0.08 
17 0 0 0 0 0.04 0.5 0 0 0 0.06 0.05 0 0.32 0.13 0.21 
18 0.06 0 0.37 0 0.8 0.28 0 0 0 0 0 0.17 1.43 0.23 0.27 
19 0.08 0 0 0 0 - 0 0.38 0 0.02 0 0.35 0.87 0.76 2.81 
20 0.03 0.08 0 0 0 0 0 0 0 0 0.05 0.62 0.63 0.17 0.22 
21 0.21 0.39 0 0 0 0 0 0 0 0.12 0 0.06 0.22 0.63 0.7 
22 0.65 0.37 0.26 0.12 0.11 0.34 0.19 0.56 0.02 0.27 0.23 0.17 0.21 0.52 0.68 
23 1.83 1.41 0.57 2.26 1.08 1.87 - - - - - - 2.83 2.76 1.12 
24 0.05 0.1 0 0 0 0 0 0 0 0 0 0.06 0 0.26 0.14 
25 0.27 0 0.08 0.5 0.25 0.4 0 0 0 0 0.04 0.07 0.65 0.42 0.44 
26 0.13 0.22 0.21 0 0.14 - 0.62 0.26 0.32 0.28 2.8 0.65 0.87 0 0.29 
27 1.41 0.4 0.2 0.32 0.13 0.19 0.54 1.94 0.4 0.71 1.32 0.5 1.55 0.11 0 
 
 
 
 
 
! "#$!
CD14+ microglia load assessment in LBD cases 
Hippocampus PD 
cases 
Frontal 
cortex 
Cingulate 
cortex 
Caudate 
nucleus 
Internal 
capsule 
Putamen NBM 
CA1 CA2 CA3 CA4 Subiculum Entorhinal 
cortex 
SN LC DMV 
1 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 
2 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 
3 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
4 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
6 2 2 2 3 3 2 2 0 1 2 3 2 2 1 2 
7 1 1 2 0 1 1 2 1 0 1 1 1 1 0 0 
8 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
9 2 2 3 3 3 0 2 1 0 2 2 2 2 2 0 
10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
11 0 0 1 1 1 0 0 0 0 0 0 0 0 - 0 
12 1 1 1 1 1 2 0 0 0 0 0 0 1 1 0 
13 1 1 1 0 2 1 0 0 0 1 0 0 1 1 2 
14 2 2 3 2 3 2 2 2 2 2 2 2 3 2 3 
15 1 0 1 1 1 0 1 0 0 0 1 1 0 0 0 
16 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 
17 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
18 0 1 0 0 1 0 1 0 0 0 0 0 2 0 0 
19 0 0 0 0 0 - 0 0 0 0 0 0 1 0 1 
20 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
22 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
23 2 1 2 1 2 2 - - - - - - 2 1 2 
24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
26 0 0 0 0 0 - 0 0 0 0 0 0 0 0 0 
27 2 2 2 2 2 0 3 3 1 2 3 2 1 2 1 
 
 
! "#$!
Appendix IV 
CD163+ microglia load assessment in TBI cases 
CD163 microglia load TBI case Age at death Survival time 
(days) 
Presence of A! 
plaques Cerebral cortex Cingulate 
cortex 
1 47 0 0 0 - 
2 1 0 0 0 - 
3 25 0 0 0 - 
4 14 0 0 0 - 
5 47 1 0 3 - 
6 65 1 1 0 0 
7 21 1 0 0 - 
8 26 1 0 0 - 
9 27 1 0 0 - 
10 62 1 1 0 - 
11 28 1 1 1 0 
12 20 2 0 0 - 
13 18 2 0 0 - 
14 37 2 0 0 - 
15 9 2 0 0 - 
16 16 2 1 0 2 
17 16 2 0 0 - 
18 56 3 0 3 - 
19 26 3 0 0 - 
20 32 3 0 2 - 
21 75 3 0 1 - 
22 24 4 0 3 - 
23 52 4 0 2 - 
24 17 4 0 0 - 
25 56 4 1 2 1 
26 59 4 1 1 1 
27 20 5 0 2 - 
28 20 5 0 3 - 
29 9 5 0 0 - 
30 32 5 0 3 - 
31 20 7 0 2 - 
32 17 7 0 2 - 
33 21 8 0 3 - 
34 5 9 0 0 0 
35 46 10 1 1 1 
36 46 10 0 0 - 
37 62 11 0 1 - 
38 43 11 0 3 - 
39 29 12 0 2 - 
40 45 13 1 3 2 
41 22 13 0 1 - 
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